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TIR   Toll/interleukin-1 receptor  
TNF   tumour necrosis factor 
TLR   Toll-like receptor 
TPL-2   tumour progression locus 2 
TRAF    tumour necrosis factor receptor-associated factor 
TRAM   TRIF-related adaptor molecule 
TRIF  TIR-domain-containing adaptor protein inducing 
interferon-β  
Tris tris(hydroxymethyl)aminomethane 
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Ub   ubiquitin 
UBA   ubiquitin-associated 
UBAN   UBD found in ABINs and NEMO 
UBD   ubiquitin-binding domain 
UBL    ubiquitin-like  
VSV-G  vesicular stomatitis virus G protein 
WT    wild type  
ZF    zinc-finger  
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VIII. Amino Acid Code 
 
Amino acid    Three letter symbol  Single letter symbol 
 
Alanine     Ala        A 
Arginine     Arg         R 
Asparagine    Asn         N 
Aspartic acid    Asp         D 
Cysteine     Cys         C 
Glutamic acid    Glu         E 
Glutamine     Gln         Q 
Glycine     Gly         G 
Histidine     His        H 
Isoleucine     Ile         I 
Leucine     Leu         L 
Lysine     Lys         K 
Methionine     Met         M 
Proline     Pro         P 
Serine     Ser         S 
Threonine     Thr         T 
Tryptophan     Trp         W 
Tyrosine     Tyr         Y 
Valine     Val         V 
Any amino acid   Xaa        X 
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IX. Summary 
 The innate immune system serves as the first line of defence against 
invading pathogens. The Toll Like Receptors (TLRs) and the interleukin-1 
receptor (IL-1R) form an integral part of innate immunity and relay information 
largely through the MyD88 (myeloid differentiation primary response gene 88) 
signalling adaptor. This rapidly leads to the activation of protein kinases and 
E3 ubiquitin ligases. These early signalling events function to activate the 
transcriptional and posttranscriptional events that trigger production of the 
inflammatory mediators required to fight infection. My thesis centres around 
the E3 ligases TRAF6 (tumour necrosis factor receptor associated factor 6), 
Pellino and LUBAC (linear ubiquitin chain assembly complex) and their 
involvement in the early and late signalling events of the MyD88-dependent 
network.  
 I have discovered that the IL-1-stimulated, LUBAC-catalysed formation 
of Met1-ubiquitin (M1-Ub) chains is dependent on the prior formation of 
Lys63-Ub (K63) chains. In contrast, I found that the loss of M1-Ub chains 
does not affect the IL-1-stimulated formation of K63-Ub chains. I additionally 
found that there was no defect in the IL-1-dependent formation of K63-Ub 
chains or ubiquitylated IRAK1, IRAK4 or MyD88 in TRAF6-null IL-1R* cells 
(IL-1R-expressing human embryonic kidney (HEK) 293 cells) that I generated 
indicating that, in contrast to the widely held view, TRAF6 is not the only E3 
ligase that generates the K63-Ub chains in this pathway. Moreover, I found 
that the E3 ligase activity of TRAF6 was dispensable for the activation of the 
canonical IκB kinase (IKK) complex and the release of IL-8 in TRAF6-null IL-
1R* cells. Remarkably, I discovered that the IL-1-dependent formation of M1-
Ub chains was almost abolished in TRAF6-null IL-1R* cells, indicating a 
unique role for TRAF6 is coordinating the formation of M1-Ub chains in these 
cells. I generated knock-in mice expressing E3 ligase-inactive mutants of 
Pellino1, 2 and 3, as well as all three double knock-in and the triple knock-in 
mice. Studies with MEFs from these mice revealed that Pellinos 1 and 2 are 
responsible for generating a significant proportion of the K63-Ub chains 
formed in response to IL-1 stimulation, but the absence of these E3 ligases 
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did not affect the acute IL-1-dependent activation of the canonical IKK 
complex and MAP kinases, significantly. 
   In the last Chapter of the thesis I demonstrate that the compound BAY 
11-7082, which is marketed as a specific IKK inhibitor, does not inhibit IKKβ at 
all, but blocks the activation of the canonical IKK complex by covalently 
modifying and inactivating E2-conjugating enzymes, including those that direct 
the formation of K63-Ub chains and M1-Ub chains. BAY 11-7082 also 
inhibited the intrinsic E3 ligase activity of LUBAC. Since BAY 11-7082 has 
beneficial effects in mouse models of inflammatory disease, these findings 
suggest that particular components of the ubiquitin system may be good drug 
targets for the treatment of inflammatory and autoimmune diseases. 
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Introduction 
1.1 The innate and adaptive immune system 
The body defends itself against invading pathogens using both the 
innate and adaptive immune systems.  The innate immune system, present in 
nearly all multicellular organisms, provides the first line of defence against 
infection.  It is swift to respond to attack due to its ability to detect foreign 
material without the need for any prior exposure. Within minutes, it promotes 
the activation of signalling networks that initiate the production of inflammatory 
mediators.  Their subsequent secretion into the extracellular space induces 
the recruitment of immune cells that help to resolve the infection. Moreover, 
the innate immune system is instrumental in promoting the activation of the 
adaptive immune system, found only in vertebrates.  Though the adaptive 
immune system is slower to act, it is able to uniquely identify the invading 
antigen and produce a precisely tailored response to remove it. Furthermore, 
it also possesses immunological memory, so that if the same pathogen is 
detected subsequently, it is able to mount a more swift and robust counter-
attack to eliminate it from the body.  
The presence of an effective immune system is crucial for healthy 
development. People that present with immunodeficiency are far more 
susceptible to infection and this can often lead to fatal consequences [1,2].  
However, like nearly every other signalling network, the immune system must 
be tightly regulated. It is often described as a ‘double-edged sword’ because if 
allowed to run awry it can cause sustained activation of inflammatory 
networks, which can lead to autoimmune diseases, chronic inflammation, 
sepsis and even cancer [3–5].   
1.2 Signal transduction and post-translational modifications 
Living cells communicate with each other by the process of signal 
transduction. This involves the relaying of signals from the exterior of a cell to 
its interior to generate a specific response, relying on arrays of signalling 
networks and cascade systems. To achieve this, a ligand will typically bind to 
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a receptor expressed on the cell surface causing the activation of one or more 
of its associated intracellular protein(s). This initiates the activation of 
signalling networks that amplify and integrate the signal. This ultimately 
enables weak or transient signals to be relayed into appropriate physiological 
responses [6]. Signal transduction is utterly dependent on the cell’s ability to 
regulate its proteins by post-translational modifications (PTMs). This is 
because a PTM can cause a change in a protein’s enzymatic activity, stability, 
interacting partners or subcellular location. Two of the largest classes of 
PTMs are phosphorylation and ubiquitylation.  
1.2.1 Protein phosphorylation 
Protein phosphorylation is a widely used PTM and is performed by a 
group of enzymes called protein kinases. They are responsible for catalysing 
the transfer of the γ-phosphate from ATP onto the hydroxyl group of serine, 
threonine or tyrosine residues in proteins (Fig. 1.1). Conversely, phosphate 
groups can be removed by protein phosphatases. 
Although the first protein kinase was described in 1954 [7] and 
phosphorylation was identified as a regulatory mechanism in 1955 [8,9], it was 
thought only to be relevant for glycogen metabolism and was relegated to the 
backbenches of scientific research for almost two decades. It was not until the 
mid 1970s and during the 1980s that phosphorylation was found to play 
crucial roles in other pathways, functioning in kinase cascades that enabled 
tailored effects to be elicited in response to stimuli [10–12]. The introduction or 
removal of a phosphate group from a protein causes a local shift in charge 
that may induce a conformational change. This can serve to modulate protein 
function by altering its enzymatic activity, subcellular localisation or half-life. 
There are over 500 protein kinases and about 140 protein phosphatases 
encoded by the human genome. The majority of cellular proteins are 
phosphorylated, meaning that phosphorylation is firmly entrenched as a 
cornerstone of signal transduction. 
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1.2.1.1 Protein kinases 
The majority of protein kinases share an archetypal catalytic domain 
composed of 250-300 residues, but the regions outwith this are subject to 
considerable variation, enabling interaction with other proteins and the 
regulation of its activity. The kinase fold is composed of N- and C-terminal 
lobes. The N-terminal lobe is responsible for binding ATP, with the VAIK (Val-
Ala-Ile-Lys) motif coordinating the α and β phosphate groups of ATP. The C-
terminal lobe is involved in substrate binding and the HRD (His-Arg-Asp) 
provides an aspartic acid essential for catalysis whilst the DFG (Asp-Phe-Gly) 
motif coordinates Mg2+ ions that orientate the γ phosphate of ATP for attack 
[13]. These three sets of invariant residues enable kinase activity to be 
predicted. Proteins, which lack one or more of these crucial sites, are 
described as pseudokinases and interestingly make up around 10% of the 
human kinome [14].  
 
 
Figure 1.1 Protein phosphorylation and its effects on target proteins 
(A) Protein kinases catalyse the transfer of the γ-phosphate of ATP onto 
target Ser, Thr and Tyr residues in proteins. This action is reversed by 
protein phosphatases. (B) Protein phosphorylation can cause a 
conformational change within a protein that can function to regulate its 
enzymatic activity, stability, sub-cellular localisation and interaction with other 
proteins.   
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1.2.2 Protein ubiquitylation 
Ubiquitylation is another form of PTM and involves the attachment of a 
small, highly conserved, highly stable protein (ubiquitin (Ub)) onto other 
proteins. The 76 amino acid protein was first identified in 1975 as a free 
ubiquitous immunopoietic polypeptide [15]. In mammals four distinct genes 
encode for it, but there is no discernable difference between monomers at the 
protein sequence level. The first evidence for the ubiquitylation of a protein 
was uncovered in the late 1970s [16,17] when it was found that ubiquitin is 
covalently attached to proteins before their subsequent degradation by the 
26S proteasome [18,19]. Since this discovery, ubiquitylation has been found 
to be involved in many cellular processes. Moreover, several ubiquitin-like 
modifiers have been identified which share structural homology with ubiquitin 
and are also involved in signal transduction pathways [20].  
1.2.2.1 Ubiquitylation 
Ubiquitin is attached to proteins by the process of ubiquitylation. It is 
initiated by the actions of a ubiquitin-activating enzyme (E1) which forms a 
thioester bond between its active site cysteine residue and the C-terminal 
glycine of ubiquitin, in an ATP-dependent manner (Fig. 1.2).  The active 
ubiquitin intermediate is then transferred to the active site cysteine of an 
ubiquitin-conjugating (E2) enzyme. Finally, a ubiquitin-ligase (E3), which binds 
both the substrate to be ubiquitylated and the E2, facilitates the conjugation of 
the C-terminal glycine of ubiquitin to the ε-amino group of lysine on the 
substrate. Ubiquitylation, much like phosphorylation, can regulate proteins in 
many different ways by either promoting a conformational change and/or 
permitting their association with one or more ubiquitin binding proteins.  
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Figure 1.2 An overview of protein ubiquitylation 
The ubiquitylation of a protein is a multi-step process. Ubiquitin (Ub) is first 
activated when a thioester bond is formed between its C-terminus and the 
active site cysteine of an E1-activating enzyme in an ATP-dependent 
manner. The activated ubiquitin is then transferred onto the active site 
cysteine of an E2-conjugating enzyme. The E2~Ub then interacts with a 
RING (really interesting new gene) E3 ligase which facilitates the transfer 
of ubiquitin onto the target lysine residue. In the case of HECT 
(homologous to E6-AP C-terminus) and RBR (RING between RING) E3 
ligases, the ubiquitin is first transferred from the E2 onto the active site 
cysteine of the E3 before it is directed to form an isopeptide bond with the 
target lysine. This process can be reversed by the actions of 
deubiquitylases (DUBs).  
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1.2.2.2 E1 activating enzymes, E2 conjugating enzymes and E3 ligases 
There are only two E1 enzymes encoded by the human genome which 
share 40% amino acid sequence homology and are thought to have both 
overlapping and distinct roles [21]. In contrast, over 40 E2s have been 
identified in humans [22,23] and they add a layer of specificity to the system 
by performing specific biological roles and by interacting with different E3 
ligases. The most diverse group of enzymes by far are the E3 ligases, of 
which there are at least 600 members [24]. E3s confer the greatest selectivity 
to the system as they dictate which substrate(s) is to be ubiquitylated. E3 
ligases can be further divided into three groups based on their catalytic 
domains. The most abundant group are the RING (really interesting new 
gene) E3 ligases, which compromise over 90%. The RING domain comprises 
arrays of cysteine and histidine residues that interact with two zinc ions to 
stabilise its overall structure. Although it does not have a catalytic centre, the 
RING domain forms a bridge between the E2 and the target substrate to 
enable ubiquitin transfer on to the lysine residue [25]. In contrast, HECT 
(homologous to E6-AP C-terminus) E3s contain a catalytic cysteine onto 
which the activated ubiquitin monomer is passed from the E2 enzyme before it 
is transferred onto the target [26]. The final group is composed of RBR (RING-
between-RING) E3s that are thought to be a hybrid of RING and HECT E3 
ligases. The E2 interacts with the RING1 domain, while a catalytic cysteine on 
the RING2 accepts the activated ubiquitin [27]. E1s and E2s are thought to be 
constitutively active, but E3 ligase activity is tightly regulated by PTMs and by 
transcription. The E3 ligase Pellino1, for example, becomes phosphorylated 
after cells are stimulated with a specific agonist, converting Pellino1 from an 
inactive to an active E3 ligase [28,29].  
1.2.2.3 Different forms of ubiquitylation 
Different combinations of E2s and E3s enable the ubiquitylation of a 
vast array of proteins and, in fact, ubiquitin signalling is further diversified by 
the array of forms it can take. Proteins can become either monoubiquitylated 
at a single lysine residue or may be subject to multi-monoubiquitylation at 
several lysine residues (Fig. 1.3). Moreover, ubiquitin itself contains seven 
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internal lysines (K6, K11, K27, K29, K33, K48 and K63) which are all able to 
serve as the final acceptor of activated ubiquitin, leading to the formation of 
ubiquitin chains. Furthermore, the α-amino group on the N-terminal 
methionine of ubiquitin can form an isopeptide bond with the C-terminal 
glycine of another ubiquitin molecule, generating Met1-linked (M1, also known 
as linear) Ub chains. The length of chain can vary quite considerably and this 
incorporates further information to specify the type of response elicited 
[30,31]. In cells, each type of polyubiquitin chain has been identified and their 
crystal structures have revealed structurally diverse topology (Fig. 1.3) [32–
35]. The most investigated forms of ubiquitin chain are those formed by M1, 
K11, K48 and K63 linkages and they have all been found to trigger distinct 
biological outcomes. The canonical and most abundant form in cells is K48-
linked ubiquitylation [32,36]. These ubiquitin chains form a compact structure 
and function to target proteins to the proteasome where the 19S subunit 
recognises the K48 ubiquitin chain, enabling the protein to be degraded by the 
catalytic 20S core [37,38]. K11 ubiquitin chains share structural similarity to 
K48 ubiquitin chains and also aid the shuttling of proteins to the proteasome 
[39,40]. However, ubiquitin chains are not limited to the proteolytic pathway. In 
contrast to K48/K11-Ub chains, K63 and M1-Ub chains have a much more 
open and extended conformation and are a key component of signalling 
pathways of the innate immune and DNA repair systems. Though little is 
currently known about other linkages, tools were recently developed to further 
study K29 and K33-Ub chains [41,42] and with increasing research conducted 
in this area the roles of these atypical chains should be elucidated in the 
future. Initially, it was assumed that ubiquitin chains were composed of a 
single type of linkage. However, it has recently been discovered that chains 
can be formed from heterogeneous linkages [43,44]. This further 
demonstrates the diverse nature of ubiquitin signalling as it allows the 
integration of multiple inputs to synchronise the control of biochemical 
processes. 
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Figure 1.3 Different forms of ubiquitylation 
(A) Proteins can be ubiquitylated with a single ubiquitin (Ub) to a single 
lysine residue (monoubiquitylation) or ubiquitylated at several lysines with 
a single Ub (multi-monoubiquitylation). Moreover, proteins can become 
covalently modified with Ub chains that are homogeneous or hybrids. 
Furthermore, Ub chains than are not covalently attached to a protein 
(unanchored) have also been identified in cells. (B) Structure of the small 
76-residue protein, ubiquitin. All seven lysines and the first methionine are 
indicated. These residues are able to form bonds with other ubiquitin 
molecules to generate Ub chains. The hydrophobic patch (Ile44) indicated 
is important for interaction with ubiquitin-binding proteins. Adapted from 
[45]. (C) A representation of the different topologies of Ub chains. K48-Ub 
chains form compact structures, whereas M1-Ub chains have a more open 
and extended conformation. Protein domains that bind specifically to a 
single type of Ub linkage have been identified [46]. 
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1.2.2.4 Deubiquitylation 
The cleavage of the isopeptide bond between ubiquitin and the target 
protein or another ubiquitin molecule is catalysed by deubiquitylating enzymes 
(DUBs). There are nearly 100 DUBs in the human genome that oppose the 
actions of E3 ligases [47]. It is the relative activities of DUBs and E3 ligases 
that determines the steady state level of ubiquitylation of a protein in cells [48]. 
In addition to their catalytic core, DUBs contain other domains that permit their 
regulation and the specific recognition of their substrate(s) [49]. Therefore 
some DUBs are able to hydrolyse all types of ubiquitin chains whereas other 
DUBs are specific for a single type of ubiquitin chain. For example, Otulin 
(also known as FAM105B and Gumby) hydrolyses M1-Ub chains specifically 
[50–52]. Antibodies that are only able to recognise a single ubiquitin linkage 
and DUBs that can only disassemble a specific ubiquitin chain have greatly 
aided our understanding of the regulation of signalling pathways by ubiquitin 
chains [40,53,54].  
1.2.2.5 Reading the ubiquitin ‘code’ 
Ubiquitin chains are recognised by proteins containing ubiquitin-binding 
domains (UBDs). To date, 20 different families of UBD have been identified 
that are structurally distinct and differ in the types of ubiquitin modification that 
they recognise [55].  These domains ‘read’ the ubiquitin signal by interacting 
with ubiquitin non-covalently. The archetypal UBD employs α-helices to 
interact with a hydrophobic β-sheet patch around Ile44 of ubiquitin (Fig. 1.3). 
The majority of UBDs interact with monomeric ubiquitin with surprisingly low 
affinity (0.1-1 mM) [56], but this is likely to be a device for preventing non-
specific binding to ubiquitin, whose intracellular concentration is ~85 µM [36]. 
Typically, to achieve high-affinity binding, multiple low-affinity interactions are 
required which also enables controlled signal progression.  
Many UBDs are able to discriminate between different ubiquitin chain 
topologies (Fig. 1.3). Two examples are the TAB2 (TAK1-binding protein 2) 
and TAB3 proteins that form complexes with the protein kinase TAK1 
(transforming growth factor-β-activated kinase 1). They both contain a Nlp4 
zinc finger (NZF) at their C-termini that are able to specifically bind two 
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ubiquitins conjugated by a K63-linkage [57]. It is clear that the ubiquitin ‘code’ 
is complex and the detailed information it contains needs to be deciphered by 
a multitude of protein UBDs.  
1.2.3 The interplay between protein phosphorylation and ubiquitylation 
In many signalling pathways, proteins will be regulated by both 
reversible phosphorylation and ubiquitylation, greatly increasing the potential 
of the system for regulation and signal integration. The recent discovery that 
ubiquitin itself can undergo phosphorylation by the protein kinase PINK1 
(PTEN-induced putative kinase 1) and that phosphoubiquitin is an allosteric 
activator of the E3 ligase PARKIN, is a wonderful example of how 
phosphorylation and ubiquitylation can operate synergistically with one 
another [58–60].  
1.3 The innate immune system 
The innate immune system is often referred to as the first line of defence 
against infection. However, it is important to remember that epithelial cells 
function as a physical barrier and protect the body from the daily assault of 
environmental bacteria. They also help keep surfaces free from pathogens 
through the substances they secrete or by simply shedding off [61]. 
Importantly, epithelial cells are able to alert the innate immune system to 
breaches in their defences by the secretion of chemotactic signals. The innate 
immune system reacts within minutes of detecting non-self material or to 
mechanical damage of self-cells by activating signalling networks with the 
ultimate goal of removing the infection. This is achieved by the process of 
inflammation, which displays clinical symptoms of redness, swelling, heat and 
pain. Inflammatory mediators promote the dilation of blood vessels and an 
increased permeability of capillaries, causing greater blood flow and fluid entry 
into infected tissues. Direct immune cell activation induces an up-regulation of 
adhesion molecule expression that promotes their migration and retention at 
infected sites [62]. Cytokines that circulate to the central nervous system are 
able to stimulate the release of prostaglandins, which act on the 
hypothalamus to induce fever.  Temperature increase is beneficial to immunity 
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as it can reduce the growth rate of some pathogens or make them more 
susceptible to immune cell attack [63,64]. Pain is a result of the mechanical 
pressure elicited on nerve cells as a result of swelling and sensitivity is 
increased through the release of cyclooxygenase type 2 and phospholipase A 
enzymes [65].  Inflammation is the coordinated process that enables the body 
to rapidly attack invading pathogens, whilst also activating the longer-term 
adaptive immune response.  
1.3.1 Cellular mediators of the innate immune response 
To eliminate pathogenic infection, the immune system requires 
specialised white blood cells, known collectively as leukocytes. These cells 
originate from the bone marrow as pluripotent stem cells and differentiate into 
myeloid and lymphoid progenitor cells, which, for the most part, form cells of 
the innate and adaptive immune system respectively. Macrophages are 
stationed in the tissues, waiting to attack any microbial pathogens that break 
through the physical endothelial barrier. Using specialised receptors, 
macrophages are able to detect and engulf invading microorganisms through 
the process of phagocytosis. Within the macrophage, the pathogen is 
bombarded with proteases, antimicrobial peptides and reactive oxygen 
species, leading to its destruction [66]. Additionally, macrophages release a 
mixture of proinflammatory cytokines and chemokines, causing the activation 
and recruitment of granulocytes, a class of innate immune cells, to sites of 
infection. Neutrophils and monocytes, circulating within the bloodstream, are 
some of the first cells to migrate into the tissues. Monocytes differentiate into 
macrophages and neutrophils are also actively phagocytic, aiding 
macrophages in the clearance of pathogens. To further prevent the spread of 
infection, neutrophils secrete fibres, chiefly compromised of their own 
chromatin, which traps pathogens and slows their migration [67]. In 
comparison to macrophages, neutrophils are relatively short-lived cells, 
unable to withstand their own assault on internalised pathogens and are 
themselves engulfed by macrophages [66]. Some pathogens, such as 
parasites, are too large to ingest and instead, macrophages, neutrophils and 
eosinophils, another phagocytic granulocyte, release their lysosomal contents 
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into the extracellular space after binding the microorganism, causing its 
destruction. Other less abundant cells, such as basophils, secrete histamine 
upon pathogenic detection, causing capillaries to dilate, aiding the infiltration 
of innate immune cells from the blood to the tissues [66]. Innate immune 
eradication of virus-infected cells is largely dependent on activities of natural 
killer cells. These cytotoxic lymphocytes bind directly to the infected cell and 
release toxins that initiate the process of apoptosis, destroying both the cell 
and the internalised virons [68]. The secretion of cytokines by activated innate 
immune cells aids the activation of cells of the adaptive immune system. 
Dendritic cells further bridge the gap between innate and adaptive immunity. 
Much like macrophages, dendritic cells are present mainly in the tissues and 
engulf pathogens upon receptor recognition. However, following this they 
migrate into the lymph nodes where they present the antigen to T-cells, 
initiating T-cell activation. Adaptive immunity is largely mediated by B and T-
cells, which are differentiated from lymphocytes. T-cells are able to recognise 
specific antigens and can initiate the destruction of the infected cells or signal 
to other cells to destroy the pathogen. Activated T-helper cells then promote 
the activation of B-cells, which enable the production and secretion of 
antibodies specific to the invading microorganism. Antibodies then bind to 
their target regions on a pathogen and help recruit phagocytic cells, which 
then engulf the antibody-coated pathogen [66].  
1.3.2 The TLR superfamily of proteins 
The innate immune system is often thought of as a generic defence 
mechanism, but it has developed some highly specialised abilities to adapt to 
constantly evolving forms of pathogenic attack. One of the most important 
functions it evolved was the capability to detect highly conserved pathogenic 
components (pattern associated molecular patterns (PAMPs)) that are both 
essential for pathogenic survival and not present within the host [69]. 
Detection of PAMPs is conferred by pattern recognition receptors (PRRs) 
which include Toll-like receptors (TLRs), NOD-like receptors (NLR), RIG 
(retinoic acid-inducible gene-1)-I-like receptors and C-type Lectin receptors 
[70]. PRRs are extremely important components of the innate immune system 
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and are found in almost every multicellular organism, including plants [71]. 
The superfamily of PRRs has evolved to recognise specific sequences found 
on bacteria, viruses, parasites, fungi and even endogenous molecules 
released from damaged cells (damage-associated molecular patterns 
(DAMPs)). Though each PRR activates a set of common components to 
promote the expression and release of inflammatory mediators, such as 
interleukin-1 (IL-1), the eventual outcome of ligand binding is cell dependent 
and tailored to the pathogen. For instance, TLR9 activation in macrophages 
promotes an anti-inflammatory response whereas in dendritic cells (DCs), 
TLR9 stimulation leads to the robust secretion of proinflammatory cytokines 
[72]. In contrast, TLR2 signalling in DCs causes the release of equivalent 
levels of proinflammatory and anti-inflammatory cytokines [73].   
1.3.2.1 The TLR and IL-1R families  
TLRs are one of the most well characterised and evolutionarily 
conserved sets of PRRs able to detect exogenous and endogenous 
pathogenic material. They were initially identified in Drosophila melanogaster 
and were later found to be required for antifungal resistance [74]. They are 
widely expressed on immune and epithelial cells. Ten have been identified in 
humans, whilst 12 are present in mice. Through mouse knock-out (KO) 
studies it was found that each TLR is responsible for responding to specific 
sets of pathogenic markers, demonstrating a degree of specificity [75]. TLRs 
are expressed on either the plasma membrane (TLR1, 2, 4, 5, 6 and 11), 
where they detect components of extracellular microorganisms, or on 
intracellular vesicles (TLR3, 7, 8 and 9), which bind to pathogenic nucleic 
acids, mainly from viruses, to alert the host cell to infection. The 
superstructure of a TLR consists of an extracellular ligand-binding domain, a 
transmembrane domain and a cytoplasmic signalling domain. TLRs function 
as homo/heterodimers which helps to diversify their range of ligand 
recognition [76]. All TLRs have tandem copies of leucine-rich repeats (LRRs) 
at their N-termini which together form a horseshoe structure essential for 
ligand binding. Residues other than leucine in the LRRs are highly variable 
and this enables a broad spectrum of antigens to be recognised [77]. The 
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cytoplasmic region however, is highly conserved and encompasses the 
Toll/interleukin-1 receptor (TIR) domain, which is also found in the receptors 
for IL-1, IL-18 and IL-33. As TLRs do not possess intrinsic catalytic activity 
they rely on signalling adaptors, which also contain TIR domains to propagate 
signalling.  
1.3.2.2 The IL-1R and IL-1 
The activation of TLRs and other PRRs in general, leads to the release 
of IL-1. This cytokine has been studied intensely for decades and although 
expression of its receptor is not ubiquitous [78], IL-1 has been shown to 
directly or indirectly affect almost all cells of the body [79]. The IL-1 family is 
composed of 11 cytokines which all possess a highly conserved gene 
structure and signal through a group of closely related receptors [79]. The IL-
1R type I (IL-1R1) is recognised by three members of the IL-1 family of 
cytokines, namely IL-1α, IL-1β and the IL-1R antagonist, which binds in a non-
productive manner. Large amounts of IL-1β are secreted from cells during 
inflammation and this is a major mediator of the systemic effects of IL-1. In 
contrast, IL-1α is not secreted during inflammation but rather is retained in the 
cytosol or membrane of a cell and only released when cells rupture as a result 
of necrosis or mechanical forces [79]. Unlike the IL-1α precursor, the IL-1β 
pro-protein is not active and must be cleaved before it is released. The 
processing of IL-1β into its active form is carried out by a large multiprotein 
complex called the NLRP3 (NLR-, LRR- and pyrin-containing protein-3) 
inflammasome [80,81]. This complex consists of the NLR protein NLRP3, the 
adaptor ASC and caspase-1, a protease responsible for processing pro-IL-1β 
into its active form. Caspase-1 also exists as an inactive pre-cursor and must 
first be cleaved by the inflammasome to become active. The activation of the 
NLRP3 complex is thought to require two distinct signals, the first is conveyed 
via TLR/IL-1R signalling and the second is through the sensing of DAMPs that 
include free ATP, uric acid and the debris from dying cells [82]. These two 
checkpoints help to prevent aberrant release of IL-1β from cells, thereby 
reducing the likelihood of deregulated immune signalling.  Like TLRs, the IL-
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1R family all contain intracellular TIR domains essential for signal 
propagation. However, unlike TLRs, their extracellular domains are composed 
of three immunoglobulin-like folds. Binding of IL-1α/β to the IL-1R1 initiates 
the recruitment of the IL-1R accessory protein (IL-1RAcP), leading to the 
formation of heterodimeric complex [83,84]. Although the IL-1RAcP is unable 
to bind IL-1, the association of the TIR domains of the IL-1R1-IL-1RAcP 
complex induces the recruitment of the signalling adaptor MyD88 (myeloid 
differentiation primary response gene 88), initiating a signalling cascade (Fig. 
1.4). IL-1α/β also bind to the IL-1R type 2 (IL-1R2), however, this functions as 
a decoy receptor as it is unable to recruit MyD88 due to the lack of a TIR 
domain. It may therefore help to dampen signalling [79].  
1.3.2.3 TIR adaptor proteins 
TLRs and the IL-1R contain TIR domains within their intracellular 
regions that are crucial for signal transduction. Ligand binding induces 
conformational changes within receptor TIR domains, permitting the 
recruitment of TIR domain-containing signalling adaptors. Five of these 
adaptors have been identified so far, namely MyD88, MAL (MyD88 adaptor-
like), TRIF (TIR-domain-containing adaptor protein inducing interferon-β (IFN-
β)),  TRAM (TRIF-related adaptor molecule) and SARM (sterile α- and 
HEAT/armadillo containing protein) [85]. A unifying feature of all TLRs, bar 
TLR3, is that they can utilise MyD88 to transmit signals. TLRs also function 
with the other four TIR adaptors to promote the activation of different aspects 
of the immune response. In contrast, The IL-1R only uses MyD88. MyD88 and 
MAL are primarily responsible for the induction of proinflammatory cytokines, 
whereas TRIF and TRAM are required for the generation of IFNs. Though not 
much is known about the function of SARM, it has been proposed to function 
as a negative regulator of TRIF and MyD88-dependent signalling [86,87].  
1.3.3 The MyD88-dependent signalling network 
The IL-1R and almost all TLRs signal through the adaptor MyD88, 
causing the same network of proteins to become activated. The function of 
this signalling cascade is to promote the production and release of 
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proinflammatory and anti-inflammatory molecules. These innate immune 
mediators aid the removal of the pathogen and also help terminate the 
immune response once the infection is resolved. The production of 
proinflammatory cytokines is achieved through the activation of master 
transcription factors, such as NF-κB (nuclear factor κB) and IRF5 (IFN 
regulatory factor 5) [88–90], which translocate into the nucleus and cause the 
transcription of genes encoding proinflammatory cytokines. In contrast, the 
production of anti-inflammatory molecules, such as IL-10, is achieved through 
the activation of the transcription factor CREB (cAMP response element-
binding protein). Although these processes takes several hours, a plethora of 
ubiquitylation and phosphorylation events takes place within minutes of 
receptor engagement by ligands. It is how these early signalling events are 
triggered that is the topic of this Thesis.  
 Mice that lack MyD88 are protected against endotoxic shock and are 
unresponsive to IL-1, demonstrating the importance of MyD88 in conveying 
signals from the IL-1R and TLRs [91,92]. Moreover, the loss of other 
components of the MyD88 signalling network has been shown to severely 
compromise innate immune functions in humans and mice (Table 1.1).  In 
contrast, chronic inflammatory conditions are often associated with the 
development of lymphomas [93], a collection of cancers caused by the 
abnormal growth of B- and T-cell lymphocytes. More recently, an activating 
mutation of MyD88 was found to be responsible for 30% of cases of an 
aggressive form of diffuse large B-cell lymphoma [5] (Fig. 1.4). Clearly, it is 
apparent that the MyD88-dependent signalling network must be tightly 
regulated.  
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Table 1.1 Consequences of mutations that affect components of 
the MyD88 signalling network 
 
Genetic defect Molecular defect Species Phenotype Study 
MyD88 
deficiency 
Failure to activate 
NF-κB 
Human Immunodeficiency – 
susceptibility to 
pyogenic bacterial 
infections  
[94] [95][96] 
MyD88 KO Failure to activate 
NF-κB 
Mouse Immunodeficiency - 
susceptibility to 
pyogenic bacterial 
infections 
[91,97] 
IRAK4 
deficiency 
Failure to activate 
NF-κB 
Human Immunodeficiency - 
susceptibility to 
pyogenic bacterial 
infections  
[98] [95] 
IRAK4 KO / 
kinase inactive 
knock-in 
Severely impaired 
activation of NF-κB 
Mouse Immunodeficiency - 
susceptibility to 
pyogenic bacterial 
infections 
[99–102] 
IκBα[S32I] Impaired 
degradation of 
IκBα due to 
mutation of IKKβ 
phosphorylation 
site 
Human Anhidrotic ectodermal 
dysplasia with 
immunodeficiency 
(EID-ID) 
[103] 
NEMO[D311N] 
NEMO[D311G] 
Unable to interact 
with M1/K63-Ub 
chains 
Human Anhidrotic ectodermal 
dysplasia with 
immunodeficiency 
(EID-ID) 
[1,104] 
NEMO[D311N] Unable to interact 
with M1/K63-Ub 
chains 
Mouse Severely impaired 
activation of the 
canonical IKK 
complex 
[105] 
HOIP 
deficiency 
Loss of M1-Ub 
chain formation 
and impaired IKK 
activation 
Human Immunodeficiency  [106] 
HOIP[C879S] 
knock-in 
Loss of M1-Ub 
chain formation 
and impaired IKK 
activation 
Mouse  Embryonic lethal [43,105] 
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Figure 1.4 Domain structure of MyD88 
MyD88 contains an N-terminal death domain (DD), which aids its 
oligomerisation with other DD-containing proteins, such as the IRAKs, 
promoting Myddosome formation. The C-terminus contains a TIR domain, 
enabling interaction with the TIR domains of the IL-1R and almost all of the 
TLRs. A activating mutation within the TIR domain is indicated, and is 
thought to drive the development of B-cell lymphomas [5]. 
 
 
1.3.3.1 The formation of the Myddosome 
MyD88 binding to the TLRs/IL-1Rs promotes the recruitment of kinases 
of the IRAK (IL-1R-associated kinases) family that interact with MyD88 via 
their reciprocal death domains (DD) (Fig. 1.4). It is thought that IRAK4 is the 
first to associate with MyD88, which is reported to induce its oligomerisation 
and activation [107–109]. This is followed by the recruitment of IRAKs 1 and 2 
to the multi-component complex, termed the Myddosome, which in turn, aids 
the recruitment and activation of ‘downstream’ protein kinases and E3 ligases 
(Fig. 1.5) [109].  
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Figure 1.5 An overview of how the MyD88 signalling network 
induces the transcription of proinflammatory cytokines 
IL-1 binding to the IL-1R or LPS (lipopolysaccharide) binding to TLR4, 
induces Myddosome formation [110], leading to the generation of K63-Ub 
and M1-Ub chains by E3 ligases. This results in the activation of the TAK1 
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complex and the canonical IKK complex which then promote the activation 
of a vast array of protein kinases and master transcription factors such as 
AP-1 (activator protein 1), IRF5 and NF-κB (p50/p65). These networks 
control the transcription of genes encoding proinflammatory cytokines, 
their translation into proteins and their secretion from the cell.  ERK 
(extracellular signal-related kinase), JNK (c-Jun N-terminal kinase), 
LUBAC (linear ubiquitin assembly complex), MEK (MAP kinase/ERK 
kinase), MK2 (MAP kinase-activated protein kinase 2), MKK (MAP kinase 
kinase), NEMO (NF-κB essential modulator) and TPL-2 (tumour 
progression locus 2). The phosphorylation of a protein is indicated by P, 
without signifying the number of phosphorylation sites. 
1.3.4 The IRAK family of protein kinases 
The IRAKs comprise four family members in mammals: IRAK1, IRAK2, 
IRAK3 (also called IRAKM) and IRAK4. Although sharing only 30-40% 
sequence homology they have highly conserved domain structures (Fig. 1.5) 
[111]. Each IRAK contains a N-terminal DD, which facilitates its interaction 
with MyD88 and other DD-containing proteins [89]. This is followed by a 
proline/serine/threonine (PST) rich domain where the multisite 
phosphorylation of the IRAKs is thought to take place (Fig. 1.6) [90]. IRAKs 2 
and 3 lack an aspartic acid in the DFG motif as well as other amino acid 
residues required for catalysis (Section 1.2.1.1), and are thought to be 
catalytically inactive ‘pseudokinases’. Consistent with this, IRAKs 2 and 3 
show negligible kinase activity when over-expressed in cells [114]. The C-
terminal domains of IRAKs 1, 2 and 3 contain Pro-X-Glu motifs that permit 
their interaction with TRAF6 (tumour necrosis factor (TNF) receptor-
associated factor 6), promoting the recruitment of TRAF6 to the Myddosome 
[110,115].  
1.3.4.1 IRAK4 
The importance of both the expression and kinase catalytic activity of 
IRAK4 was demonstrated using mice in which IRAK4 was knocked-out (KO) 
or replaced by a kinase-inactive (KI) mutant. Firstly, like MyD88 KO mice [91], 
these mice displayed complete resistance to LPS-induced septic shock 
[99,101]. Secondly, in cells isolated from IRAK4 KO and KI mice, the 
activation of MAP (mitogen-activated protein) kinases and the canonical IKK 
 21 
(IκB kinase) complex was severely diminished in response to stimulation with 
either TLR agonists or IL-1 [99–101]. IRAK4 is thought to become activated by 
a process of trans-autophosphorylation, when it oligomerises upon interaction 
with MyD88 [107,116]. However, an unexpected observation made recently by 
the Cohen laboratory was that IRAK4 immunoprecipitated from cells was 
active even when cells had not been stimulated with IL-1. Moreover, its kinase 
activity was not increased further when the MyD88 signalling network was 
activated (S. Vollmer, unpublished results). The autophosphorylation of IRAK4 
therefore appears to be a consequence of its oligomerisation and not the 
cause of activation.  
The essential role of IRAK4 for human innate immunity has been 
demonstrated by the serious consequences for individuals who lack it. From 
birth, these patients are given antibiotics and yet 50% still die before the age 
of eight due to recurrent pyogenic bacterial infections [95,98]. Very similar 
complications are observed in individuals who lack expression of MyD88 
[94,96].   Interestingly, during adolescence these patients begin to show an 
improved prognosis and normal resistance to pathogenic attack [95,98].  
1.3.4.2 IRAK1 
Bone marrow derived macrophages (BMDMs) isolated from mice in 
which IRAK1 is replaced with a catalytically inactive mutant have shown that 
IRAK1 catalytic activity is not required for the activation of the canonical IKK 
complex, MAP kinases and the release of proinflammatory cytokines [117]. In 
contrast, the kinase activity of IRAK1 is essential for the production of IFNβ in 
plasmacytoid dendritic cells (pDCs) in response to activation of TLR7, 8 and 
9, demonstrating that is has cell-specific functions. [117,118].  However, 
BMDMs and mouse embryonic fibroblasts (MEFs) from IRAK1 KO mice 
display reduced signalling and impaired release of inflammatory cytokines 
[119–121]. This suggests that the non-catalytic domains of IRAK1 have 
important scaffolding roles and, perhaps, its kinase activity functions 
redundantly with another protein kinase in BMDMs.  
It is not clear how IRAK1 becomes activated when it is recruited to the 
Myddosome, but one mechanism that has been proposed it that its 
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oligomerisation prompts it to autophosphorylate at Thr209, which is required 
for its activation in vitro [122]. Although IRAK1 associates with TRAF6 in vitro, 
the importance of this interaction for the activation of the IKKs and MAP 
kinases has not yet been established by genetic experiments [115].  
1.3.4.3 IRAK2 
 Though IRAK2 is unlikely to function as a kinase, its ability to interact 
with TRAF6 is critical for the MyD88-dependent production of proinflammatory 
cytokines in mice. BMDMs isolated from mice in which IRAK2 was replaced 
by the IRAK2[E525A] mutant, which cannot interact with TRAF6, displayed no 
defect in the early phase of MyD88-dependent signalling (0-2 h) [117]. 
However, the production of mRNAs encoding proinflammatory cytokines, and 
hence their secretion, was severely impaired during the late phase of 
signalling (2-8 h) [117]. One possible explanation for this finding is that during 
the early phase of signalling IRAK2 may operate redundantly with IRAK1, 
whilst during the late phase the IRAK2-TRAF6 interaction becomes rate-
limiting for signalling. This is because IRAK1 is largely degraded 2-4 h after 
the initial activation of the MyD88 signalling network [117]. Similar 
observations have also been made in IRAK2 KO cells [123].  
1.3.4.4 IRAK3 
IRAK3, another pseudokinase, is the least investigated IRAK family 
member. Its expression is thought to be restricted to monocytes, whereas the 
expression of the other IRAKs is essentially ubiquitous [111]. BMDMs isolated 
from IRAK3 KO mice displayed enhanced inflammatory cytokine secretion in 
response to TLR stimulation, suggesting that IRAK3 negatively regulates the 
signalling network. It has been suggested that IRAK3 sequesters TRAF6, 
preventing it from interacting with IRAK1 and IRAK2. However, it has also 
been suggested that IRAK3 may function to promote the expression of genes 
that limit signalling [124,125].   
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Figure 1.6 Domain organisation of the IRAK family of protein 
kinases 
The IRAKs each contain an N-terminal DD which enables oligomerisation 
with MyD88 and other IRAKs [110]. This is followed by a PST rich region, 
a kinase domain and a C-terminal (CT) domain that is important for 
interaction with TRAF6 [115,117]. IRAK4 lacks a CT domain and IRAK2 
and IRAK3 are thought to function as catalytically inactive pseudokinases 
[14] 
 
 
1.3.5 TRAF6 
The TRAF family of proteins were originally discovered through their 
interaction with the cytosolic regions of the TNF receptor [126]. To date six 
TRAF family members have been identified and they have all been found to 
share a characteristic domain structure (Fig. 1.7). They all possess a RING 
domain at their N-terminus, apart from TRAF1, which is followed by a variable 
number of zinc fingers, a coiled-coil TRAF-N domain and finally a β-sandwich 
TRAF-C domain [127]. The TRAF-C region is important for mediating protein-
protein interactions, while the RING domain is thought to confer E3 ligase 
activity. However, TRAF6 is the only member of the TRAFs that has been 
convincingly shown to possess E3 ligase activity [128,129]. Other TRAF 
family members are thought to mediate their functions by interacting with 
active E3 ligases. One such example is the formation a complex between 
TRAF2 and cIAP following cellular stimulation with TNF [130,131].  
TRAF6 was the first TRAF family member to evolve and the last to be 
identified in a homology screen where it was initially implicated in IL-1 signal 
transduction [132,133]. The generation of the TRAF6 KO mouse revealed that 
it was an essential component of all MyD88-dependent signalling networks 
but not the TNF pathway [134,135]. In vitro, TRAF6 forms a productive 
complex with the E2 enzyme complex Ubc13-Uev1a which directs the 
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formation of K63-Ub chains [128]. Ubc13 is an active E2 and Uev1a, although 
structurally resembling an E2, lacks a catalytic cysteine reside and is often 
referred to as a pseudo-E2. However, Ubc13 can only catalyse the formation 
of K63-Ub chains when it is complexed with Uev1a, which orientates the 
acceptor Ub so that its Lys63 residue is exposed to attack by Ubc13 
[136,137]. The interaction of Ubc13 with the RING domain of TRAF6 also 
requires contacts made by the first of the four zinc fingers of TRAF6 [129,138] 
(Fig. 1.7). Interestingly, TRAF6 is the only TRAF that is capable of interacting 
with Ubc13 in vitro as the residues that are critical for this interaction are 
absent in other TRAFs [129]. Later, it was concluded that the E3 ligase activity 
of TRAF6 was essential for its function, since wild-type (WT) TRAF6, but not 
E3 ligase defective mutants of TRAF6 could restore IL-1-dependent signalling 
to TRAF6 KO MEFs [139,140]. It is not clear how or whether TRAF6 is 
converted from an E3 ligase-inactive form in unstimulated cells to an active E3 
ligase upon TLR/IL-1R stimulation. However, it has been proposed that its 
oligomerisation, promoted by interaction with the IRAKs, may induce its 
activation [141,142]. Moreover, TRAF6 mutants that are unable to oligomerise 
in vitro, failed to restore IL-1 signalling to TRAF6 KO MEFs [129]. The 
ubiquitylation of TRAF6 has been assumed to result from autoubiquitylation 
and to be essential for signalling as the TRAF6[K124R] mutant was not 
ubiquitylated in cells and failed to restore IL-1 signalling to KO MEFs [139]. 
However, a later study demonstrated that a TRAF6 mutant, in which all 10 N-
terminal lysines were mutated to arginine, was able to robustly restore 
signalling in the absence of any TRAF6 ubiquitylation [140]. Thus, TRAF6 
ubiquitylation is not essential for signalling. The E3 ligase activity of TRAF6 is 
thought to be essential for the generation of K63-Ub chains, which then 
activate the TAK1 kinase complex.  
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Figure 1.7 The domain structure of the TRAF6 E3 ligase 
TRAF6 has an N-terminal RING domain and any of the three indicated 
point mutations destroy its E3 ligase activity. The RING domain is followed 
by four zinc-fingers (ZF). Interaction with Ubc13 involves contacts with ZF1 
and the RING domain [129]. The coiled-coil (CC) region enables self-
oligomerisation and the TRAF-C domain permits the interaction with 
IRAKs 1, 2 and 3 [115,129]. TRAFs 1-6 share a similar domain structure, 
with the exception of TRAF1, which lacks a RING domain. The mutations 
that inactivate the catalytic activity of TRAF6 are indicated. 
 
1.3.6 The TAK1 kinase complex 
TAK1 is a protein kinase that exists in a complex with TAB1, a 
regulatory component [143,144] and either TAB2 or TAB3 [145–147]. The C-
terminal NZF motifs of TAB2 and TAB3 bind to K63-Ub chains specifically 
(Fig. 1.5) [57], whereas TAB1 has not been reported to interact with ubiquitin 
oligomers. TRAF6-generated K63-Ub chains are able to activate the 
TAK1/TAB1/TAB2 complex in vitro [148–150]. This suggests that the 
interaction of K63-Ub chains with the TAB2/3 subunits induces a 
conformational change that permits TAK1 to auto-activate.  
The IL-1-stimulated activation of JNK1/2, p38 and the IKKs, and the 
secretion of the proinflammatory cytokine IL-6, was abolished in TAK1 KO 
MEFs or in MEFs expressing a truncated, catalytically inactive form of TAK1 
[151,152]. In addition, two structurally unrelated inhibitors of TAK1, 5Z-7-
Oxozeanol [153] and NG-25 [154], prevented the IL-1-stimulated activation of 
the canonical IKK complex and MAP kinases [153,154]. Moreover, in pDCs, 
both TAK1 inhibitors blocked the production of IFNα and IFNβ and IKK 
activation in response to TLR ligands that signal through MyD88 [155].  Taken 
together, these results indicate that TAK1 is a ‘master kinase’, essential for 
the activation of MAP kinases and the canonical IKK complex, within the 
MyD88 signalling network (Fig. 1.5). 
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1.3.7 The canonical IKK complex  
The canonical IKK complex is composed of two protein kinases, IKKα 
and IKKβ and a regulatory component, NEMO (NF-κB essential modulator, 
also known as IKKγ) (Fig. 1.8) [156,157]. The N-terminal region of NEMO is 
required for its dimerisation and interaction with IKKα/β [158]. It is followed by 
a coiled-coil region with an adjacent leucine zipper motif, which together form 
the UBD of NEMO. The UBD has also been termed the UBAN (UBD found in 
ABINs and NEMO) domain (Fig. 1.8) [159]. NEMO can interact with both K63-
Ub and M1-Ub chains in vitro, but shows a 100-fold greater affinity towards 
M1-Ub dimers over K63-Ub dimers [43,160]. It is therefore likely that NEMO 
binds preferentially to M1-Ub chains in cells (Fig. 1.5) [159,161].  The 
interaction of NEMO with ubiquitin chains has been proposed to induce a 
conformational change within the complex [149]. This may permit the co-
localised TAK1 complex to initiate the activation of the IKKs (Fig. 1.5) which is 
then completed by autophosphorylation [43,105]. IL-1 is unable to activate the 
IKK complex in MEFs from mice in which NEMO has been replaced with a 
mutant form, NEMO[D311N], that is unable to interact with K63-Ub or M1-Ub 
chains [105]. Moreover, individuals have been identified who suffer from a 
disease called anhidrotic ectodermal dysplasia with immunodeficiency (EDA-
ID). Their symptoms are thought to be caused by their expression of either the 
NEMO[D311N] or NEMO[D311G] mutations.  The latter mutation is also 
unable to interact with ubiquitin oligomers [104]. Taken together these findings 
demonstrate that the interaction of NEMO with ubiquitin chains is crucial for 
the activation of the canonical IKK complex by IL-1.  
IKKβ has multiple cellular targets, one of which is the NF-κB inhibitory protein, 
IκBα. The IKKβ-mediated phosphorylation of IκBα  leads to its recognition by 
the E3 ligase complex SCFβTrCP which catalyses its K48-linked ubiquitylation 
(Fig. 1.5) [162–164]. This leads to its subsequent degradation by the 
proteasome, allowing the NF-κB p65/p50 dimer to translocate into the nucleus 
and stimulate gene transcription. Another IKKβ substrate is p105, the inactive 
NF-κB p50 precursor. The phosphorylation of p105 triggers its processing by 
the proteasome and additionally, relieves its inhibition of the kinase TPL-2 
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(tumour progression locus 2). This then allows TPL-2 to initiate the activation 
of ERKs (extracellular signal-related kinase) 1 and 2 (Fig. 1.5) and regulate 
the processing of pre-TNFα into TNFα [165–167]. More recently, it was 
discovered that the IKKβ−catalysed phosphorylation of IRF5, a master 
transcription factor for proinflammatory cytokines, was crucial for its 
dimerisation and translocation into the nucleus (Fig. 1.5) [168,169]. The 
phosphorylation of the C-terminal inhibitory domain of IRF5 causes it to 
dimerise, allowing its entry into the nucleus to stimulate gene transcription 
[168,169]. In macrophages and conventional dendritic cells, IRF5 is essential 
for the production of IL-12, IL-6 and TNFα whereas in pDCs it is required for 
IFNβ gene transcription [90,170].  
 
 
 
 
 
Figure 1.8 Domain structure of NEMO and the canonical IKK 
complex 
NEMO contains an N-terminal coiled-coil region (CC1) that facilitates its 
dimerisation and interaction with IKKα and IKKβ. This is followed by 
another CC region with an adjacent leucine zipper (LZ) that collectively 
forms the UBAN domain, which binds M1-Ub chains. A point mutation of 
the UBAN domain that abolishes NEMO’s ability to interact with Ub chains 
is indicated. NEMO’s C-terminal NZF domain is thought to permit 
interaction with IκBα. The catalytic components, IKKα and IKKβ, contain 
kinase domains at their N-termini, which, in the case of IKKβ, is followed 
by a ubiquitin like domain (ULD) that is thought to modulate its kinase 
activity. The LZ domains of IKKα and IKKβ permit their homo- or 
heterodimerisation and the helix-loop-helix (HLH) domain is thought to 
function in regulating thier catalytic activity. The C-terminal domains of 
IKKα and IKKβ contain NEMO binding domains (NBD).  
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1.3.8 LUBAC 
In 2006 a large protein complex containing two proteins, termed HOIL-
1 (haem-oxidised IRP2 ubiquitin ligase-1) and HOIP (HOIL-1-interacting 
protein) was identified [171]. The authors made the surprising discovery that 
this complex was capable of catalysing the formation of M1-Ub chains in vitro 
and was therefore aptly named LUBAC (linear ubiquitin chain assembly 
complex) [171]. Subsequently it was found that Sharpin (SHANK-associated 
RH domain interactor) interacted with HOIP and in cells LUBAC was found to 
exist as a hetero-trimeric complex (Fig. 1.9) [43,172–174]. Although HOIP and 
HOIL-1 both contain RBR domains, only HOIP has been found to possess E3 
ligase activity [171,174]. It is also thought that HOIL-1 and Sharpin function to 
relieve HOIP auto-inhibition [175]. The RING1 domain of HOIP enables its 
association with ubiquitin-loaded E2, suggested to be UbcH7 (also known as 
Ube2L3) [176,177]. This allows a catalytic cysteine (C885) within the RING2 
domain to accept the activated ubiquitin from the E2, before it conjugates it to 
another ubiquitin molecule [178,179]. The IL-1-stimulated activation of the 
canonical IKK complex was drastically reduced in cells isolated from mice 
expressing an E3 ligase-inactive form of HOIP (HOIP[C879S]) [43,105]. This 
demonstrates that M1-Ub chains are required for robust activation of the IKKs 
within the MyD88 signalling network. Although LUBAC can use ubiquitin as a 
substrate in vitro to produce M1-Ub linkages [171], in the MyD88 signalling 
network LUBAC only uses pre-formed K63-Ub chains as a substrate onto 
which it attaches M1-Ub chains, generating hybrid K63/M1-Ub chains (Fig. 
1.4) [43].  Why this is the case is unknown and one of the topics of this 
Thesis.  
LUBAC that has been immunoprecipitated from cells displays robust 
E3 ligase activity. Perplexingly, the E3 ligase activity of LUBAC is not 
increased further by stimulation with IL-1R or TLR agonists, yet M1-Ub chain 
formation is only observed after stimulation with these ligands [43]. It therefore 
appears that LUBAC activity is not regulated by a stable covalent 
modification(s) and that M1-Ub chain formation is controlled in another way. 
The steady state levels of ubiquitin chain formation in cells reflect the activities 
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of E3 ligases and DUBs. It is therefore possible that the activation of the 
MyD88 pathway might induce the inactivation of one or more M1-Ub 
hydrolases. Otulin is a DUB that cleaves M1-Ub chains specifically and it was 
discovered that some of the Otulin in cells is tightly associated with LUBAC 
[50,51]. Moreover, the expression of a mutated form of Otulin, Otulin[W96R],  
was revealed in a genetic screen to identify the cause of embryonic lethality in 
a mouse model of disease [51].  In vitro, Otulin[W96R] had reduced DUB 
activity and higher basal levels of M1-Ub chains were observed in cells 
isolated from Otulin[W96R] embryos [51]. These findings implicate Otulin in 
the hydrolysis of M1-Ub chains in cells. However, at present it is unclear how 
or if the DUB activity of Otulin is regulated. Another DUB, CYLD 
(Cylindromatosis), was initially identified as a tumour suppressor [180] and 
was later found to be able to hydrolyse both K63-Ub and M1-Ub chains in 
vitro [35,52,181]. Moreover, CYLD binds to the same region of HOIP as Otulin 
(Fig. 1.9), suggesting that CYLD could potentially counteract the E3 ligase 
activity of LUBAC in cells when it associates with HOIP [182–184]. 
Additionally, CYLD has been reported to undergo phosphorylation when cells 
are stimulated with LPS, and this is thought to decrease its DUB activity [185], 
but whether inactivation is a cause or consequence of M1-Ub chain formation 
is unclear. The CYLD KO mouse is viable and displays autoimmune 
symptoms, implying that CYLD may negatively regulate immune signalling 
pathways [186]. However, whether the MyD88-dependent formation of M1-Ub 
chains is enhanced in cells from CYLD KO mice does not appear to have 
been investigated.  
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Figure 1.9 Domain structures of the three components of LUBAC 
The position of the catalytic cysteine 885 residue of HOIP is indicated and 
is essential for the formation of M1-Ub chains [178]. HOIP contains an 
PUB (peptide N-glycanase and ubiquitin-associated (UBA)- or UBX-
containing) domain that is required for its interaction with Otulin and CYLD 
[182,184]. This is followed by a ZF and two NZF motifs that may permit its 
association with K63-Ub oligomers [43]. The second NZF domain is 
important for interaction with Sharpin whereas its UBA domain is important 
for its interaction with HOIL-1. The N-terminal ubiquitin-like (UBL) domain 
of HOIL-1 interacts with HOIP and the NZF region is thought to bind to 
K63 and M1-Ub oligomers. Sharpin also contains a UBL domain that 
interacts with HOIP and a C-terminal NZF domain that may also interact 
with Ub oligomers [27].  
 
 
 
1.3.9 Pellinos 
Aspects of the MyD88-dependent immune signalling network are 
evolutionarily conserved from Drosophila to mammals [187]. A protein in 
Drosophila was identified as a binding partner of Pelle, an IRAK homologue, 
through a yeast two hybrid screen and was therefore termed Pellino [188]. 
Later it was found that a mutation of Pellino in Drosophila severely 
compromised the innate immune response of the fruit fly, suggesting it may 
function as a positive regulator [189]. In humans, three orthologues of 
Drosophila Pellino have been identified: Pellino1, Pellino2 and Pellino3, which 
share 80% sequence similarity [190–192].  The last mentioned is expressed 
as two alternatively spliced forms, Pellino3a and Pellino3b. Over-expression 
studies demonstrated that all Pellino isoforms interacted with one or more 
components of the MyD88-signalling network [190–192]. A bioinformatics 
investigation later identified a putative RING-like domain within the C-termini 
of the Pellinos (Fig. 1.8) [193]. Consistent with this, Pellinos display E3 ligase 
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activity in vitro with the Ubc13-Uev1a E2-conjugating complex and this can be 
enhanced enormously by phosphorylation with IRAK1 and IRAK4 in vitro 
[194,195]. Further structural analysis revealed the presence of a ‘cryptic’ FHA 
(forkhead-associated) domain formed by several disparate sections of the 
protein. The FHA domain is flanked by a ‘wing-like’ appendage composed of 
two inserts within the FHA homology domain (Fig. 1.8) [196]. This domain is 
thought to allow the Pellinos to interact with one or more phospho-threonine 
residues on IRAK1 to enable their phosphorylation by IRAK1.  
1.3.9.1 Pellino1 
The E3 ligase activity of Pellino1 can be activated in vitro following 
phosphorylation by IRAK1 or IRAK4 [28,195]. Ten sites of phosphorylation 
were identified on Pellino1 that were clustered around the ‘wing-like’ 
appendage and the region just N-terminal to the RING-like domain (Fig. 1.8) 
[28]. Moreover, the mutation of these phospho-sites to alanine prevented the 
IRAK1/IRAK4 catalysed activation of Pellino1 in vitro [28]. Furthermore, in 
response to IL-1 stimulation, the endogenous Pellino1 was converted from an 
inactive to an active E3 ligase [29]. This activation could be reversed by 
incubation of the Pellino1 immunoprecipitates with phage λ phosphatase, 
demonstrating that a phosphorylation event is required for its activation or 
interaction with Ubc13 [29]. IRAK1 is thought to mediate the IL-1-stimulated 
activation of Pellino1 as its E3 ligase activity is reduced in MEFs that express 
a catalytically inactive form of IRAK1 [29]. Additionally, the IL-1-dependent 
activation of Pellino1 can be prevented by a pharmacological inhibitor of 
IRAK1 that does not inhibit IRAK4 [29]. Studies with cells from Pellino1 KO 
mice demonstrated that Pellino1 was dispensable for the IL-1-stimulated 
activation of the canonical IKK complex and the release of proinflammatory 
cytokines [197]. However, in MEFs from mice expressing an E3 ligase-
inactive form of Pellino1 the IL-1-stimulated formation of K63-Ub chains was 
reduced by 50% (Alban Ordureau, Cohen group, unpublished data). This 
suggests that Pellino1 contributes to the generation of K63-Ub chains that are 
formed when the MyD88 signalling network is activated by IL-1.  
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1.3.9.2 Pellino2 
Pellino2 is assumed to function in much the same way as Pellino1, that 
is, its stimulation-dependent phosphorylation promotes activation of its E3 
ligase activity. However, the lack of a Pellino2 specific antibody has impeded 
detailed investigation of this specific isoform and its regulation. Over-
expression studies have demonstrated that when Pellino2 and IRAK1 are co-
expressed, Pellino2 becomes phosphorylated and IRAK1 becomes covalently 
modified with K63-Ub chains, presumably through the E3 ligase activity of the 
Pellino2 it has activated [195]. The phosphorylation of Pellino2 and the 
ubiquitylation of IRAK1 did not occur when wild type (WT) Pellino2 was co-
transfected with a KI mutant of IRAK1. Conversely, Pellino2 became 
phosphorylated but IRAK1 was not ubiquitylated when WT IRAK1 was co-
expressed with an E3 ligase-inactive mutant of Pellino2 [195]. Moreover, 
when the expression of Pellino2 was knocked-down in cells it was reported 
reduce the IL-1-induced activation of the canonical IKK complex and IRAK1 
ubiquitylation [198]. These studies have implicated Pellino2 in the regulation 
of the MyD88 signalling network by IL-1. 
1.3.9.3 Pellino3 
 Pellino3 has been reported to be phosphorylated and activated by 
IRAK1 and IRAK4 in vitro [195]. However, much like Pellino2, the lack of a 
specific antibody has prevented detailed characterisation of the endogenous 
protein and its regulation. It has been reported that Pellino3b acts as a 
negative regulator of the IL-1R pathway as its knock-down caused enhanced 
IL-1-stimulated activation of the IKK complex and MAP kinases [199]. Further 
evidence against Pellino3’s ability to positively regulate the IL-1 pathway 
came from a mouse expressing an E3 ligase-inactive mutant of Pellino3. 
MEFs from this mouse showed no defect in IL-1 signalling or formation of 
K63-Ub chains (Alban Ordureau, Cohen group, unpublished data). However, 
Pellino3 was recently found to function within the innate immune NOD2  
(nucleotide-binding oligomerisation domain-containing protein 2) signalling 
pathway, which is responsible for detecting cellular infection by bacteria 
[200,201]. Activation of NOD2, a cytoplasmic PRR, results in the recruitment 
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and ubiquitylation of the kinase RIP2 (receptor-interacting protein 2) with K63-
Ub chains. The K63-Ub chains formed after NOD2 activation are thought to 
promote the recruitment and activation of the TAK1 complex [201]. It was 
reported that following NOD2 activation, the formation of K63-Ub chains 
associated with RIP2 and the secretion of proinflammatory cytokines was 
impaired in Pellino3 KO BMDMs [200]. However, in BMDMs from mice 
expressing an E3 ligase inactive mutant of Pellino3, I found that the 
ubiquitylation of RIP2 and the activation of the canonical IKK complex and 
MAP kinases was enhanced (unpublished observations).  Taken together, 
these results indicate that Pellino3 may have a scaffolding role to permit the 
NOD2-induced formation of K63-Ub chains. It also suggests that the E3 ligase 
activity of Pellino3 may function, in part, to negatively regulate NOD2 
signalling.  
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Figure 1.10 Structural features of the Pellino1 E3 ligase 
(A) Pellino1 contains a cryptic FHA domain containing two inserts that 
form an anti-parallel β-sheet structure termed the ‘wing’ appendage. The 
wing and the region just N-terminal to the RING-like domain are 
phosphorylated (P) at several residues in vitro by IRAK1 [28]. All Pellinos 
share very similar structural characteristics. (B) A homology model of 
Pellino1 generated using PyMOL [202], based on the structure of the same 
region of Pellino2 [196]. The N-terminal IRAK1-catalysed phosphorylation 
sites are indicated in red and are all located within the ‘wing’ appendage 
[28]. 
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1.3.10 A brief overview of the signalling events that follow the activation 
of the TAK1 and canonical IKK complex   
TAK1 and the canonical IKK complex promote the activation of many 
other protein kinases and master transcription factors, such as AP-1 (activator 
protein 1), NF-κB and IRF5, which initiate the transcription of genes encoding 
proinflammatory cytokines (Fig. 1.4) [168,203]. The protein kinases activated 
by TAK1 and the IKKs also regulate the stability of cytokine mRNAs, their 
translation into protein and their processing into active forms. For example, 
the protein kinases MK2 (MAP kinase-activated protein kinase 2) and MK3 
are required for the translation of tnf mRNA, while the TPL-2-MEK1/2-ERK1/2 
pathway controls the proteolytic processing of pre-TNFα to its mature 
secreted form (Fig. 1.4) [167,204].  
1.3.11 How the activation of the MyD88 signalling network is restricted 
and terminated 
Activation of the MyD88 signalling network must be tightly controlled to 
prevent the deregulated production and release of inflammatory mediators. 
Kinases that are activated within the MyD88 signalling network to positively 
promote the production of proinflammatory cytokines also function to limit the 
strength of signalling. For example, in response to IL-1 stimulation, p38 MAP 
kinase phosphorylates TAB1, resulting in decreased TAK1 activity [205]. This 
subsequently reduces the TAK1-dependent activation of the MAP kinases 
JNK1/2. Additionally, the IKK-related kinases IKKε and TBK1 (TANK-binding 
kinase 1), protein kinases phosphorylated and activated by the IKKs, 
phosphorylate IKKα and IKKβ at inhibitory sites that suppress activity [206].  
Moreover, the MyD88-dependent activation of MAP kinases activate the 
protein kinases MSK1 (mitogen- and stress-activated protein kinase 1) and 
MSK2 [207] which phosphorylate the transcription factor CREB [208]. This 
activates CREB promoting the transcription of its target genes, which include 
the DUSPs (dual-specificity protein phosphatases) and the key anti-
inflammatory cytokine IL-10 [209]. DUSPs catalyse the removal of phosphate 
groups from the Thr and Tyr residues within the activation loops of MAP 
kinases, causing their inactivation [207]. IL-10 is a potent anti-inflammatory 
 36 
cytokine and functions in an autocrine manner to repress the production and 
actions of inflammatory mediators and cell proliferation [210,211]. The 
disassembly of K63-Ub and M1-Ub chains is also important to promote the 
disassociation and inactivation of TAK1 and the IKKs. DUBs such as CYLD 
and Otulin, as well as USP4 and USP2a, have been implicated in the 
deubiquitylation of proteins within the MyD88 signalling network 
[50,185,212,213]. How these DUBs are regulated is still not clear.  
 NF-κB activation rapidly induces the transcription of A20 [214,215]. 
A20 KO mice develop severe multi-organ inflammation and die prematurely 
[216]. Moreover, the loss of A20 expression has been linked to 
lymphomagenesis in humans [217], demonstrating that A20 is crucial for the 
restriction of innate immune signalling. It has been reported that A20 functions 
as a negative regulator by multiple mechanisms which includes its DUB 
activity against K63-Ub [218] chains and its ability to interact with M1-Ub 
chains and NEMO to prevent the activation of the IKKs [219–221]. 
Furthermore, a protein that forms a complex with A20, ABIN1 (A20-binding 
inhibitor of NF-κB) [222,223], is also involved in constraining MyD88-
dependent signalling [224]. ABIN1 can bind both K63-Ub and M1-Ub 
oligomers in vitro and the loss of its ability to interact with ubiquitin chains in a 
knock-in mouse (ABIN1[D485N]) causes the development of autoimmunity 
[224]. It is proposed that ABIN1 sequesters ubiquitin chains to limit the 
activation of TAK1 and the canonical IKK complex. A multitude of other 
signalling events also helps to modulate the actions of the MyD88 network.  
 
 
 
 
 
 
 
 
 
 
 37 
1.4 Aims of the thesis 
Although the activation of the MyD88 signalling network was known to 
induce the formation of K63 and M1-Ub chains [172,174,225] at the time the 
work described in this thesis started, there was little information about how 
these events were regulated. For example, it was not known if the formation of 
these ubiquitin chains occurred independently of one another, or were 
coordinated in some way.  TRAF6 was known to be an essential component 
of the MyD88 signalling network [134,135], and thought to generate the K63-
Ub chains required for the activation of TAK1 [149],  the genetic evidence 
needed to establish whether this hypothesis was correct was lacking.  
Moreover, the E3 ligase Pellino1 had also been shown to be capable of 
forming K63-Ub chains in vitro and to be activated by stimulating MEFs with 
IL-1 [29]. It was therefore important to find out how the E3 ligase activity of the 
Pellino isoforms contributed to the formation of K63-Ub chains in the MyD88 
signalling network and hence to the activation of TAK1 and the canonical IKK 
complex, and the production and secretion of proinflammatory cytokines. 
These issues are addressed in the results presented in Chapter 3 of this 
Thesis. 
I was also interested in a lymphoma caused by a mutation of MyD88 [5] 
and whether pharmacological inhibitors of the MyD88 signalling network might 
suppress the proliferation of these lymphoma cells or even induce cell death.  
This led me to identify a compound that that destroyed these lymphoma cells 
and to discover that its effects were exerted by a mechanism that was 
completely different from that described in the literature [226]. These findings 
are presented in Chapter 4 of the Thesis. 
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2 Methods 
2.1 Materials 
2.1.1 Chemicals  
Ethanol, glycerol, glycine, 4‐(2‐Hydroxyethyl)piperazine‐1‐ethanesulfonic acid 
(HEPES), isopropanol, methanol, β‐mercaptoethanol (βME), sodium chloride 
(NaCl), sodium ethylenediaminetetraacetic acid (EDTA), magnesium acetate, 
magnesium chloride (MgCl2), sodium ethylene glycol tetra acetic acid (EGTA), 
sodium fluoride, sodium 2-glycerophosphate, sodium orthovanadate, t-
octylphenoxypolyethoxyethanol (Triton)-X-100, adenosine 5’-triphosphate 
sodium salt (ATP), ammonium bicarbonate, ammonium persulphate (APS), 
bovine serum albumin (BSA), dimethyl sulphoxide (DMSO), iodoacetamide, 
phenylmethanesulphonylfluoride (PMSF), benzamidine, Ponceau S, sodium 
dodecyl sulphate (SDS), sodium tetraborate, tetramethylethylenediamine 
(TEMED), polyethylene glycol sorbitan monolaurate (Tween-20), Bovine 
serum albumin (BSA), polyethylene glycol (23) lauryl ether (Brij-35), 4-(2-
Aminoethyl)benzenesulfonyl fluoride hydrochloride (Pefabloc), Ampicillin, 
Kanamycin, 1,4-piperazinediethanesulfonic acid (PIPES), donkey serum, fish 
skin gelatin, puromycin, Geneticin (G418), dithiothreitol (DTT), Isopropyl β-D-
1-thiogalactopyranoside (IPTG), resazurin, MG132, sodium azide, 
hexadimethrine bromide (polybrene), chicken egg lysozyme, tris(2-
carboxyethyl)phosphine (TCEP), leupeptin, doxycycline, sodium azide, 
tetraethylammonium bicarbonate (TEAB), sulphuric acid and trifluoroacetic 
acid (TFA) were from Sigma‐Aldrich (Poole,UK). Lipopolysaccharide (LPS) 
was from Enzo Life Sciences (USA). InstantBlue coomassie stain was from 
Expedeon (Cambridge, UK). Protease inhibitor Complete cocktail tablets were 
from Roche (Lewes, UK). Sucrose and Tris(hydroxymethyl)aminomethane 
(Tris) were from BDH (Lutterworth, UK). Halo-link resin was from Promega 
(Wisconsin, USA). 5Z-7-oxozeaenol was from BioAustralis (Australia). 
Precision Plus protein markers and Bradford reagent were from BioRad 
(Herts, UK). ProLong® Gold Antifade Mountant with DAPI (4',6-
diamidino-2-phenylindole) and 2,2'-Azino-bis [3-ethylbenzothiazoline-6-
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sulfonic acid]-diammonium salt (ABTS) were from Thermo Fisher Scientific 
(MA, USA). γ32ATP was from PerkinElmer (MA, USA). Dialysed foetal bovine 
serum (FBS) was from Biowest (Nuaillé, France). 6, 12, 24 and 96 well tissue 
culture plates, 10 cm and 15 cm cell culture dishes, cell scrapers, cryovials 
and Spin-X columns were from Corning Incorporated (NY, USA). N-acetyl 
cysteine was from Tokyo Chemical Industry (Tokyo, Japan). 40% (w/v) 29:1 
Acrylamide: Bis-Acrylamide solution was from Flowgen Bioscience 
(Humberside, UK). Protein G-sepharose, Glutathione-sepharose, Enhanced 
chemiluminescence (ECL) kit and Hyperfilm MP and were purchased from GE 
Healthcare (Piscataway, USA). E2 scan kit was from Ubiquigent (Dundee, 
UK). Authentic K63-Ub oligomers of 3-7 linkages were from BostonBiochem 
(MA, USA). Cytokine ELISA kits were from Peprotech (New Jersey, USA). 
Dulbecco’s modified eagle medium (DMEM), Roswell Park Memorial Institute 
medium (RPMI), McCoy's 5A Modified Medium, Opti-MEM reduced serum 
media, Dulbecco’s phosphate buffered saline (PBS), Trypsin/EDTA solution, 
sodium pyruvate, L-glutamine, non-essential amino acids and HEPES buffer 
were from GIBCO (Paisley, UK). TALON metal affinity resin was from 
Clonetech (California, USA). Precast NuPAGE Novex SDS polyacrylamide 4-
12% Bis-Tris gels, NuPAGE MOPS running buffer (20X) and Lipofectamine 
2000 transfection reagent were from Invitrogen (MA, USA). Photographic 
developer (LX24) and liquid fixer (FX40) were from Kodak (Liverpool, UK). X-
ray films were from Konica Corporation (Japan). Polyethylenimine (PEI) was 
from Polysciences (Warrington, PA). Skimmed milk (Marvel) was from 
Premier Beverages (Stafford, UK). Plasmid Maxi kits were from Qiagen Ltd 
(Crawley, UK). Acetonitrile (HPLC grade) was from Rathburn Chemicals 
(Walkerburn, UK). Immobilon Western Cemiluminescent HRP Substrate, 
Immobilon-P Polyvinylidene fluoride (PVDF) 0.45 µm membrane, Strong 
Antibody Stripping Solution (10X), GeneJucie transfection reagent, BAY 11-
7082 and BAY 11-7085 were from EMD Millipore (Germany). Luria Bertani 
broth (LB) and LB agar plates were provided by the Central Technical 
Services team, University of Dundee. Inhibitors NG25, BI 605906, MLN4924 
and NSC697923 were synthesised by Natalia Shpiro, Medical Research 
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Council Protein Phosphorylation and Ubiquitylation Unit (MRC-PPU), 
University of Dundee. 
2.1.2 Commercial antibodies 
The commercial antibodies used throughout this thesis are listed in Table 
2.1. For immunoblotting the antibodies were diluted into 5% (w/v) BSA in TBS-
T containing 0.01% (w/v) sodium azide. Polyvinylidene fluoride (PVDF) 
membranes were probed overnight at 4°C with the antibody solution. Typically 
the antibody was diluted by 1000-fold from the stock. 
 
Table 2.1 Commercial antibodies  
Antibody Source Catalogue No Host 
p-IKKα (S176/S180)  
p-IKKβ (S177/S181) 
CST 2697 Rabbit 
p-p38 MAP kinase 
(T180/Y182) 
CST 9211 Rabbit 
p38 MAP kinase CST 9212 Rabbit 
p-TAK1 (T187) CST 4536 Rabbit 
TAK1 CST 4505 Rabbit 
p-MKK6 (S207) CST 9236 Rabbit 
MKK6  CST 9264 Rabbit 
p-p105/NFκB1 (S933) CST 4806 Rabbit 
IRAK1 CST 4504 Rabbit 
IRAK4 CST 4363 Rabbit 
MyD88 CST 4823 Rabbit 
GAPDH CST 2118 Rabbit 
p-IRAK4 (T345/T346) CST 11927 Rabbit 
p-TBK1 (S172) CST 5483 Rabbit 
IKKα CST 2682 Rabbit 
IκBα CST 4814 Mouse 
p-JNK1/2 (T183/Y185) Invitrogen 44682 Rabbit 
Ubc13 Invitrogen 37-1100 Mouse 
Cullin-2  Invitrogen 51-1800 Rabbit 
Ubiquitin  Dako Z0458 Rabbit 
TRAF6 Santa Cruz 
Biotechnology 
sc-7221 Rabbit 
Pellino1/2 Santa Cruz 
Biotechnology 
sc-271065 Mouse 
IRAK1 Santa Cruz 
Biotechnology 
H-273 
 
Rabbit 
IL-1R1 Santa Cruz 
Biotechnology 
Sc-688 Rabbit 
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IKKβ  Merck-Millipore 05-535 Mouse 
K63-ubiquitin linkage 
specific 
Merck-Millipore PW0600 Rabbit 
K48-ubiquitin linkage 
specific 
Merck-Millipore 05-1307 Rabbit 
p-H2AX (S139)  Merck-Millipore 05-636 Mouse 
IKKβ Merck-Millipore 05-535 Mouse 
HOIL-1 Sigma-Aldrich HPA024185 Rabbit 
FLAG M2 Sigma-Aldrich F3165 Mouse 
Sharpin Proteintech 
Group 
14626-1-AP Rabbit 
p-IRAK4 (T345/T346) Pfizer N/A Rabbit 
M1-ubiquitin linkage 
specific 
Genentech N/A Human 
Pellino1 Dr Peter Cheung 
(Singapore) 
N/A Rabbit 
GFP Abcam ab290 Rabbit 
HIF1α R&D systems 241809 Mouse 
Anti-rabbit IgG HRP Pierce 31210 Goat 
Anti-mouse IgA HRP Pierce 62-6720 Goat 
Anti-sheep IgG HRP Pierce 81-8620 Rabbit 
Anti-rabbit IgG Alexa 
Fluor 488 
Thermo Fisher A-11008 Goat 
Anti-mouse IgG Alexa 
Fluor 594 
Thermo Fisher A-11005 Goat 
 
 
 
2.1.3 In-house antibodies 
The antibody production group of the Division of Signal Transduction 
Therapy (DSTT), MRC-PPU, University of Dundee generates in-house 
antibodies, which are presented in Table 2.2. All antibodies were raised in 
sheep at Diagnostics Scotland (Carluke, Lanarkshire, U.K.). The adjuvant, 
either a short peptide or a purified protein, was injected into sheep and after a 
three-week interval the injection was repeated. A week later a bleed was 
taken and was designated the first bleed, this could be repeated up to five 
times. The serum was affinity purified on 5-Carboxypentyl-Sepharose 
covalently coupled to the specific antigen, supervised by James Hastie, 
DSTT. 
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Table 2.2 In-house antibodies  
Antibody Sheep No. Bleed No. 
HOIP S174D 3 
IRAK4 S522C 3 
TRAF6 S691C 1-3 
TAK1 S828A 1 
 
2.1.4 Proteins 
The proteins used throughout this Thesis (Table 2.3) were expressed and 
purified by the Protein Production and Assay Development Team (PPAD), 
headed by Axel Knebel, MRC-PPU, by the Protein Production Team, headed 
by James Hastie, DSTT, MRC-PPU or by myself.  All proteins are human 
unless otherwise stated.  
 
Table 2.3 Proteins 
 
Protein Code Source 
Phage λ phosphatase DU4170 DSTT 
PreScission proteinase DU34905 DSTT 
Tobacco Etch Virus (TEV)-
protease[S219N] 
DU6811 DSTT 
Pellino1 DU8981 DSTT 
Murine IL-1α[115-270] DU46302 DSTT 
IL-1β[117-269] DU8685 DSTT 
p38α  DU979 DSTT 
p38γ DU980 DSTT 
IKKα[1-745] DU46017 DSTT 
IKKβ[1736] DU3167 DSTT 
TAK1[1-303]-TAB1[437-504]  DU753 DSTT 
IRAK1[1-712] DU8915 DSTT 
IRAK4[160-460] DU15580 DSTT 
His6-Ubc13 DU15705 PPAD 
His6-UbcH7 DU12798 PPAD 
His6-UBE1 DU32888 PPAD 
His6-UbcH5a DU4315 PPAD 
His6-UbcH9 DU14049 PPAD 
Ubiquitin DU21287 PPAD 
FLAG-Ubiquitin DU46789 PPAD 
Otulin DU43487 PPAD 
IsoT DU15641 PPAD 
TRAF6 DU43249 PPAD 
TRAF6[C70A] DU43527 PPAD 
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TRAF6[L74H] DU46742 PPAD 
MKK6 DU32175 Sam Strickson 
His6-TAB3/TAK1/TAB1 DU45364 DSTT/Yogesh 
Kulathu/Sam Strickson 
Halo-NEMO DU35939 Sam Strickson 
Halo-NZF2(644-692 dimer) 
TAB2 
DU23839 Sam Strickson 
  
 
2.1.5 Mice 
Wild type C57/BL6 mice were obtained from Charles River 
Laboratories (MA, USA) and knock-in mice were obtained from Taconic 
Artemis (Cologne, Germany). The generation of Pellino1 knock-in mice was 
described previously [227]. Knock-in mice carrying a Phe398Ala mutation in 
Pellino2 or Phe424Ala mutation in Pellino3 were generated using 
conventional methods.  Briefly, targeting vectors, designed by Simon Arthur 
(University of Dundee) were constructed by recombinase-mediated cloning to 
generate the desired mutations.  These were then used to target Art B6.3.5 
(C57BL/6 NTac) embryonic stem (ES) cells. Positive colonies were identified 
by Southern blotting and the presence of the point mutation confirmed by PCR 
and sequencing of the appropriate genomic region.  Correctly targeted ES 
cells were used to generate chimeric mice via blastocyst injection.  To remove 
the neomycin and puromycin resistance selectable markers, mice were 
crossed to a constitutive flp transgenic line (also on a C57BL/6 background).  
Once deletion had occurred, the Pellino alleles were crossed away from the 
flp transgene.  As Pellinos 1, 2 and 3 are located on different chromosomes 
(11, 14 and 19, respectively) double and triple Pellino knock-in mice were 
generated by conventional breeding.  Routine genotyping was carried out by 
PCR of ear biopsies by Gail Fraser, MRC-PPU.  For Pellino2, the sequence of 
the primers used were GAGCCAATGCTTCGATTACC and 
GCTCCTTCCTCTAGCAGAGC which resulted in a band of 305bp for a wild 
type allele and 424bp for a knock-in allele.  Primers corresponding to 
GATATGGAAGCCACTTTGAGG and ACTTCCACAGGTCAAATCAGG were 
used for Pellino3 and resulted in bands of 303bp and 422bp for the wild type 
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and knock-in alleles respectively. All animals were held under specific 
pathogen free conditions in individually ventilated cages in accordance with 
UK and EU law.  Work was carried out under a UK Home Office project 
license and subject to local ethical review. 
 
2.1.6 Buffers 
Commonly used buffers and their composition are listed in Table 2.4.  
Table 2.4 Buffers. 
Buffer Composition 
Mammalian cell 
lysis buffer 
50 mM Tris/HCl (pH 7.5), 1 mM EDTA, 1 mM EGTA, 50 mM 
sodium fluoride, 5 mM sodium pyrophosphate, 10 mM sodium 
2-glycerophosphate, 1 mM sodium orthovanadate, 0.27 M 
sucrose, 1% (v/v) Triton X-100, 1 mM phenylmethylsulfonyl 
fluoride (PMSF), 1 mM benzamidine, one tablet of complete 
protease inhibitor cocktail per 50 ml of buffer and 1 mM 
dithiothreitol (DTT). If ubiquitin chains were being investigated 
DTT was excluded and 100 mM iodoacetamide was used.  
Bacterial cell lysis 
buffer 
50 mM Tris/HCl, pH 7.5, 150 mM NaCl, 1 mM EGTA, 1 mM 
EDTA, 0.1% (v/v) β-mercaptoethanol (βME), 1 mM 
benzamidine and 0.2 mM phenylmethylsulfonyl fluoride 
(PMSF).  
 
Halo-link resin 
wash buffer 
50 mM Tris/HCl, pH 7.5, 0.5 M NaCl and 1% (v/v) Triton-X100 
Halo-link resin 
storage buffer 
50 mM Tris/HCl (pH 7.5), 150 mM NaCl, 0.1 mM EGTA,  
270 mM sucrose, 0.07 % (v/v) βME 
Lithium dodecyl 
sulphate (LDS) 
sample buffer 4x 
(Purchased from 
Invitrogen) 
141 mM Tris base, 2% (w/v) LDS, 10% Glycerol (v/v), 0.51 
mM EDTA, 0.22 mM SERVA Blue G, 0.175 mM Phenol Red 
(pH 8.5). 1 mM DTT was added fresh.  
 
8-12% acrylamide 
resolving gels 
375 mM Tris/HCl (pH 8.6), 0.1% SDS (w/v) and 8-12% (w/v) 
acrylamide. 0.1% (w/v) ammonium persulfate (APS) and 0.1% 
(v/v) TEMED were used to polymerise the gels.  
Stacking gel 125 mM Tris/HCl (pH 6.8), 0.1% SDS (w/v) and 4% 
acrylamide (w/v). 0.1% (w/v) ammonium persulfate (APS) and 
0.1% (v/v) TEMED were used to polymerise the gels. 
Tris-glycine 
SDS/PAGE running 
buffer 
25 mM Tris base, 192 mM glycine, 0.1% (w/v) SDS, pH 8.3 
Tris-glycine 
transfer buffer 
48 mM Tris base, 39 mM glycine, 20% (v/v) methanol.  
MOPS running 
buffer (Purchased 
from Invitrogen) 
50 mM MOPS, 50 mM Tris base, 0.1% (w/v) SDS, 1 mM 
EDTA, pH 7.7.  
Ubiquitylation 
assay buffer 
50 mM Tris/HCl (pH 7.5) and 5 mM magnesium chloride. 
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Phosphatase 
assay buffer 
(Purchased from 
New England 
Biolabs) 
50 mM HEPES, 100 mM NaCl, 2 mM DTT, 0.01% (w/v) Brij 
35, 1 mM manganese chloride, pH 7.5.  
Tris buffered 
saline (TBS) 
20 mM Tris/HCl (pH 7.5), 150 mM NaCl. 
TBS plus Tween 
(TBS-T) 
TBS plus 0.2% (v/v) Tween-20  
PVDF blocking TBS-T containing 5% (w/v) non-fat milk.  
Phosphate 
buffered saline 
(PBS) (Purchased 
from Invitrogen) 
2.7 mM potassium chloride, 1.5 mM potassium phosphate 
monobasic, 138 mM NaCl, 8.1 mM sodium shosphate dibasic. 
 
 
 
2.1.6.1 Lysis buffer composition  
EDTA was used to chelate Mg2+ ions to inactivate protein kinases. 
EGTA was used to chelate Ca2+ ions to inactivate calmodulin-dependent 
enzymes and proteases. Sodium fluoride, sodium pyrophosphate and sodium 
2-glycerophosphate were used to inhibit serine/threonine protein 
phosphatases. Sodium orthovanadate was added to inhibit protein tyrosine 
phosphatases. PMSF and benzamidine were added to inhibit serine 
proteases. The protease inhibitor cocktail (Roche) was used to inhibit a broad 
spectrum of metallo-, aspartyl-, cysteine and serine proteinases. Sucrose 
helps to stabilise lysosomal membranes to prevent protease release. DTT is 
used as a reducing agent to prevent oxidative damage caused by the 
presence of cysteine residues.  
2.2 Methods 
2.2.1 Mammalian cell culture and the generation of stable cell lines 
All procedures were carried out under aseptic conditions meeting 
biological safety requirements. Cells were maintained in growth media at 37°C 
with 5% CO2 in a water-saturated incubator.  
2.2.1.1 Cell culture growth media 
Growth media was composed of Dulbeccos’s modified eagles medium 
(DMEM), 10% (v/v) foetal bovine serum (FBS), 2 mM L-Glutamine, 100 U/ml 
penicillin, 100 μg/ml streptomycin.  
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2.2.1.2 Cell passaging 
Cells were grown to 80-90% confluency in a 10 or 15 cm cell culture 
dish. The media was aspirated from the dish and the cells were washed with 
PBS and then incubated with 2 ml of Trypsin/0.05% EDTA at 37°C for 3 min to 
detach the cells. The cell suspension was then diluted 1/10 and used to seed 
a new tissue culture dish. 
2.2.1.3 Immortalised cell lines 
2.2.1.3.1 Human embryonic kidney (HEK) 293 cells 
Several lines of modified HEK293 cells were used during the course of 
this Thesis, they were all maintained in growth media. HEK293 cells stably 
overexpressing the IL-1R, termed IL-1R cells, were provided by Dr George 
Stark and Dr Xiaoxia Li (Cleveland Clinic Foundation, Cleveland, Ohio, 
U.S.A.). Flp-In™ HEK293 T-Rex cells were purchased from Invitrogen and 
Yosua Kristariyanto (MRC-PPU) used them to make a HEK293 cell line that 
expresses Cas9 under a doxycycline-inducible promoter, described previously 
in [228]. Jiazhen Zhang (Cohen lab) then generated retroviral particles 
(Section 2.2.1.6) containing the IL-1R (Table 2.6) and used them to infect the 
HEK293-Cas9 cell line to generate the IL-1R* cell line.  The IL-1R* cells stably 
express the IL-1R, though at much lower levels than IL-1R cells. HEK293FT 
cells, transformed with the SV40 large T antigen, were purchased from 
Invitrogen and used for the generation of retro- and lentiviral particles.  
2.2.1.3.2 RAW264.7 macrophages 
This is a macrophage-like mouse cell line purchased from the 
European Tissue Culture Collection and maintained in growth media. The 
cells were not trypsinised to detach, instead a sterile scraper was used to 
gently dislodge the cells from the tissue culture dish and they were diluted 
appropriately (1/10) into a new dish containing fresh media.  
2.2.1.3.3 HBL-1 cells 
This is a B-cell lymphoma cell line carrying the MyD88[L265p] mutation 
[5], provided by Dr Louis Staudt (National Cancer Institute, Bethesda, MD, 
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U.S.A.). This cell line was maintained in growth media, except that Roswell 
Park Memorial Institute medium (RPMI) was substituted DMEM. The 
lymphoma cells did not attach to the tissue culture dish and could simply be 
diluted (1:10) into fresh media to passage.  
2.2.1.3.4 Mouse embryonic fibroblasts (MEFs) 
Wild type (WT) and TRAF6 knock out (KO) MEFs were provided by Dr 
Tak Mak (Department of Medical Biophysics, Toronto, Canada) and were 
maintained in growth media. TRAF6 KO MEFs displayed distinctly slower 
growth rates compared to WT MEFs. 
2.2.1.3.5 U2OS cells 
A human osteosarcoma cell line that adheres well to glass slides, 
making them suitable for immunofluorescence. Maintained in growth media 
with DMEM substituted for McCoy's 5A growth medium. The cells were 
trypsinised to passage.  
2.2.1.4 Generation of primary MEFs 
MEFs were isolated from embryos 13.5 days after the detection of the 
vaginal ‘plug’ by the Transgenic Mouse Unit, University of Dundee. The head 
and internal organs were removed and a small sample was sent for 
genotyping by the MRC-PPU genotyping service, University of Dundee. The 
rest of the embryo was minced with a scalpel and then incubated with 5 ml 
trypsin (Invitrogen) at 37°C for 10 min. 10 ml of growth media was added to 
quench trypsin activity and then pipetted up and down to break the tissue up. 
The cells were then plated into 15 cm tissue culture dishes and were 
designated as passage 1 (P1). Primary MEFs were not grown past P8. 
Primary MEFs were maintained in growth media supplemented with 1x 
nonessential amino acids (100x stock, Invitrogen), 20 mM HEPES (pH 7.3) 
and 0.1 mM βME.  
2.2.1.5 Freezing and thawing of cells 
A confluent 15 cm tissue culture dish was trypsinised, the cell 
suspension was then briefly centrifuged to pellet the cells. The trypsin was 
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removed and the cells were re-suspended into 5 ml of FBS containing 10% 
(v/v) DMSO. The cells were then split into 5 x 1 ml cryo vials and placed into a 
cell-freezing chamber (Thermo Scientific) for 24 h at -80°C. The vials were 
then transferred into liquid nitrogen for long-term storage.  
To thaw, the cryo vials were placed into a water bath (37°C) for two 
minutes and then transferred to a 15 cm tissue culture dish containing 25 ml 
of growth media, pre-warmed to 37°C.  
2.2.1.6 Generation of lenti- and retroviruses for the stable knock-down 
or integration of a protein into cells 
To knock-down the expression of proteins, MISSION short-hairpin 
RNAs (shRNA) inserted into lentiviral vectors were obtained from Sigma-
Aldrich (Table 2.6). To generate lentiviral particles, the shRNA vectors (6 µg) 
were transfected into 293FT cells with 3.8 µg of a vector containing the 
gag/pol genes (packaging plasmid) and 2.2 µg of a vector containing the 
vesicular stomatitis virus G protein (VSV-G) (envelope plasmid) (Table 2.6) 
per 10 cm tissue culture dish using Lipofectamine 2000 (Invitrogen) in 5ml of 
Opti-MEM (Invitrogen), as per the manufacturer’s instructions. The Opti-MEM 
was removed 5 h after transfection and replaced with growth media for the 
next 19 h. The media was replaced with fresh growth media and 24 h later the 
media, containing lentivirus, was harvested and passed through a 45 µm filter 
to remove cell debris. The virus (2 ml) was added to the target cells (5x104) in 
a 6 well plate in the presence of 10 µg/ml of polybrene, which assists viral 
infection [229]. 24 h after exposure to lentiviral particles the media was 
refreshed and then a further 24 h later the media was replaced to include 
selection antibiotics puromycin (2 µg/ml) or G418 (1 mg/ml). Cell survival was 
dependent upon the stable integration of the cDNA resistance marker. 
Successfully selected cells were then further analysed by immunoblotting to 
confirm the stable knock-down of the target protein. The lentiviral particles 
could be stored at -80°C in 2 ml aliquots.  
To stably express proteins in cells, the cDNA of interest was inserted 
into a pBABE retroviral vector (Table 2.6). Retroviral particles were prepared 
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and added to target cells in the same manner as lentiviral particles, except 
that retroviral gag/pol and VSV-G packaging and envelope vectors were used 
in place of lentiviral vectors (Table 2.6). Immunoblotting was used to confirm 
protein expression. 
To stably express proteins in cells under the control of an inducible 
promoter, the cDNA of interest was inserted into a pRetroX-tight retroviral 
vector, which contained a puromycin resistance gene (Table 2.6). Retroviral 
particles were generated as described previously for the pRetroX-tight vectors 
and vectors containing Tet-On (Table 2.6), a doxycycline-controlled 
transcriptional transactivator. 2 ml of each virus was added to target cells 
(5x104) and selected for as described previously. Immunoblotting was used to 
confirm protein expression. 
Viral production and infection was carried out in accordance with 
biological safety regulations.  
2.2.1.7 Generation of TRAF6-null IL-1R* cells and the re-expression of 
WT and mutant TRAF6 constructs 
This was carried out essentially as described [228]. Three guide RNAs 
(gRNAs) were generated to target exon 2 of human TRAF6. The three gRNA 
plasmids were pooled and 10 µg was used to transfect IL-1R* cells for 8 h 
using the GeneJuice transfection reagent (EMD Millipore). Doxycycline was 
then added to the cells to a final concentration of 1 µg/ml to induce expression 
of Cas9. A further 18 h later the cells were again transfected with the same 
amounts of gRNA plasmids. After 48 h, cells were single-cell plated into 96 
well plates and left until colonies began to form (2-3 weeks). The mutation 
efficiency was analysed by immunoblotting cell extracts for TRAF6. One 
TRAF6-null clone was found after screening 70 clones. Many other clones 
produced a truncated form of TRAF6 that was expressed at lower levels than 
wild-type TRAF6 and these clones were discarded. 
To restore TRAF6 expression and remove the gene for Cas9, TRAF6-
null IL-1R* cells were co-transfected using GeneJuice with 9 µg of POG44 
recombinase (Invitrogen) and 1 µg of pcDNA5 FRT/TO vectors containing 
human TRAF6 or TRAF6 mutants (Table 2.6).  48 h after transfection, cells 
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were selected with 2 μg/ml puromycin. To induce TRAF6 expression 
equivalent to endogenous levels, reconstituted cells were incubated for 16 h 
with 0.03 ng/ml doxycycline for WT TRAF6 and TRAF6[L74H] and 0.3 ng/ml 
for TRAF6[C70A].  
2.2.1.8 Generation of TRAF6 KO MEFs and TRAF6-null IL-1R* cells that 
stably express WT and mutant forms of mouse TRAF6 
TRAF6 KO MEFs and TRAF6-null IL-1R* cells were infected with 
retrovirus (Section 2.2.1.7) containing untagged murine forms of WT TRAF6, 
TRAF6[C70A] and TRAF6[L74H] inserted into pRetroX-tight vectors (Table 
2.6). To induce the expression of TRAF6 similar to endogenous levels, MEFs 
were incubated with 1.0 ng/ml of doxycycline for 16 h and IL-1R* cells were 
incubated with 10 ng/ml of doxycycline for 16 h.   
2.2.1.9 Generation of TRAF6-null IL-1R* cells that stably express FLAG-
tagged WT and mutant forms of TRAF6 
TRAF6-null IL-1R* cells were infected with retrovirus (Section 2.2.1.7) 
containing FLAG-tagged forms of WT TRAF6, TRAF6[C70A] and 
TRAF6[L74H] inserted into pBABE vectors (Table 2.6). 
2.2.1.10 Cell transfection  
2.2.1.10.1 PEI 
Polyethylenimine (PEI, Polysciences) was dissolved in 20 mM HEPES, pH 
7.5 to give a 1 mg/ml stock and passed through a 22 µM filter to sterilise. In 1 ml 
of DMEM, 30 µg of PEI per 10 µg plasmid DNA were mixed in 1 ml Opti-MEM 
and incubated for 15 min at room temperature (RT). This solution was added 
drop-wise to the culture medium of cells, which were 40-60% confluent. The 
media was replaced 16 hours post-transfection and the cells were lysed after 24-
48 hours.  
2.2.1.10.2 Lipofectamine 2000  
Lipofectamine 2000 was used to transfect 293FT cells for virus 
production and U2OS cells. 36 µl of Lipofectamine 2000 was mixed with 300 
µl of Opti-MEM before being gently mixed with 300 µl of Opti-MEM containing 
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10 µg of plasmid DNA. This solution was incubated for 15 min a RT before 
being added drop-wise, to the culture medium of cells that contained no 
antibiotics.   
2.2.1.10.3 GeneJuice 
For the transfection of IL-1R* cells with gRNA, 60 µl of GeneJuice was 
mixed with 10 µg of gRNA plasmid in 1 ml Opti-MEM followed by incubation 
for 10 min at RT.  The solution was added to the culture medium of cells that 
contained no antibiotics, drop-wise.  
2.2.1.11 Treatment of cells with inhibitors and agonists 
The inhibitors used in this Thesis are listed in Table 2.5. The inhibitors 
were re-suspended in DMSO to give a 10 mM stock solution and stored in 
aliquots at -20°C. Typically the inhibitor solution was pipetted directly into the 
culture medium of cells before being placed back into the 37°C incubator for 1 
h. An equivalent volume of DMSO was used as a vehicle control. 
Agonists were diluted into PBS to give a 1000x stock and stored in 
aliquots at -20°C. After thawing they were pipetted into the cell culture 
medium at the concentrations indicated in the figure legends. 
 
Table 2.5 Inhibitors  
 
Inhibitor Reported molecular target Concentration used at (µM) 
BAY 11-7082 IKK / NF-κB [226] 3 / 15 
BAY 11-7085 IKK / NF-κB [226] 3 
NG-25 TAK1 [154] 1 
5Z-7-oxozeaenol TAK1[153] 1 
BI 605906 IKKβ [206] 10 
MLN4924 NAE1 [230] 1 
MG132 Proteasome [231] 25 
Bortezomib Proteasome [232] 0.1 
NSC697923 Ubc13 [233] 20 
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2.2.1.12 Cell proliferation and viability assays 
HBL-1 cells were seeded into a black 96-well plate at 25,000 cells per 
well in 0.1 ml of RPMI growth medium. The pharmacological inhibitors were 
diluted appropriately in RPMI growth medium and 50 μl was added to each 
well. All assays were performed in triplicate. To assess cell viability and 
proliferation, 15 μl of a 0.11 mg/ml solution of resazurin in water was then 
added to each well. The solution was incubated for 3 h at 37°C before reading 
the emitted fluorescence at 590 nm after excitation at 540 nm on a 
SpectraMax M2 Fluorescence Plate Reader [234]. A blank reaction in which 
0.15 ml of RPMI medium was incubated with 15 μl of 0.11 mg/ml rezaurin was 
used as the control. 
2.2.2 Molecular biology techniques 
2.2.2.1 Plasmid transformation, amplification and isolation 
Competent E. coli DH5α (plasmid isolation) or BL21 (protein expression) cells, 
generated by the DSTT, University of Dundee, were thawed on ice and 1 µl of 
plasmid DNA was added to the cells, followed by incubation on ice for 5 min. 
Cells were then heat-shocked at 42°C for 90 sec to facilitate DNA uptake and 
placed back on ice for 5 min. 500 µl of Luria-Bertani (LB) media was added to 
the cells and they were placed in a 37°C incubator to recover for 30 min.  
Subsequently 50 µl was pipetted onto an LB agar plate containing containing 
100 μg/ml ampicillin or 50 µg/ml kanamycin and left overnight in a 37°C 
incubator. To amplify the plasmid, one transformed colony was used to 
inoculate 200 ml LB media containing 100 μg/ml ampicillin or 50 µg/ml 
kanamycin for 16 h on a shaking incubator at 37°C. The transformed cells 
were pelleted by centrifugation (3000 rpm, 30 min, 4°C) and the plasmid DNA 
was extracted using the Qiagen DNA Midi or Maxi kit according to the 
manufacturer’s instructions.   
Transformed BL21 cells were made into glycerol stocks to allow for 
quick expression of proteins without the need to transform further BL21 cells. 
To achieve this 500 µl of BL21-inoculated LB media was mixed with 500 µl of 
glycerol and placed into a cryovial at -80 oC. To inoculate a new flask of LB 
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media the cryovial was thawed a small aliquot was placed into LB media.  
2.2.2.2 Measurement of DNA and mRNA concentration  
Using a NanoDrop® spectrophotometer (Thermo Scientific) the 
absorbance of isolated DNA or mRNA in aqueous solution was measured at 
260 nm, after previous calibration with nuclease-free water. 
2.2.2.3 DNA cloning techniques 
All recombinant DNA procedures, restriction digests and ligations were 
performed using standard protocols by the DSTT cloning team, University of 
Dundee, jointly headed by Mark Peggie and Rachel Toth. The cDNA 
constructs used in this Thesis are listed in Table 2.6. All PCR reactions were 
carried out using KOD Hot Start DNA polymerase (Novagen). DNA 
sequencing was performed by the DNA Sequencing Service, College of Life 
Sciences, University of Dundee (www.dnaseq.co.uk). The MultiBac 
expression system [235] was used for expression of the multiprotein complex 
comprising TAB1, TAK1 and TAB3 (DU45364). The cDNAs coding for TAB1, 
TAK1 and TAB3 were re-amplified by PCR from existing clones, (accession 
numbers NM_006116.2, NM_003188.3 and NM_152787.3 GI:98991766 
respectively), adding the appropriate restriction sites at the 5’ and 3’ ends of 
the open reading frames. The 5’ PCR oligonucleotide for TAB3 included 6His 
and PreScission protease site sequences. TAB1 was cloned into pFBDM as a 
XhoI/KpnI insert. TAK1 was cloned into the resulting pFBDM TAB1 clone as a 
BamHI/NotI insert to create pFBDM TAB1/TAK1. 6His-PreScission-TAB3 was 
cloned into pFBDM as a BamHI/NotI insert to create pFBDM 6His-
PreScission-TAB3. The triple expression construct was created by cloning the 
PmeI/AvrII fragment from pFBDM 6His-PreScission-TAB3 into the SpeI/NruI 
sites of pFBDM TAB1/TAK1. Clones were sequence-verified at every stage. 
The pFastBac Dual DAC-TEV expression system was created by sub-
cloning a BglII-BamH1 flanked PCR product encoding the full-length DAC tag 
[236] followed by a TEV protease cleavage site into the BamH1 site of 
pFastBacTM Dual (Life Technologies, Paisley, U.K.). In this vector untagged 
proteins can be expressed from the p10 promoter in cassette 1 alongside N-
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terminally DAC-tagged proteins expressed from the polyhedron promoter in 
Cassette 2. The ORF encoding TRAF6 (NCBI NM_145803.2) was cloned and 
then inserted into the BamHI NotI sites to create a DAC-TEV-TRAF6 
expression cassette. Mutants were created using the Quickchange Site 
Directed Mutagenesis method (Agilent), but using KOD DNA Hotstart 
Polymerase (Merck Millipore). 
DNA clones encoding TRAF6 (DU46785), TRAF6[C70A] (DU46824) 
and TRAF6[L74H] (DU46823) were inserted in pcDNA5-FRT/TO vectors [228] 
 
Table 2.6 Plasmids  
 
Protein/Target Vector Source Code Resistance 
marker 
Purpose 
IL-1R1  pBABE DSTT DU46481 G418 Stable 
constitutive 
expression 
TRAF6 (Exon 2) pU6 gRNA DSTT DU48406  KO of TRAF6 
TRAF6 (Exon 2) pU6 gRNA DSTT DU48407  KO of TRAF6 
TRAF6 (Exon 2) pU6 gRNA DSTT DU48408  KO of TRAF6 
TRAF6 pcDNA5 
FRT/TO 
DSTT DU46785 Puromycin Stable inducible 
expression  
TRAF6[C70A] pcDNA5 
FRT/TO 
DSTT DU46824 Puromycin Stable inducible 
expression 
TRAF6[L74H] pcDNA5 
FRT/TO 
DSTT DU46823 Puromycin Stable inducible 
expression 
FLAG-TRAF6 pBABE DSTT DU32495 Puromycin Stable 
constitutive 
expression 
FLAG-
TRAF6[C70A] 
pBABE DSTT DU32513 Puromycin Stable 
constitutive 
expression 
FLAG-
TRAF6[L74H] 
pBABE DSTT DU46743 Puromycin Stable 
constitutive 
expression 
DAC-TRAF6 pFBDAC 
TEV 
DSTT DU43249  Insect cell 
expression 
DAC-
TRAF6[C70A] 
pFBDAC 
TEV 
DSTT DU43527  Insect cell 
expression 
DAC-
TRAF6[L74H] 
pFBDAC 
TEV 
DSTT DU46742  Insect cell 
expression 
Mouse TRAF6 pRetroX-
Tight 
DSTT DU51028 Puromycin Stable inducible 
expression 
Mouse 
TRAF6[C70A] 
pRetroX-
Tight 
DSTT DU51027 Puromycin Stable inducible 
expression 
Mouse 
TRAF6[L74H] 
pRetroX-
Tight 
DSTT DU51041 Puromycin Stable inducible 
expression 
Tet-On Tet-On 
Advanced 
Clontech 630930 G418 Doxycycline-
controlled 
transcriptional 
transactivator 
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GFP-RAP80[1-
200]  
pcDNA3.1 Daniel 
Durocher 
(Toronto, 
Canada) 
N/A  Mammalian cell 
expression 
HA-Ubc13 pCMV5 DSTT DU3415  Transient 
expression 
His6-
TAB3/TAB1/TAK1 
pFBDM DSTT DU45364  Insect cell 
expression 
GST-MKK6 pGEX6P DSTT DU32175  Bacterial 
expression 
Halo-NEMO pFN18A DSTT DU35939  Bacterial 
expression 
Halo-NZF2 (644-
692 TAB2)  
pET28a DSTT DU23839  Bacterial 
expression 
VSV-G pCMV DSTT DU35309  Retrovirus 
Gag/pol pCMV DSTT DU35085  Retrovirus 
Gag/pol Lenti-X Clonetech 631247  Lentivirus 
VSV-G Lenti-X Clonetech 631247  Lentivirus 
Flp-Recombinase pOG44 Invitrogen V6005-20  Remove Cas9 
Ubc13 pLKO.1 Sigma 
Mission 
shRNA 
TRCN0000
349623 
Puromycin Stable protein 
knock-down 
Ubc13 pLKO.1 Sigma 
Mission 
shRNA 
TRCN0000
318499 
Puromycin Stable protein 
knock-down 
HOIP pLKO.1 Sigma 
Mission 
shRNA 
TRCN0000
168448 
Puromycin Stable protein 
knock-down 
HOIP pLKO.1 Sigma 
Mission 
shRNA 
TRCN0000
250111 
Puromycin Stable protein 
knock-down 
HOIL-1 pLKO.1 Sigma 
Mission 
shRNA 
TRCN0000
007599 
Puromycin Stable protein 
knock-down 
Otulin pLKO.1 Sigma 
Mission 
shRNA 
TRCN0000
134518 
Puromycin Stable protein 
knock-down 
None pLKO.1 Sigma 
Mission 
shRNA 
SHC001 Puromycin shRNA control 
 
 
2.2.2.4 Real-time quantitative reverse transcription PCR (qRT-PCR) 
 IL-1R* cells and primary MEFs were seeded at a final concentration of 
1.5 x 105 into 24 well and 12 well plates respectively. After stimulation with IL-
1, total RNA was extracted using a RNA MicroElute kit from VWR (R6831-01). 
RNA (0.5 µg) was reverse transcribed using the iScript cDNA synthesis kit 
from Bio-Rad (170-8891). PCR was performed in a 384 well plate and each 
10 µl reaction included 0.5% cDNA, 0.5 µM primers (Table 2.7) and 5 µl 
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SsoFast EvaGreen Supermix from Bio-Rad (172-5204) according to the 
manufacturer’s instructions on a CFX 384 machine (BioRad). The mRNA 
measurements were normalised to 18S RNA and the relative gene expression 
levels, in comparison to control (not stimulated with IL-1), were calculated 
according to the comparative cycle threshold Method [237] 
 
Table 2.7 qRT-PCR primers 
 
Target Sequence 5’- 3’ 
IL-8 Forward: ATAAAGACATACTCCAAACCTTTCCAC 
Reverse: AAGCTTTACAATAATTTCTGTGTTGGC 
MIP-2 Forward: CATTCGCTAATTCACTGTA 
Reverse: TTATCACCTTCCAACTATATAAG 
18S Forward: GTAACCCGTTGAACCCCATT 
Reverse: CCATCCAATCGGTAGTAGCG 
 
2.2.3 Biochemistry techniques 
2.2.3.1 Cell lysis 
Cells were washed twice with ice-cold PBS and scraped on ice into 
lysis buffer, which was supplemented with 100 mM iodoacetamide if ubiquitin 
chains were to be studied. The lysates were then clarified by centrifugation at 
14,000 rpm for 30 min at 4oC. The protein concentration of the supernatants 
was then calculated. 
2.2.3.2 Quantification of protein concentration 
The protein concentration of a sample was estimated according to the 
Bradford method [238]. In principle, the binding of Coomassie dye to proteins 
in acidic medium causes the absorbance maximum to shift from 465 nm to 
595 nm resulting in a colour change from brown to blue. A standard curve was 
generated by plotting absorbance against a serial dilution of BSA standards 
(0.06 mg/ml – 1 mg/ml). Samples were diluted in water by a factor of 30 and 
were added to a 96 well plate in triplicate (10 µl) along with 200 µl Bradford 
reagent. After incubation for 5 min at room temperature absorbance at 595 nM 
was measured and the concentrations of samples were calculated using the 
BSA standard curve.  
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2.2.3.3 Immunoprecipitation  
Protein G–Sepharose (20 μl packed beads) was washed three times 
with lysis buffer and incubated with cell extract protein (2 mg) and anti-IRAK4 
(S522C) antibody (2 µg) for 16 h at 4°C on a rotating wheel. The beads were 
collected by brief centrifugation, washed three times with 0.5 ml of 50 mM 
Tris/HCl, pH 7.5, 1% (v/v) Triton X-100, 0.05% (v/v) βME and 0.2 M NaCl and 
once with 50 mM Tris/HCl. After denaturation in LDS, the samples were 
subjected to SDS/PAGE.  
2.2.3.4 Assay of endogenous E3 ligases 
Anti-HOIP (S174D), Anti-Pellino1 and Anti-TRAF6 (S691D) antibodies 
(1 μg) were incubated with 1 mg cell extract protein in the presence of Protein 
G–Sepharose (10 μl packed beads) for 16 h at 4°C on a rotating wheel. The 
beads were collected by brief centrifugation, washed three times with 0.5 ml of 
50 mM Tris/HCl, pH 7.5, 1% (v/v) Triton X-100 and 0.2 M NaCl and once with 
50 mM Tris/HCl, pH 7.5, and 5 mM MgCl2. The immunoprecipitated TRAF6 
and Pellino1 E3 ligases were resuspended in 20 μl of 20 mM Tris/HCl, pH 7.5, 
2 mM DTT, 0.1 μM UBE1, 0.4 μM Ubc13, 0.4 μM Ubc13, 10 μM FLAG-Ub, 
5 mM MgCl2 and 2 mM ATP. After incubation for 1 h at 30°C, reactions were 
stopped by denaturation in LDS and immunoblotting with anti-FLAG or anti-
Ub. The LUBAC complex was subjected to the same assay conditions, except 
that UbcH7 was substituted for Ubc13 and untagged ubiquitin was used in 
place of FLAG-tagged ubiquitin.  
2.2.3.5 Halo-NEMO/NZF2 pulldown assays and treatment with DUBs and 
phosphatase 
To capture ubiquitin chains from cell extract, 10 µl of packed beads were 
incubated per 1 mg cell extract protein. After end-over-end mixing for 16 h at 4°C, 
the beads were washed 3 times with 1 ml of Halo resin wash buffer (Table 2.4) 
and once with 600 µl of 10 mM Tris/HCl (pH 7.5). The slurry was transferred to 
SpinX tubes (Corning) to remove the 10 mM Tris/HCl solution. The dried resin was 
incubated with LDS sample buffer and placed on a thermomixer for 3 min at room 
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temperature. The SpinX tube was briefly centrifuged and the sample was 
subjected to SDS/PAGE.  
If the resin was to be treated with the DUBs, Otulin (1 µM) or IsoT (0.5 µM), 
or phage λ phosphatase (2 µg) (Table 2.3), following the 10 mM Tris/HCl wash, 
the resin was re-suspended in 30 µl of phosphatase buffer containing the DUB 
and/or phosphatase (Table 2.4). The samples were incubated on a thermomixer 
for 1 h at 30°C and the reaction was terminated by the addition of LDS. The 
samples were placed through a SpinX colum and subjected to SDS/PAGE.  
2.2.3.6 Assay of TAK1 activation in cells 
The endogenous TAK1 was immunoprecipitated from the cell extracts 
as in Section 2.2.4.3 using the TAK1 S828A antibody (Table 2.2) and its 
activity measured in a coupled assay using MKK6 and p38α MAP kinase 
(Table 2.3) as described [205]. The active p38α MAP kinase formed in the 
assay was then measured by its ability to incorporate32P-radioactivity from 
[γ32P]ATP into myelin basic protein. This assay was carried out by Jiazhen 
Zhang, Cohen lab. 
2.2.3.7 Protein resolution by SDS/PAGE and transfer to PVDF 
SDS polyacrylamide gel electrophoresis (SDS/PAGE) helps to resolve 
proteins according to their apparent molecular weight. SDS and LDS are 
anionic detergents, which coat proteins to give them a net negative charge 
that is proportional to their molecular weight. This enables the migration of 
proteins through an acrylamide gel at a rate that is proportional to their size. 
Samples are also incubated with reducing agents, DTT or βME, to break 
disulphide linkages and unravel the protein further, to ensure it is linear.  
Cell extract protein in an LDS buffer (20 µg) was subjected to 
SDS/PAGE. A stacking gel (pH 6.8) (Table 2.4) helps to concentrate the 
proteins into a narrow band so that they all enter the resolving gel (pH 8.8) 
(Table 2.4) at the same time, enabling proteins of similar molecular weight to 
migrate in tight bands. Resolving gels were composed of different 
percentages of acrylamide, which helped to best resolve proteins of a 
particular molecular weight. The gels were run in Tris-glycine SDS running 
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buffer (Table 2.4) at a constant 120 V until the dye front had reached the 
bottom of the gel. The electric field applied to the gel promotes the migration 
of the negatively charged proteins away from the cathode, at the top of the 
gel, to the anode. On occasion, the migration of a phosphorylated protein 
compared to the non-phosphorylated form was retarded. This generates a 
band-shift that appears to be much greater than the 80 Da mass of a 
phosphate group. This is caused by less SDS binding to the phosphorylated 
region, which hinders the protein’s progression through the gel and gives it a 
larger apparent molecular weight. Commercial pre-cast gels (4-12% Bis-Tris, 
NuPAGE) were used if ubiquitin chains were to be investigated or if proteins 
were to be subjected to mass spectrometry. Commercial gels were run in 
MOPS buffer (NuPAGE) (Table 2.4) at a constant 120 V. Both gel types were 
transferred onto PVDF membranes, which had been activated in 100% 
methanol, in Tris-glycine transfer buffer (Table 2.4) for 80 min at 80 V.   
2.2.3.8 Coomassie staining of SDS/PAGE gels 
After SDS/PAGE gels were washed in deionised waster and incubated 
in 20 ml of InstantBlue (Expedeon) on a rocking platform for 1 – 24 h. 
Following this the gel was repeatedly washed in deionised water to de-stain.  
2.2.3.9 Immunoblotting (Western blotting)   
Proteins that had been transferred onto PVDF membranes were 
stained with Ponceau S and destained in deionised water to visualise protein 
bands and evaluate the quality of the SDS/PAGE gel. The membranes were 
cut with a scalpel so that several proteins could be immuboblotted for on one 
PVDF membrane.  The non-specific binding of antibodies to the PVDF 
membrane was prevented by incubating the membranes with PVDF blocking 
solution (Table 2.4) for 30 min at RT. PVDF membranes were incubated with 
primary antibodies for 16 h at 4°C on a rotating wheel. Membranes were 
washed five times for 3 min in TBS-T (Table 2.4) followed by 5 min in TBS 
(Table 2.4). Horseradish peroxidase (HRP) conjugated secondary antibodies 
(Table 2.2) were diluted at 1:10000 in PVDF blocking solution and incubated 
for 1 hr at RT with the PVDF membranes. The membranes were then washed 
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as before with TBS-T and TBS.  The PVDF membrane was then incubated 
with enhanced chemiluminescence (ECL) substrate for 1 min, placed in an X-
ray cassette and exposed to X-ray films for increasing periods of time until the 
best exposure was found.  X-ray films were developed using a Konica 
automatic developer.  
2.2.3.10 Immunofluorescence and induction of DNA damage 
U2OS cells were seeded onto sterile coverslips (1.5 x 105) in a 6-well 
plate. The next day they were transfected with GFP-RAP80[1-200] using 
Lipofectamine (Section 2.2.1.8.2). After 24 h the cells were exposed to 
ionising radiation (2 Grays) with a 137Cs radiation source. The cells were fixed 
for 10 min at 21°C using 4% paraformaldehyde. Soluble proteins were 
removed before fixation by extraction for 5 min in ice-cold 10 mM Pipes, 
pH 7.0, 300 mM sucrose, 100 mM NaCl, 3 mM MgCl2, 1 mM EGTA and 0.5% 
(v/v) Triton X-100. Cells were permeabilised for 20 min at 21°C with PBS 
containing 0.2% (v/v) Triton X-100, washed several times in PBS and then 
incubated in blocking solution (PBS containing 5% (v/v) donkey serum, 0.1% 
(w/v) fish skin gelatin and 0.05% (v/v) Tween-20). Cover slips were incubated 
for 1 h at 21°C with primary antibodies in blocking solution, then washed in 
PBS and incubated for 1.5 h with the fluorophore-conjugated secondary 
antibodies. The nuclei were stained for 30 min with DAPI before coverslips 
were mounted on to glass slides. Slides were viewed using a Nikon eclipse Ti 
inverted microscope.  
2.2.3.11 Measurement of cytokines by an enzyme-linked 
immunosorbant assay (ELISA) 
IL-1R* cells and primary MEFs were seeded at a final concentration of 
1.5 x 105 into 24 well and 12 well plates respectively. After stimulation the cell 
culture medium was collected. IL-8 and MIP-2 secretion was measured from 
50 µl of cell culture medium in triplicate in a 96-well plate using the (ELISA) 
kits from Peprotech (900-K18 and 900-K152) according to the manufacturers 
instructions. ABTS  (2,2'-Azino-bis[3-ethylbenzothiazoline-6-sulfonicacid]- 
diammonium salt) was used as a substrate. The ELISA was stopped by the 
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addition of 0.5 M sulphuric acid and absorbance was measured at 450 nM. A 
standard curve was generated by plotting the absorbance against a dilution of 
cytokine standards. This was used to calculate the concentration of cytokines 
in the samples.  
2.2.3.12 Preparation of Halo-tagged proteins from bacteria 
The Ub-binding proteins NEMO or NZF2 (from TAB2) were expressed 
in E. coli as Halo-tagged proteins (Table 2.6). One transformed BL21 clone 
was grown in 25 ml of LB with ampicillin/kanamycin for 16 h. This was used to 
inoculate 1 L of LB + antibiotics which was incubated at 37°C on a shaking 
platform until the optical density reached 600 nM. The expression of Halo-
NEMO/Halo-NZF2 was induced by the addition of 500 µM 
isopropylthiogalactoside (IPTG) and the cells were placed on a shaking 
platform at 20°C overnight. Subsequently the cells were pelleted by 
centrifugation at 4600 rpm for 30 min at 4°C. The pellet was resuspended in 
40 ml bacterial lysis buffer (Table 2.4) and incubated with 1 mg/ml lysozyme 
for 20 min at 4°C on a rotating wheel. The solution was sonicated on ice at 
30% amplification for a 10 s pulse followed by 15 s break, 8 consecutive times. 
The lysate was clarified by centrifugation at 14,000 rpm for 30 min (4°C) and 
the supernatant was passed through a 0.45 µM filter. The protein extract (20 
µg) was subjected to SDS/PAGE alongside protein extract (20 µg) from BL21 
cells not induced to express Halo-tagged proteins. The SDS/PAGE gel was 
stained with coomassie to check the expression of Halo-tagged proteins. To 
covalently couple Halo-tagged proteins to the Halo-link resin (Promega), 35 
mg of BL21 protein extract was incubated with 1.5 ml packed Halo-link resin 
overnight at 4°C on a rotating wheel. The beads were washed 5 times with 10 
ml of Halo resin wash buffer and 5 times with Halo resin storage buffer (Table 
2.4). The beads were stored as a 20% slurry in Halo resin storage buffer and 
were stable up to 1 year at 4°C.  
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2.2.3.13 Purification of the His6-TAB3/TAK1/TAB1 complex from 
Sf21 insect cells 
The Protein Production Team (DSTT) infected 1 L of culture medium 
containing insect Sf21 cells with baculovirus encoding the TAB1, TAK1 and 
His6-TAB3 proteins. After the cells were pelleted they were re-suspended in 
lysis buffer (25 mM Tris/HCl pH 7.5, 0.02 mM EDTA, 270 mM sucrose, 1% 
(v/v) Triton-X100, 0.03% (w/v) Brij-35, 1.0 mM 4-(2-Aminoethyl) 
benzenesulfonyl fluoride hydrochloride, protease inhibitor cocktail (Roche, 
#11836170001 one tablet per 50 ml) and 0.5 mM Tris(2-
carboxyethyl)phosphine/HCl (TCEP) pH 7.0). After end-over-end rotation for 
30 min at 4°C, followed by centrifugation for 20 min at 15,000 x g at 4°C, the 
supernatant was removed. NaCl was added to a final concentration of 0.3 M 
and the cell extract was then mixed with Talon cobalt-Sepharose resin (3 ml 
packed volume) (Clontech) followed by incubation for 60 min at 4°C on a 
rotating wheel. The suspension was poured into a 30 ml column and the resin 
was washed with 500 ml of 25 mM Tris/HCl pH 7.5, 0.02 mM EDTA, 0.07% 
(v/v) βME, 0.3 M NaCl and 0.2 mM PMSF (Buffer A), containing 10 mM 
imidazole, and then with Buffer A.  The TAB1-TAK1-TAB3 complex was 
eluted from the resin by cleaving the His6 tag attached to the N-terminus of the 
TAB3 component with GST-tagged-PreScission protease (Table 2.3). The 
protease (0.1 mg in 10 ml of Buffer A) was incubated with the re-suspended 
resin for 16 h at 4°C and the supernatant retained.  The resin was washed 
with a further 2 ml of Buffer A and the two supernatants were combined and 
incubated with 0.3 ml of glutathione-Sepharose beads to remove the GST-
PreScission Protease. The eluate was then concentrated to 0.5 ml using an 
Amicon Ultra tube (Millipore) with a 50 kDa cut-off limit to give a 0.05 mg/ml 
solution.  
2.2.3.14 Expression and purification of MKK6  
MKK6 was expressed in E. coli with an N-terminal GST tag (Table 2.6) 
as in Section 2.2.3.12.  After induction of GST-MKK6 by incubation of the 
bacteria for 16 h with 0.5 M IPTG, the cells were harvested, lysed in 50 mM 
Tris/HCl, pH 7.5, 150 mM NaCl, 1 mM EGTA, 1 mM EDTA, 0.1% (v/v) βME, 1 
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mM benzamidine, 0.2 mM PMSF and 1% (v/v) Triton-X100 and sonicated as 
in Section 2.2.3.12. The cell lysate was centrifuged to remove debris, passed 
through a 22 µM filter and the supernatant incubated for 1 h at 4°C with 4 ml 
packed glutathione-Sepharose beads. The beads were washed with 50 mM 
Tris/HCl pH 7.5, 1% (v/v) Triton-X100 and 0.5 M NaCl (Buffer B) and then 
resuspended in 4 ml of 50 mM HEPES pH 7.0, 10 mM NaCl , 2 mM DTT, 
0.01% (w/v) Brij 35 and 1 mM MnCl2  containing 0.1 mg  phage protein 
phosphatase (Table 2.3).  After incubation for 1 h at 30°C, the resin was 
washed in Buffer B to remove the phosphatase and then incubated for 16 h at 
4°C with 0.1 mg of PreScission Protease in 1 ml of 50 mM Tris/HCl pH 7.5, 
150 mM NaCl, 1 mM EDTA, 1 mM DTT and 0.035% (w/v) Brij-35. The 
supernatant was retained and analysed for purity by SDS/PAGE. 
2.2.3.15 Expression and purification of WT and E3 ligase-inactive 
mutants of Dac-TRAF6    
Purified by Axel Knebel, PPAD, MRC-PPU. Human TRAF6 (DU43249), 
or TRAF6 mutants in which Cys70 and Leu74 were changed to Ala 
(DU43527) and His (DU46742), respectively, were expressed in insect cells 
as Dac-tagged fusion proteins [236]. The insect cells were sedimented by 
centrifugation, lysed in 50 mM Tris/HCl pH 7.5, 0.2% (v/v) Triton X-100, 1 mM 
TCEP, 0.1 mM EDTA, 0.1 mM EGTA, 20 µg/ml leupeptin, 1 mM Pefabloc® 
and insoluble material was removed by centrifugation. The supernatant made 
250 mM in NaCl and incubated for 45 min at 21oC with 2 ml freshly prepared 
ampicillin-Sepharose. Contaminants were washed away by repeatedly (5 
times) re-suspending the ampicillin Sepharose in 13 vol of 50 mM Tris/HCl pH 
7.5, 150 mM NaCl, 0.03% (w/v) Brij35, 1 mM TCEP (Buffer C). To cleave 
TRAF6 from the Dac-tag, the ampicillin Sepharose was re-suspended in 0.5 
vol of Buffer C and incubated for 3 h at 21oC with 20 µg of recombinant 
Tobacco Etch Virus (TEV)-protease with occasional agitation. TRAF6 was the 
major protein-staining band in the final preparation, the only significant 
contaminant being HSP70. Between 0.5 and 1.0 mg of TRAF6 was purified 
from each litre of cell culture medium. 
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2.2.4 In vitro assays 
2.2.4.1 E1 and E2 loading assays 
UBE1 (0.17 μM) in 22.5 μl of 20 mM Hepes, pH 7.5, containing 10 μM 
ubiquitin was incubated for 45 min at 21°C with 1 μl of DMSO or 1 μl of an 
inhibitor in DMSO. A 2.5 μl solution of 10 mM magnesium acetate and 0.2 mM 
ATP was added, incubated for 10 min at 30°C, and the reactions were 
terminated by the addition of 2.5 μl of LDS and heating for 6 min at 75°C. The 
samples were subjected to SDS/PAGE in the absence of any thiol. The gels 
were stained for 1 h with Coomassie Instant Blue and destained by washing 
with water. The loading of ubiquitin to E2 conjugating enzymes was carried 
out in an identical manner, except that UBE1 (0.17 μM) was mixed with 
Ubc13 (2.4 μM) or UbcH7 (2.9 μM) prior to incubation with the inhibitor. 
To assay 26 E2s, the E2 scan kit was purchased from Ubiquigent. The 
E2s were incubated with 1 µl of inhibitor for 45 min at 21°C and the assays 
were carried out according to the manufacturers instructions in a 96-well plate. 
To terminate the reaction LDS was added and the samples were subjected to 
SDS/PAGE following staining with coomassie.   
2.2.4.2 Assay of purified TRAF6 
 WT TRAF6 (5 nM) or TRAF6 mutants (50 nM) (Table 2.3) were 
incubated with 0.2 µM UBE1, 2 µM of the indicated E2 and 10 µM of FLAG-
ubiquitin in 50 mM Tris/HCl, pH 7.5, 5.0 mM MgCl2 and 2.0 mM ATP in a total 
reaction volume of 0.03 ml. After incubation for 1 h at 30°C the reactions were 
terminated by the addition of SDS. The samples were subjected to 
SDS/PAGE and the formation of ubiquitin chains by TRAF6 was assessed by 
immunoblotting with anti-FLAG (Table 2.1). 
2.2.4.3 Activation of the TAK1 complex  
The purified TAB1-TAK1-TAB3 complex (1.0 nM) was activated by 
incubation for 1 h at 30 °C with 0.2 µM UBE1, 1.0 µM Ubc13-Uev1a, 12.5 µM 
ubiquitin and either 0.4 µM TRAF6 or 0.4 µM Pellino1 in 50 mM Tris/HCl pH 
7.5, 2.0 mM ATP and 5.0 mM MgCl2 in a total reaction volume of 0.03 ml. 
MKK6 (0.1 mM) and p38γ MAP kinase (0.5 mM) were also included to 
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monitor the activation of TAK1. The reaction was terminated by the addition of 
LDS and subjected to SDS/PAGE.  
2.2.4.4 The effect of BAY 11-7082 on kinase activity 
Assays were performed by Lorna Plater, DSTT, University of Dundee. IKKα, 
IKKβ, TAK1, IRAK1 and IRAK4 were assayed at 0.1mM ATP in the absence 
of any thiol. The results are presented as the activity in the presence of BAY 
11-7082 divided by the activity in the absence of BAY 11-7082 multiplied by 
100.  
2.2.5 Mass spectrometry (MS) and nuclear magnetic resonance (NMR) 
spectroscopy  
2.2.5.1 In-gel digestion of proteins for peptide analysis by liquid 
chromatography-MS/MS 
To identify covalent modifications to Ubc13 and Ubch7 caused by BAY 
11-7082, mass spectrometry was employed. E2 loading assays were carried 
out as in Section 2.2.4.1 and the samples were then subjected to SDS/PAGE 
and stained with coomassie followed by destaining in ionised water. To 
minimise contamination, all following steps for sample preparation were 
carried out in a laminar flow hood (Model A3VB, Bassaire Limited). Clean 
scalpels were used to excise the protein bands containing Ubc13 and UbcH7 
from the coomassie-stained SDS-PAGE gel. Gel pieces were then minced into 
small ~1 mm cubes and placed into a LoBind 1.5 ml tube (Eppendorf). The gel 
pieces were sequentially washed for 10 min in 0.5 ml of water and then 50% 
acetonitrile (ACN) followed by 100 mM NH4HCO3 and finally 50% ACN/50 mM 
NH4HCO3. Gel pieces were incubated with 10 mM DTT/100 mM NH4HCO3 for 
45 min at 65°C to reduce disulphide bonds and were then alkylated with 50 
mM iodoacetamide/100 mM NH4HCO3 for 30 min at room temperature in the 
dark. Gel pieces were repeatedly washed with 100 mM NH4HCO3 and 50% 
ACN/50 mM NH4HCO3 to remove all coomassie dye. The gel pieces the 
dehydrated by the addition of 0.3 ml ACN for 30 min at room temperature. The 
ACN was aspirated from the gel pieces and a SpeedVac was then used to 
remove residual moisture. The gel pieces were swollen by the addition of 100 
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μl of 25 mM Triethylammonium bicarbonate (TEAB) and Trypsin (5 μg/ml), 
pre-activated by incubation at 30°C for 30 min. After 30 min, further 25 mM 
TEAB was added to ensure the gel pieces were sufficiently covered and they 
were incubated for 16 hours at 30°C on a shaking platform. An equivalent 
volume of ACN was added to the digest for 15 min at room temperature. 
Supernatants were transferred to clean LoBind 1.5 ml tubes. To maximise the 
recovery of peptide, 150 μl of 50% ACN/ 2.5% formic acid was added to the 
dehydrated gel pieces and incubated for 15 min at room temperature. The 
supernatant was combined with the first and dried completely using a 
SpeedVac. Samples were logged in and sent to the Proteomics and Mass 
Spectrometry Team, MRC-PPU for analysis by David Campbell.  
Tryptic peptide analysis using LC (liquid crystallography)-MS/MS 
(tandem MS) was performed on an Easy-nLC HPLC coupled to an LTQ-
Orbitrap Classic (Thermo) and data was analysed using the Mascot search 
program (http://www.matrixscience.com). Peptides were analysed for 
modification by BAY 11-7082 by the addition of a cysteine-specific 
modification of +C(3) H(1) N(1) (+51.011 Da) to Mascot. Gluconylation, +C(6) 
H(10) O(6) (+178.048 Da), was a standard Mascot modification. Edman 
sequencing was performed on an Applied Biosystems ProCis e494c 
sequencer according to the manufacturer's instructions. 
2.2.5.2 Measurement of the molecular mass of Ubc13 by MALDI–TOF 
(matrix-assisted laser-desorption ionisation–time-of-flight)-MS 
Ubc13 (2.6 μM) was incubated for 30 min at 21°C without or with 
10 μM BAY 11-7082 or NSC697923 in 25 mM Hepes, pH 7.5, and then 
exchanged into 5 mM Tris/HCl, pH 7.5 using Amicon ultra 5 kDa 1.5 ml tubes 
(EMD Millipore). Samples were then sent to the Proteomics and Mass 
Spectrometry Team, MRC-PPU for analysis by Stella Ritorto. An aliquot of the 
reaction (2 μl) was added to 2 μl of the matrix (2,5-dihydroxyacetophenone) 
and 2 μl of 2% (v/v) trifluoroacetic acid was added before spotting 1 μl of the 
sample on to a steel target. The analysis was performed manually in reflector 
positive mode using an UltrafleXtreme (Bruker Daltonics) MALDI–TOF mass 
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spectrometer. For external calibration, two mono-isotopic masses were used: 
cytochrome c [M+H]+ (12361 Da) and myoglobin [M+H]+ (16952 Da).  
2.2.5.3 Reaction of N-acetyl cysteine with BAY 11-7082 and analysis of 
the products of the reaction by NMR spectroscopy and MS 
This analysis was performed by Natalia Shpiro, MRC-PPU. A solution 
of BAY 11-7082 (0.0037 g, 0.018 mmol) in DMSO (0.2 ml) was added at 20°C 
to a solution of N-acetyl cysteine (0.003 g, 0.018 mmol) and Tris (2-
carboxyethyl) phosphine hydrochloride (0.011 g, 0.038 mmol) in 1 M 
phosphate buffer, pH 8.5 (1 ml). The reaction was vortex-mixed for 2 min, 
allowed to stand for 15 min, diluted with 1 ml of 5:95 ACN/water (0.1% (v/v) 
formic acid) and applied to a Waters Xbridge 19 μm×100 μm diameter, 5 μm 
particle size C18 column. The column was developed with a gradient from 5% 
to 95% acetonitrile in water (0.1% (v/v) formic acid) at a flow rate of 25 ml/min. 
The appropriate fractions were pooled and concentrated, and the structures of 
the products (R,E)-2-acetamido-3-[(2-cyanovinyl)thio] propanoic acid 
(Compound 1) (2.0 mg, 0.009 mmol, 50%) and 4-methylbenzene-sulfinic acid 
(Compound 2) (0.002 g, 0.0128 mmol, 71%) deduced from NMR spectra were 
recorded on a Bruker AVANCE II 500 spectrometer. HRMS (high-resolution 
mass spectra) were obtained on a microTOF Bruker Daltonics instrument. 
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3 The regulation of E3 ligases and ubiquitin chain 
formation within the MyD88 signalling network 
3.1 Introduction 
For a long time it has been known that TRAF6 is an essential 
component of the MyD88 signalling network [134,135]. Without it, IL-1 is 
unable to promote the activation of the ‘master kinase’, TAK1 and hence 
activation of the canonical IKK complex in MEFs [140]. Later, TRAF6 was 
found to be able to form a productive complex with the E2 conjugating 
complex, Ubc13-Uev1a, and generate K63-Ub chains in vitro [128,149]. 
Moreover, the K63-Ub chains generated by TRAF6 were able to activate the 
TAK1 complex in vitro [149]. TRAF6 mutants that lacked E3 ligase activity in 
vitro, failed to restore IL-1 signalling to TRAF6 KO MEFs [129,138,140]. It was 
therefore concluded that TRAF6 is crucial to IL-1 signalling because it 
generates the K63-Ub chains needed to activate the TAK1 complex. A 
subsequent important discovery made by our group was that almost all of the 
M1-Ub chains formed in response to IL-1 stimulation were covalently attached 
to K63-Ub chains, which, in turn, were attached to the IRAKs and MyD88 [43]. 
We believed that, within the context of cell signalling, this made a lot of sense. 
This is because the TAK1 complex interacts specifically with K63-Ub chains 
via its TAB2 or TAB3 subunits and the IKK complex predominantly interacts 
with M1-Ub chains via its regulatory NEMO component. Therefore, this would 
potentially enable the co-localisation of the TAK1 complex and the IKK 
complex on a hybrid M1/K63-Ub chain, which would be expected to facilitate 
the TAK1-dependent activation of the IKK complex [105].  
However, there are aspects of this model that have still to be 
addressed with genetic evidence. For example, it has never been reported 
whether the IL-1-stimulated formation of K63-Ub chains fails to occur in a 
TRAF6 KO cell line.  Moreover, although the conditional Ubc13 KO mouse 
has been generated, the formation of K63-Ub chains in response to IL-1 
stimulation was never assessed [239]. Furthermore, our group has shown that 
another E3 ubiquitin ligase, Pellino1, is converted from an inactive to an active 
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E3 ligase following IL-1 stimulation. In vitro, Pellino1 can catalyse the 
formation of K63-Ub chains in the presence of Ubc13-Uev1a, and in cells 
Pellino2 can induce the K63-linked ubiquitylation of IRAK1 in co-transfection 
experiments [195]. The Pellino family of E3 ligases were therefore also 
candidates to generate K63-Ub chains upon activation of the MyD88 
signalling network. Consequently, I was interested in seeing if Pellino1 was 
still activated in cells that lacked TRAF6. Additionally, I was curious as to 
whether IL-1 signalling would be affected by a loss of Pellino E3 ligase 
activity. Over the course of my PhD I attempted to tackle these issues and the 
results are presented in this Chapter. A few of the figures included in this 
Chapter were generated by other members of the Cohen lab, namely 
Christoph Emmerich and Jiazhen Zhang, and this is mentioned in the relevant 
figure legends.  
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3.2 Results 
3.2.1 The IL-1-stimulated formation of M1-Ub chains is dependent on 
the prior formation of K63-Ub chains 
 The M1-Ub chains formed in response IL-1 stimulation are covalently 
attached to K63-Ub chains, which, in turn, are linked proteins, such as IRAK1, 
IRAK4 and MyD88 [43]. This would suggest that in the absence of K63-Ub 
chains, the IL-1-stimulated formation of M1-Ub chains should not occur. 
Ubc13 is an E2-conjugating enzyme that forms a complex with Uev1a and is 
the only E2 identified, so far, capable of directing the formation of K63-Ub 
chains specifically. To investigate whether M1-Ub chain formation is 
dependent on prior formation of K63-Ub chains and if these K63-Ub chains 
can only be generated by Ubc13, I stably knocked-down Ubc13 expression 
with a specific shRNA in IL-1R cells (Fig. 3.1A). I was able to study the 
regulation of both Ub chain types using antibodies that detect M1-Ub or K63-
Ub chains specifically (Fig. 1B in [43] and Figs. 4B and 6 in [240]).  The large 
reduction in Ubc13 expression greatly reduced the IL-1-stimulated formation 
of K63-Ub chains and also severely impaired the activation of the IKKs and 
MAP kinases (Fig. 3.1A). Moreover, the formation of M1-Ub chains was also 
greatly diminished, consistent with the notion that M1-Ub chain production is 
dependent on prior K63-Ub chain formation (Fig. 3.1A). Crucially, the re-
expression of Ubc13 in the Ubc13-knock-down cells was able to restore both 
the IL-1-induced formation of K63-Ub and M1-Ub chains, in addition to the 
activation of the canonical IKK complex and MAP kinases (Fig. 3.1B, lanes 7-
9). 
To investigate whether conversely, the loss of M1-Ub chains would 
affect the IL-1-stimulated formation of K63-Ub chains, I generated cells in 
which the expression of two components of LUBAC, HOIP and HOIL-1, were 
stably reduced using specific shRNA (Fig. 3.1C). In these cells the IL-1-
dependent formation of M1-Ub chains and the activation of IKKβ was 
impaired, as judged by reduced phosphorylation of its substrate p105 (Fig. 
3.1C). However, the IL-1-dependent generation of K63-Ub chains was 
unaffected (Fig. 3.1C). Taken together, these experiments infer that the IL-1-  
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Figure 3.1 K63-Ub chain formation is required for the IL-1-
stimulated generation of M1-Ub chains 
(A) IL-1R cells stably expressing either an empty shRNA vector or shRNA 
specific to Ubc13 were stimulated for the times indicated with IL-1β and 
then lysed. The Ub chains were captured from cell extracts (2 mg protein) 
on immobilised Halo-NEMO before being released in SDS and 
immunoblotted with Ub linkage-specific antibodies (top two panels). 
Aliquots of the cell extracts were also immunoblotted with the antibodies 
indicated (bottom 8 panels). (B) As in A, except that, IL-1R cells with 
Ubc13 stably knocked-down were transiently transfected with shRNA-
resistant Ubc13 DNA which restored the IL-1-induced formation of K63 
and M1-Ub chains and the activation of the MAP kinases JNK1/2 and 
IKKβ, as judged by phosphorylation of its substrate p105 (C) As in A, 
except that shRNA specific for HOIP and HOIL-1 was used in place of 
Ubc13 shRNA and Halo-TAB2(NZF2) was used to capture K63-Ub chains.  
 72 
 
stimulated formation of K63-Ub is a prerequisite for the generation of M1-Ub 
chains.    
3.2.2  The role of TRAF6 within the IL-1 signalling pathway in HEK293 
cells expressing the IL-1R 
3.2.2.1 The generation of TRAF6-null IL-1R* cells 
 It has been assumed that the expression of TRAF6 is essential for the 
MyD88 signalling network because it generates the K63-Ub chains necessary 
for the activation of TAK1 [149,225]. However, the genetic evidence for this 
has never been reported. To investigate the role of TRAF6 in the MyD88 
signalling network I generated TRAF6-null cells. I used the newly developed 
CRISPR/Cas9 (clustered regularly interspaced short palindromic 
repeat/CRISPR associated protein 9) method to abolish the expression of 
TRAF6 instead of shRNA, because knock-down will still leave residual 
expression. To begin with, the IL-1R was stably inserted into HEK293 cells 
(Section 2.2.1.3.1) generated within the MRC-PPU that inducibly express the 
DNA endonuclease, Cas9 [228]. These cells express much lower levels of the 
IL-1R than the IL-1R cells used in Fig. 3.1 (Fig. 3.2A) and hence, were termed 
IL-1R* cells to distinguish them from IL-1R cells.  
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Figure 3.2 Comparison of IL-1R levels and early IL-1 signalling 
events in IL-1R cells and IL-1R* cells 
(A) IL-1R cells, HEK293 and IL-1R* cells (generated by Jiazhen Zhang, 
Cohen lab) were lysed and aliquots of the cell extract were immunoblotted 
with antibodies that recognise the IL-1R and GAPDH. (B) IL-1R and IL-1R* 
cells were stimulated for the times indicated with IL-1β (5 ng/ml) before 
lysis and subjected to SDS/PAGE. Samples were immunoblotted with the 
antibodies indicated. p-, phospho. 
   
The IL-1R* cells responded robustly to IL-1, although not as strongly or as fast 
as the IL-1R cells (Fig. 3.2). I then targeted exon 2 of TRAF6 in IL-1R* cells 
using specific guide RNAs (gRNAs) [228] to generate TRAF6-null cells (Fig. 
3.3A). I was also able to confirm through mass spectrometry analysis of 
TRAF6 immunoprecipitates, that TRAF6-null IL-1R* cells completely lacked 
TRAF6 expression (data not shown).  
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3.2.2.2 The IL-1-stimulated activation of TAK1 and the canonical IKK 
complex does not occur in TRAF6-null IL-1R* cells  
 The IL-1-stimulated activation of the canonical IKK complex and MAP 
kinases, which is dependent on TAK1 catalytic activity, was abolished in 
TRAF6-null IL-1R* cells (Fig. 3.3A).  These results implied that much like 
TRAF6 KO MEFs, TAK1 was not activated in TRAF6-null IL-1R* cells. 
Consistent with this notion, the commonly used readouts for TAK1 activation; 
phosphorylation at Thr187 and a decrease in its electrophoretic mobility, did 
not occur in TRAF6-null IL-1R* cells (Fig. 3.3A). As it is unclear whether 
Thr187 phosphorylation is sufficient for TAK1 activation, TAK1 activity was 
measured by a kinase assay after it was immunoprecipitated from cells (Fig. 
3.3B). These experiments established that TRAF6 is required for the 
activation of TAK1 in IL-1R* cells, as has been reported in MEFs. However, 
the IL-1-dependent phosphorylation of IRAK4 was actually enhanced in 
TRAF6-null IL-1R* cells (Fig. 3.3A). This shows that the loss of TRAF6 does 
not impair the IL-1-dependent recruitment of IRAK4 to the Myddosome and its 
auto-phosphorylation. 
I also investigated whether the secretion of the proinflammatory 
cytokine, IL-8, occurred in IL-1-stimulated WT and TRAF6-null IL-1R* cells. I 
found that the production of IL-8 mRNA was rapidly induced 1 h after IL-1 
stimulation in WT IL-1R* cells and this peaked at 4 h before beginning to 
decline at 8 h (Fig. 3.3C). Consistent with this, I found that the secretion of IL-
8 occurred 4 h after IL-1 stimulation and the amount secreted had increased 
further at 8 h (Fig. 3.3D). In contrast, the IL-1-stimulated production of IL-8 
mRNA and its secretion was completely suppressed in TRAF6-null IL-1R* 
cells, as expected from the failure to activate the signalling network (Fig. 3.3C 
and D).  
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Figure 3.3 The IL-1-stimulated activation of the MyD88 signalling 
network in WT and TRAF6-null IL-1R* cells 
(A) WT and TRAF6-null cells were stimulated with IL-1β (5 ng/ml) for the 
times indicated and aliquots of the cell extract were immunoblotted with 
the antibodies indicated. (B) As in A, except that after IL-1β stimulation, 
TAK1 was immunoprecipitated from the cell extracts and assayed as 
described in Methods. The ordinate shows the incorporation of 32P-
radioactivity into myelin basic protein, which is phosphorylated by p38α in 
the coupled assay. Experiment performed by Jiazhen Zhang (Cohen lab). 
(C) As in A, except that after IL-1β stimulation RNA was extracted from the 
cells. mRNA encoding IL-8 was determined by quantitative PCR and the 
results are plotted as a fold-increase of mRNA relative to the level found in 
unstimulated cells. The results are presented as mean ±S.E. (n=3). (D) As 
in C, except that the concentration of IL-8 secreted into the cell culture 
medium was determined by ELISA. The results are presented as mean 
±S.E. (n=3). 
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3.2.2.3 Ubiquitin chain formation in TRAF6-null IL-1R* cells 
The E3 ligase activity of TRAF6 has been reported to be essential for 
IL-1 signalling, suggesting that a loss of TRAF6 will prevent the IL-1-
dependent formation of K63-Ub chains. However, to my surprise, I found that 
the IL-1-stimulated formation of K63-Ub chains was not diminished in TRAF6-
null cells (Fig. 3.4A). I next looked to see whether the formation of M1-Ub 
chains was similarly unaffected. Even more unexpectedly, the IL-1 formation 
of M1-Ub chains was greatly diminished in TRAF6-null cells (Fig. 3.4A).  This 
result is not explained by a loss of the expression of HOIP, HOIL-1 or Sharpin 
since the expression of these three components of LUBAC was slightly 
increased in TRAF6-null IL-1R* cells (Fig. 3.4B). Moreover, LUBAC E3 ligase 
activity measured from the extracts of TRAF6-null IL-1R* cells was actually 
higher than measured in the extracts of WT IL-1R* cells, as shown by the 
near-complete depletion of the free ubiquitin added to the assay (Fig. 3.4C, 
compare lanes 1-4 with lanes 5-8). This shows that the intrinsic activity of 
LUBAC is not impaired in WT or TRAF6-null IL-1R* cells after IL-1β 
stimulation.  
We have reported previously that IRAK1, IRAK4, MyD88 and Pellino1 
are ubiquitylated with M1-Ub chains and/or K63-Ub chains in response to IL-1 
stimulation of IL-1R cells [43]. I therefore investigated whether the 
ubiquitylation of these proteins was affected in TRAF6-null IL-1R* cells. To do 
this I used Halo-NEMO resin, which predominantly binds M1-Ub chains, and 
immobilised Halo-NZF2, which binds K63-Ub chains specifically, to capture 
proteins modified with M1-Ub, K63-Ub or hybrid M1/K63-Ub chains [43]. It is 
apparent that IRAK1, IRAK4, MyD88 and Pellino1 are ubiquitylated in 
response to IL-1 stimulation of WT IL-1R* cells (Fig. 3.4D). Moreover, in 
TRAF6-null IL-1R* cells, the ubiquitylation of these proteins was not 
diminished, but was markedly enhanced (Fig. 3.4D, compare lanes 2-3 and 8-
9 with lanes 5-6 and 11-12, respectively). 
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Figure 3.4 Analysis of ubiquitylation events in IL-1-stimulated TRAF6 
WT and null IL-1R* cells 
(A) WT and TRAF6-null IL-1R* cells were stimulated with IL-1β (5 ng/ml) where 
indicated for 15 min and lysed. Ub chains were captured from cell extract on Halo-
NEMO and immunoblotted with K63-Ub and M1-Ub antibodies. IKKβ binds to Halo-
NEMO independently of IL-1 stimulation and therefore served as a loading control. (B) 
IL-1R* WT and TRAF6-null cells were lysed and aliquots of the cell extract were 
immunoblotted with the antibodies indicated. (C) As in A, except that after IL-1β 
stimulation LUBAC was immunoprecipitated from the cell extract using anti-HOIP or 
control IgG. LUBAC was assayed in vitro as described in Methods (top panel) and HOIP 
was also immunoblotted for (lower panel). * indicates a non-specific band detected by 
the Ub antibody. (D) As in A, except that Halo-TAB2(NZF2) was also used to capture Ub 
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chains. (E) As in A, except that after Ub chain capture the samples were incubated with 
IsoT, where indicated, to hydrolyse ‘unanchored’ Ub chains. Authentic ‘unanchored’ 
K63-Ub chains served as the control for IsoT hydrolysis. The immunoblot was probed 
with anti-K63-Ub. The experiments presented in C and E were performed by Christoph 
Emmerich (Cohen lab). 
 
 
The expression of IRAKs 1 and 4 and MyD88 in cell extracts from TRAF6-null 
IL-1R* cells was unchanged and is therefore not the reason for their enhanced 
ubiquitylation (Fig. 3.4B). However, the expression of Pellino1 is slightly 
increased in TRAF6-null IL-1R* cells (Fig. 3.4B). Taken together, these 
experiments show that the K63-Ub chains formed in TRAF6-null IL-1R* cells 
become attached to proteins that are normally ubiquitylated in IL-1-stimulated 
WT IL-1R* cells, again indicating that Myddosome formation is not impaired in 
TRAF6-null IL-1R* cells.   
The TAK1 complex can be activated in vitro by TRAF6-generated K63-
Ub chains that are not attached covalently to any protein (termed 
‘unanchored’ ubiquitin chains) [149]. Based on these results it was suggested 
that ‘unanchored’ K63-Ub chains and not ‘anchored’ K63-Ub chains may 
activate the TAK1 complex in vivo. It was therefore possible that TRAF6 had a 
specific role in generating ‘unanchored’ K63-Ub chains, explaining why TAK1 
and its downstream targets were not activated in TRAF6-null IL-1R* cells. To 
test whether the proportion of ‘unanchored’ and ‘anchored’ K63-Ub chains, 
formed in response to IL-1, was different in WT and TRAF6-null IL-1R* cells, 
the K63-Ub chains captured by Halo-NEMO were incubated with IsoT (also 
called USP5), a DUB that can only hydrolyse ‘unanchored’ ubiquitin chains 
[149]. Around half of the K63-Ub chains, captured by Halo-NEMO from 
TRAF6-null or WT IL-1R* cells, were hydrolysed by IsoT (Fig. 3.4E, compare 
lanes 3-4 and 7-8 with lanes 1-2 and 5-6, respectively), indicating that similar 
amounts of ‘unanchored’ K63-Ub chains are formed in TRAF6-null and WT IL-
1R* cells. In parallel, ‘unanchored’ K63-Ub chains obtained from a commercial 
supplier, were completely hydrolysed by IsoT, in a control incubation (Fig. 
3.4E, compare lanes 9 and 10). Clearly, the failure to produce ‘unanchored’ 
K63-Ub chains does not explain why TAK1 is not activated by IL-1 in TRAF6-
null IL-1R* cells.  
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3.2.2.4 The E3 ligase activity of TRAF6 is dispensable for the activation 
of the canonical IKK complex and MAP kinases by IL-1 in IL-1R* 
cells 
The E3 ligase activity of TRAF6 is reported to be essential for the 
activation of the MyD88 signalling network by IL-1 in MEFs (Section 3.1). The 
E3 ligase-inactive TRAF6 mutant of TRAF6 most commonly used to make this 
point is TRAF6[C70A] in which a Cys residue in the RING domain, that aids 
the coordination of a zinc ion, is mutated, causing disruption of the RING 
domain architecture [128,138,140]. Another reported mutation, TRAF6[L74H], 
prevents the interaction with Ubc13 whilst maintaining the ability of the RING 
domain to coordinate zinc ions [129].  I found that both of these mutants, even 
at a 10 fold higher concentration than WT TRAF6, displayed no E3 ligase 
activity in vitro when assayed with Ubc13-Uev1a (Fig. 3.5A). Our lab has 
found that TRAF6 can also form a productive complex with two other E2s out 
of the 20 tested; UbcH5a (also called UBE2D1) and UbcH9 (also called 
UBE2E3) (Alban Ordureau, unpublished observations). Similarly, I found that 
both the TRAF6 mutants displayed no E3 ligase activity when incubated with 
UbcH5a or UbcH9 (Fig. 3.5A).  I then reconstituted TRAF6-null IL-1R* cells 
with untagged versions of WT TRAF6, the TRAF6[C70A] mutant  and the 
TRAF6[L74H] mutant, that were expressed under an inducible promoter. This 
enabled the re-expression of TRAF6 to near-endogenous levels in IL-1R* cells 
(Fig. 3.5B). Surprisingly, I found that both E3 ligase-inactive TRAF6 mutants 
were able to restore the IL-1-dependent formation of M1-Ub chains and the 
activation of the IKKs and MAP kinases, although not as efficiently as WT 
TRAF6 (Fig. 3.5B).  
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Figure 3.5 Reconstitution of TRAF6-null IL-1R* cells with WT 
TRAF6 and E3 ligase-inactive mutants 
(A) WT TRAF6 (5.0 nM) and the indicated TRAF6 mutants (50 nM) were 
assayed with the indicated E2s (see Methods). The reaction was 
terminated with SDS an ubiquitin chains were detected by immunoblotting 
with anti-FLAG. (B) TRAF6-null IL-1R* cells were reconstituted with 
untagged forms of either WT or mutant TRAF6 under the control of a 
doxycycline promoter. The cells were stimulated with IL-1β (5 ng/ml) for 
the times indicated and M1-Ub and K63-Ub chains were captured (top two 
panels) on Halo-NEMO beads. IKKβ binds to Halo-NEMO independently of 
IL-1 stimulation and therefore served as a loading control (third panel from 
top). Cell extracts were subjected to SDS-PAGE and immunoblotted with 
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the antibodies indicated (bottom nine panels). (C) As in B, except that the 
mRNA encoding IL-8 was determined by quantitative PCR after IL-1β 
stimulation for the times indicated. Results are plotted as fold-increase in 
mRNA relative to that found prior to stimulation. The results are presented 
as mean ± S.E. (n=3). (D) As in C, except that IL-8 secreted into the 
culture medium was determined by ELISA. 
 
These findings demonstrate that while TRAF6 expression is essential for IL-1 
signal transduction, its E3 ligase activity is not essential in IL-1R* cells. 
Consistent with these observations, the IL-1-dependent production of IL-8 
mRNA and its secretion from cells, which was abolished in TRAF6-null IL-1R* 
cells (Figs. 3.3D and 3.3E), could be partially restored when E3 ligase-inactive 
TRAF6 mutants were re-expressed, and fully restored when WT TRAF6 was 
re-introduced (Figs. 3.5C and 3.5D).    
3.2.3 The function of TRAF6 within the IL-1 signalling complex in MEFs 
3.2.3.1 The IL-1-induced formation of ubiquitin chains  
The results presented in Fig 3.5 were completely unexpected, as they 
were in disagreement with the model for how TRAF6 functions in the IL-1 
pathway, which has been largely based on results obtained in MEFs. I 
therefore investigated whether the results I had obtained using TRAF6-null IL-
1R* cells were similar in TRAF6 KO MEFs. I found that, as reported previously 
[140], the loss of the TRAF6 protein prevented the IL-1-stimulated activation 
of TAK1 and the IKK complex (Fig. 3.6A). I then studied the formation of K63-
Ub and M1-Ub chains before and after IL-1 treatment. In WT MEFs, IL-1 
promoted the formation of both K63-Ub and M1-Ub chains (Fig. 3.6B). 
However, K63-Ub chains were also detected in cells that had not been 
stimulated with IL-1 (Fig. 3.6B). In agreement with my previous findings, the 
loss of the TRAF6 protein did not affect the IL-1-induced formation of K63-Ub 
chains, but severely impaired the generation of M1-Ub chains (Fig. 3.6B). As 
in TRAF6-null IL1R* cells, the expression of LUBAC was slightly higher in 
TRAF6 KO MEFs, than in wild type MEFs and does not explain the reduced 
formation of M1-Ub chains (Fig. 3.6C). Since IL-1 does not induce the 
activation of TAK1 in TRAF6 KO MEFs (Fig. 3.6A) the possibility that TAK1 
catalytic activity is required for the formation of M1-Ub chains was also 
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explored in MEFs from knock-in mice expressing a truncated, catalytically 
inactive, form of TAK1 [152]. As expected, IL-1 stimulation failed to induce the 
activation of the IKK or MAP kinases in TAK1 knock-in MEFs (Fig. 3.6D).  
 
  
 
 
 
Figure 3.6 Characterisation of the ubiquitylation events triggered 
by IL-1 stimulation of WT and TRAF6 KO MEFs  
(A) TRAF6 WT and KO MEFs were stimulated for the times indicated with 
IL-1α (5 ng/ml) before lysis. Aliquots of the cell extract were 
immunoblotted with the antibodies indicated (B) As in A, except that, after 
IL-1β stimulation, the hybrid K63/M1-Ub chains present in cell extracts (3 
mg protein) were captured on Halo-NEMO before immunoblotting with the 
indicated ubiquitin antibodies. (C) As in A, except that PVDF membranes 
were immunoblotted with the indicated antibodies. (D) As in A and B, 
except that, WT and TAK1 knock-in MEFs were used.  (E) As in A, except 
that MEFs that are devoid of LUBAC E3 ligase activity (HOIP[C879S] 
knock-in MEFs) were used. The experiments presented in B and D were 
performed by Christoph Emmerich (Cohen lab).  
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Nonetheless, the IL-1-stimulated formation of M1-Ub chains was not reduced 
in TAK1 knock-in MEFs (Fig. 3.6D). In addition, the IL-1-induced 
phosphorylation of TAK1 was not diminished in HOIP knock-in MEFs that are 
unable make M1-Ub chains [43] (Fig. 3.6E). This indicates that the IL-1-
induced production of M1-Ub chains and TAK1 activation occur independently 
of one another. Moreover, the results again demonstrated that TRAF6 was not 
the only E3 ligase that generates K63-Ub chains after stimulation with IL-1. 
3.2.3.2 E3 ligase-inactive mutants of TRAF6 fail to restore the IL-1-
stimulated formation of M1-Ub chains and activation of the IKK 
complex to TRAF6 KO MEFs 
In contrast to the results presented in Fig. 3.5, the E3 ligase-inactive 
mouse TRAF6[L74H] mutant was only able to promote the activation of p38 
MAP kinase and p105 phosphorylation very weakly, whilst the TRAF6[C70A] 
mutant did not induce any detectable phosphorylation (Fig. 3.7A). Moreover, 
neither mutant was able to restore the IL-1dependent formation of M1-Ub 
chains in TRAF6 KO MEFs, whereas, WT mouse TRAF6 completely rescued 
these early signalling events (Fig. 3.7A). The untagged versions of mouse 
TRAF6 that were re-expressed in TRAF6 KO MEFs appeared as a doublet on 
an SDS/PAGE gel (Fig. 3.7A). To rule out the possibility that one of the 
components of the doublet has impaired the restoration of signalling, I re-
expressed these DNA constructs in TRAF6-null IL-1R* cells (Fig. 3.7B). It is 
clear that in IL-1R* cells, all versions of re-expressed mouse TRAF6 still 
existed as a doublet (Fig. 3.7B). Nevertheless, the E3 ligase-inactive mutants 
of mouse TRAF6 were able to partially restore IL-1 signalling and promote the 
activation of TAK1 and the IKKs in the human IL-1R* cells (Fig. 3.7B). These 
findings, which indicate that there are cell-specific and/or species-specific 
differences in the IL-1 signalling network, are considered further in the 
Discussion.   
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Figure 3.7 Reconstitution of TRAF6 KO MEFs with WT TRAF6 and 
E3 ligase-inactive mutants of TRAF6 
(A) TRAF6 KO MEFs were reconstituted with untagged forms of either WT 
or mutant mouse TRAF6, under the control of a doxycycline promoter. The 
MEFs were stimulated with IL-1α (5 ng/m) for the times indicated and M1-
Ub chains were detected (top panel) after pulldown using Halo-NEMO. 
IKKβ binds to Halo-NEMO independently of IL-1 stimulation and therefore 
serves as a loading control (second panel from top). Cell extracts were 
subjected to SDS-PAGE and immunoblotted with the antibodies indicated. 
(B) TRAF6-null IL-1R* cells were reconstituted with the constructs 
presented in A. Following stimulation with IL-1β for the times indicated, cell 
extract protein was subjected to SDS/PAGE and immunoblotted with the 
indicated antibodies.  
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3.2.3.3 Pellino1 E3 ligase activity is not diminished in TRAF6 KO MEFs 
Previously, our lab has demonstrated that Pellino1 is converted into an 
active E3 ligase after IL-1 stimulation of MEFs or IL-1R cells [29]. In vitro we 
have also found that Pellino1 is capable of forming a productive complex with 
Ubc13-Uev1a [195]. Intriguingly, I found that in TRAF6-null IL-1R* cells (Fig. 
3.4B) and TRAF6 KO MEFs (Fig 3.8) the expression of Pellino1 was 
increased compared to the parent WT cells. Moreover, I discovered that in 
TRAF6 KO MEFs, the E3 ligase activity of Pellino1 is still switched on in an IL-
1-dependent manner and that this is somewhat enhanced (Fig 3.8). These 
results indicate that Pellino1 is still fully capable of generating ubiquitin chains 
in IL-1-stimulated TRAF6-null cells.  
 
 
 
Figure 3.8 The E3 ligase activity of Pellino1 measured from the 
extracts of MEFs 
WT and TRAF6 KO MEFs were stimulated with IL-1α (5 ng/ml) for the 
times indicated before lysis. Pellino1 was immunoprecipitated (IP) from the 
cell extract (1 mg protein) and its ability to form ubiquitin chains (top panel) 
was assessed in an E3 ligase activity assay (see Methods). The 
immunoprecipitates were blotted with an antibody that recognises Pellino1 
and Pellino2 (second panel from top). Aliquots of the cell extract were also 
subjected to SDS/PAGE and immunoblotted with the antibodies indicated 
(bottom two panels). 
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3.2.4 The K63-Ub chains generated by TRAF6 or Pellino1 activate the 
TAK1 complex with similar efficiency in vitro 
 It has been shown that ‘unanchored’ K63-Ub chains generated by 
TRAF6 are sufficient to activate the TAK1 complex in vitro [149]. It was 
therefore curious that, in TRAF6-null IL-1R* cells and TRAF6 KO MEFs, the 
K63-Ub chains formed after IL-1 treatment, do not cause any activation of 
TAK1 (Fig. 3.4A and 3.7A). To begin to explore the reason for this, I first 
investigated whether there was any difference in the ability of K63-Ub chains 
generated by TRAF6 and Pellino1 to activate the TAK1 complex in vitro. To 
study this I purified the human TAB1-TAK1-TAB3 complex, which had been 
expressed in insect Sf21 cells, by affinity chromatography. Using this 
preparation and human TRAF6 expressed in and purified from insect Sf21 
cells, I confirmed that TRAF6-generated K63-Ub chains could induce the 
phosphorylation of TAK1 at Thr187, and enable TAK1 to phosphorylate the 
activation loop of MAP kinase kinase 6 (MKK6), which could then 
phosphorylate the activation loop of p38γ MAP kinase (Fig. 3.9, panels 1-5). 
However, TAK1 could be activated just as efficiently when Pellino1-generated 
K63-Ub chains were substituted for those generated by TRAF6 (Fig. 3.9, 
panels 1-5). Interestingly, the E2 conjugating complex Ubc13-Uev1a was able 
to generate small amounts of ubiquitin chains in the absence of any E3 
ubiquitin ligase (Fig. 3.9, panel 8), which were sufficient to weakly promote the 
phosphorylation of TAK1 at Thr187 (Fig. 3.9, panel 2). However, no 
phosphorylation of MKK6 was observed (Fig. 3.9, panel 4). In summary, the 
TAK1 complex can be activated equally well by K63-Ub chains in vitro 
irrespective of whether they are generated by TRAF6 or Pellino1. There must 
therefore be another reason why the K63-Ub chains formed in TRAF6 KO 
cells, in response to IL-1, do not activate the TAK1 complex. 
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Figure 3.9 TAK1 is activated similarly by K63-Ub chains generated 
by either TRAF6 or Pellino1 
The purified TAB1-TAK1-TAB3 complex, expressed by James Hastie 
(DSTT) was incubated with either TRAF6 or Pellino1, Ub, Mg-ATP, UBE1, 
Ubc13-Uev1a, and the inactive dephosphorylated forms of MKK6 and its 
substrate p38γ MAP kinase (see Methods). After 1 h at 30°C the reaction 
was terminated with LDS and samples were subjected to SDS/PAGE. The 
PVDF membranes were probed with phospho-specific antibodies that 
recognise the activation loops of TAK1, MKK6 and p38g MAP kinase and 
antibodies that recognise all forms of TAK1, MKK6 and Ub. p38γ MAP 
kinase was detected by staining for protein with Ponceau S. 
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3.2.5 The function of Pellino E3 ligase activity within the IL-1 signalling 
network in MEFs 
3.2.5.1 The contribution of Pellino family members to the generation of 
K63-Ub chains within the IL-1 pathway   
 The finding that the IL-1-induced formation of K63-Ub chains was not 
diminished in TRAF6-null IL-1R* cells (Fig. 3.4A) or TRAF6 KO MEFs (Fig. 
3.6B) implied that a distinct E3 ligase(s) was generating K63-Ub oligomers 
under these conditions. Since Pellino isoforms can be phosphorylated by 
IRAK1 and IRAK4 in vitro, which converts them from inactive to active E3 
ubiquitin ligases [195], they were potential candidates to generate the K63-Ub 
chains formed in IL-1-stimulated TRAF6-null cells. To investigate this 
possibility we made knock-in mice in which Pellino1 [227], Pellino2 and 
Pellino3 were replaced by E3 ligase-inactive mutants that were unable to 
interact with E2 conjugating enzymes. We achieved this by mutating an 
equivalent Phe residue in the RING domains of the Pellinos that had been 
shown to mediate the interaction between the E3 ligase c-Cbl and the E2 
conjugating enzyme UbcH7 [227,241]. In vitro, Pellino1[F397A] was unable to 
form a productive complex with Ubc13-Uev1a to generate Ub chains (Fig. 
S1B in [227]). Moreover, when immunoprecipitated from cells it also lacked E3 
ligase activity (Fig. S2A in [29]). Similarly, purified Pellino2[F398A] and 
Pellino3[F424A] lacked E3 ligase activity in an in vitro assay (Alban Ordureau, 
Cohen Lab, unpublished results).  
 My initial findings indicated that the IL-1-dependent activation of the 
canonical IKK complex and MAP kinases in MEFs from Pellino1[F397A], 
Pellino2[F398A] and Pellino3[F424A] knock-in mice was similar to MEFs from 
wild type mice (Fig. 3.10A).  In case one or more isoforms of Pellino were 
operating redundantly with one another in the IL-1 pathway, I crossed the 
single knock-in mice with each other to generate the three possible double 
knock-in mice and the triple knock-in mouse. All the Pellino knock-in mice 
were viable and healthy in the relatively germ-free environment of the animal 
house. However, the expression of the Pellino1[F397A] was much lower than 
WT Pellino1 (Fig. 3.10A) as reported previously [227]. I found that the IL-1-
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dependent formation of K63-Ub chains was greatly reduced in MEFs from 
Pellino1/2 and Pellino1/2/3 knock-in mice, (Fig. 3.10B), but to a lesser extent 
in the Pellino1/3 and Pellino2/3 knock-in MEFs (Fig. 3.10B). However, the 
ubiquitylation of IRAK1 was only reduced slightly in MEFs from the Pellino1/2 
and Pellino1/2/3 knock-in mice and the formation of M1-Ub chains was not 
affected significantly (Fig. 3.10B and C). The IL-1-stimulated activation of the 
canonical IKK complex and MAP kinases was not diminished in MEFs from 
any of the double knock-in mice or the triple knock-in mouse (Fig. 3.10B). 
These results indicate that Pellino1 and Pellino2 produce a significant 
proportion of the K63-Ub chains formed when MEFs are stimulated with IL-1, 
but these Ub chains either do not contribute to the activation of the IKK 
complex and MAP kinases, or the residual formation of K63-Ub chains is 
sufficient for maximal activation of these protein kinases in cells. 
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Figure 3.10 A comparison of early signalling events in Pellino WT 
and E3 ligase-inactive knock-in MEFs 
(A) Primary MEFs from WT mice and Pellino1[F397A], Pellino2[F398A] 
and Pellino3[F424A] single knock-in mice were stimulated with IL-1α (5 
ng/ml) for the times indicated and lysed. Aliquots of the cell extracts were 
subjected to SDS/PAGE before immunoblotting with the indicated 
antibodies. An antibody that recognises Pellino1 (lower lane) and Pellino2 
(potentially the upper lane) was also used. (B) As in A, except that MEFs 
from each Pellino double knock-in mouse and the triple knock-in mouse 
were used. Ubiquitin chains were captured from the cell extracts (3 mg 
protein) on Halo-NEMO and blotted with the antibodies that recognise 
K63-Ub chains and IRAK1 (top two panels). IKKα binds to Halo-NEMO 
independently of IL-1 stimulation and served as a loading control (third 
panel from top). Aliquots of the cell extracts were immunoblotted with 
phospho-specific antibodies and with GAPDH as a loading control (bottom 
five panels). (C) As in B, except that after Halo-NEMO capture of ubiquitin 
chains, M1-Ub chains were blotted for specifically.  
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3.2.5.2 Pellino E3 ligase activity is required for robust secretion of 
proinflammatory cytokines 
The IL-1-stimulated activation of the E3 ligase activity of Pellino1 is 
sustained for at least 60 min [29]. To investigate whether Pellino E3 ligase 
activity might contribute to the production of inflammatory cytokines, I 
stimulated MEFs from Pellino1/2 and Pellino1/2/3 knock-in mice and WT mice 
for up to 60 minutes and assessed signalling. The initial activation of TAK1 
and the IKK complex was comparable in all three MEF lines up until 30 min 
(Fig. 3.11A). However, IKK activity appeared to decrease more rapidly in 
MEFs from the knock-in mice than in WT MEFs (Fig. 3.11A). Similar results 
were obtained using a second set of WT, Pellino1/2 double knock-in and 
Pellino1/2/3 triple knock-in MEFs (data not shown).  To assess whether the 
loss of Pellino E3 ligase activity affected pro-inflammatory cytokine production 
I studied the induction of the mRNA encoding the proinflammatory cytokine 
MIP-2, and the secretion of this protein in three separate MEF sets of each 
genotype (Fig. 3.11B and 3.11C). In WT MEFs there was a strong induction of 
MIP-2 mRNA, which peaked at 1 h before subsequently declining (Fig. 3.11B). 
Interestingly, in MEFs from the Pellino1/2 and Pellino1/2/3 knock-in mice, the 
induction of MIP-2 mRNA was reduced significantly (Fig. 3.11B). Consistent 
with this, the amount of MIP-2 released from knock-in MEFs was less than the 
amount released by WT MEFs (Fig. 3.11C). Taken together, these findings 
suggest that although Pellino E3 ligase activity is not required for the initial 
activation of TAK1 and the IKKs, it is important for robust induction of at least 
one pro-inflammatory cytokine mRNA and its secretion from the cell. 
Unfortunately, time did not permit a more detailed analysis. 
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Figure 3.11 Pellino E3 ligase activity is important for 
proinflammatory cytokine release  
(A) Primary Pellino WT MEFs, Pellino1/2 and Pellino1/2/3 knock-in MEFs 
were stimulated with IL-1α (5 ng/ml) for the times indicated. Aliquots of the 
cell extract were subjected to SDS/PAGE before immunoblotting with the 
indicated antibodies. (B) As in A, except that after IL-1α stimulation, the 
mRNA encoding MIP-2 was determined by quantitative PCR. Results are 
plotted as fold-increase in mRNA relative to that found prior to stimulation. 
Three separate sets of primary MEFs were used for each genotype. The 
results are presented as mean ± S.E. (n=3). (C) As in B, except that MIP-2 
secreted into the culture medium was determined by ELISA. The results 
are presented as mean ± S.E. (n=3). 
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3.2.6 TRAF6 interacts with an unknown E3 ligase in response to IL-1 
stimulation  
 To investigate whether, like Pellino1 (Fig. 3.8), the E3 ligase activity of 
TRAF6 is regulated in an IL-1-dependent manner, I immunoprecipitated 
TRAF6 from the extracts of IL-1R* cells and assayed whether the 
immunoprecipitates could generate K63-Ub chains in E3 ligase assays 
containing the E2 conjugating complex Ubc13-Uev1a. I found that I was only 
able to detect the formation of K63-Ub chains if TRAF6 was 
immunoprecipitated from the extracts of cells stimulated with IL-1 (Fig. 3.12A, 
top panel, lanes 1-3). This initially suggested that IL-1 promotes the 
conversion of TRAF6 from an inactive to an active E3 ligase. Consistent with 
these observations, this E3 ligase activity was not present in the extracts of 
TRAF6-null IL-1R* cells (Fig. 3.12A, top panel, lanes 4-6) but reappeared 
when I restored the expression of WT TRAF6 to the TRAF6-null cells (Fig. 
3.12A, top panel, lanes 7-9). Surprisingly, the re-expression of two E3 ligase-
inactive TRAF6 mutants was also able to restore the E3 ligase activity 
measured in these assays (Fig. 3.12A, top panel, lanes 10-15). This indicated 
that I was not, after all, assaying the E3 ligase activity of TRAF6 directly, but 
another E3 ligase that associates with TRAF6 in IL-1-stimulated cells. To 
explore whether the putative E3 ligase was an isoform of Pellino, I performed 
the same assay using TRAF6 immunoprecipitated from the extracts of WT 
and Pellino1/2/3 triple knock-in MEFs.  It is clear that the loss of all three 
Pellino E3 ligase activities did not affect my ability to measure the activity of 
the TRAF6-associated E3 ligase (Fig. 3.12B, top panel). This E3 ligase, which 
is activated when the IL-1 network is activated, therefore appears to be 
distinct from both TRAF6 and Pellino.   
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Figure 3.12 E3 ligase activity measured in TRAF6 
immunoprecipitates 
(A) TRAF6-null IL-1R* cells were reconstituted with FLAG-tagged forms of 
either WT or mutant human TRAF6. The cells were stimulated with IL-1β 
(5 ng/ml) for the times indicated. TRAF6 was then immunoprecipitated 
from the cell extract and its ability to form K63-Ub chains was assayed as 
described in Methods (top panel – immunoblot anti-FLAG). TRAF6 
immunoprecipitation (IP) was confirmed by immunoblotting with anti-
TRAF6 (second panel from top).  Cell extracts were subjected to 
SDS/PAGE and immunoblotted with the antibodies indicated. (B) As in A, 
except that primary WT MEFs and two independent lines of Pellino1/2/3 
knock-in MEFs were stimulated with IL-1α (5 ng/ml).  
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3.2.7 Otulin hydrolyses M1-Ub chains in IL-1R cells  
Otulin, a DUB that cleaves M1-Ub chains specifically in vitro, is thought 
to counteract the formation of M1-Ub chains by LUBAC in the TNF pathway 
[50].  To explore whether Otulin was also involved in the IL-1 signalling 
network, I used a specific shRNA to knock-down the expression of Otulin to 
near-undetectable levels (Fig. 3.13). The formation of M1-Ub chains was 
greatly enhanced in cells stimulated with IL-1, as predicted (Fig. 3.13). 
However, only traces of M1-Ub chains were present in Otulin knock-down 
cells, that had not been exposed to IL-1 (Fig. 3.13). Unexpectedly, the IL-1-
stimulated formation of K63-Ub chains was also increased, although this did 
not cause a similar enhancement of IKK or TAK1 activity, as judged by p105 
phosphorylation or JNK activation respectively  (Fig. 3.13). In summary, this 
experiment suggests that Otulin is a physiological DUB that regulates M1-Ub 
chain formation within the context of IL-1 signalling. Moreover, it also infers 
that other DUBs may regulate M1-Ub chain formation, however, due to the 
constraints of time, I was unable to explore this further.  
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Figure 3.13 Otulin regulates M1-Ub chains in IL-1R cells 
IL-1R cells stably expressing either an empty shRNA vector or shRNA 
specific to Otulin were stimulated for the times indicated with IL-1β (5 
ng/ml) and then lysed. The ubiquitin chains were captured from cell 
extracts (2 mg protein) on immobilised Halo-NEMO before being released 
in LDS and immunoblotted with ubiquitin linkage-specific antibodies (top 
two panels). IKKα binds to Halo-NEMO independently of IL-1 stimulation 
and serves as the loading control (third panel from top). Aliquots of the cell 
extracts were also immunoblotted with the antibodies indicated (bottom 4 
panels). 
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3.3 Discussion 
This project was initiated because the widely accepted model for how IL-
1 induces the formation of K63-Ub chains and M1-Ub chains and the 
activation of TAK1, lacked genetic evidence. Such studies were essential to 
assess whether the hypotheses implicit in the model were valid. The 
unexpected findings reported in this Chapter have shown that concerns about 
the model were well justified and revealed that these signalling events are far 
more complex than envisaged previously. In the following sections I discuss 
the implication of my findings for future studies that should lead to a more 
complete elucidation of the IL-1-signaling network. 
3.3.1 The generation of M1-Ub chains is dependent on the prior 
formation of K63-Ub chains within the IL-1 pathway 
I have shown that I can largely suppress the IL-1-induced formation of 
K63-Ub chains by reducing the expression of the E2 conjugating enzyme 
Ubc13 using shRNA (Fig. 3.1A). My findings suggest that, within the context 
of IL-1 signalling, Ubc13 is the major E2 involved in the formation of K63-Ub 
chains. Consistent with the established model for TAK1 activation, the 
reduction in K63-Ub chains impaired the activation of kinases ‘downstream’ of 
TAK1, namely the canonical IKK complex and MAP kinases (Fig. 3.1A).  
I also demonstrated that the IL-1-stimulated formation of M1-Ub chains 
was greatly impaired in Ubc13 knock-down cells (Fig. 3.1A). This is consistent 
with other findings from our lab, which established that LUBAC attaches M1-
Ub chains to preformed K63-Ub chains [43].  Therefore, since K63-Ub chains 
are the major substrate for LUBAC in these cells, preventing their formation 
would be expected to also prevent M1-Ub chain formation. In contrast, when I 
restricted the formation of M1-Ub chains by reducing the expression of the 
HOIP and HOIL-1 components of LUBAC (Fig. 3.1C), I found that it did not 
affect the IL-1-stimulated generation of K63-Ub chains. This finding was 
consistent with results obtained using HOIP[C879S] knock-in MEFs, which are 
devoid of LUBAC E3 ligase activity but produce similar levels of K63-Ub 
chains to WT MEFs upon IL-1 stimulation [43] (Christoph Emmerich, Cohen 
Lab, unpublished results). These observations suggest that M1-Ub chains can 
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only be formed after K63-Ub chains are generated and that K63-Ub chain 
stability does not require the production of M1-Ub chains. Interestingly, we 
have discovered that, in vitro, HOIP interacts with K63-Ub chains specifically 
[43]. This suggests how IL-1-stimulation might recruit LUBAC to K63-Ub 
chains and use them as a preferred substrate in cells. However, this cannot 
explain why M1-Ub chains are not made in significant amounts in the absence 
of IL-1 stimulation, since substantial quantities of K63-Ub chains are present 
under these conditions [43].  
3.3.2 The essential roles of TRAF6 within the IL-1 network in IL-1R* 
cells 
3.3.2.1 Ubiquitin chain formation 
TRAF6 is assumed to catalyse the formation of K63-Ub chains after IL-
1 stimulation [138,140]. However, I have shown that in TRAF6-null IL-1R* 
cells, the IL-1-dependent formation of K63-Ub chains is similar to the parent 
TRAF6-expressing IL-1R* cells (Fig. 3.4A). This clearly indicates that TRAF6 
is not the only E3 ligase capable of generating K63-Ub chains in response to 
IL-1 stimulation. Moreover, I found that the proteins reported to be 
ubiquitylated in IL-1R cells [43] were also ubiquitylated in WT and TRAF6-null 
IL-1R* cells (Fig. 3.4D), demonstrating that Myddosome formation and its 
covalent modification does not require TRAF6. Furthermore, the ubiquitylation 
of IRAK1, IRAK4 and MyD88 was significantly enhanced in TRAF6-null IL-1R* 
cells (Fig. 3.4D), possibly because the pathways that function to negatively 
regulate ubiquitin chain formation were not activated.  
The finding that TRAF6 is not the only E3 ligase that generates K63-Ub 
chains in response to IL-1-stimulation was not completely unanticipated since 
our group has shown previously that the E3 ligase activity of Pellino1, which is 
able to form K63-Ub chains in vitro [195], is activated when IL-1R cells are 
stimulated with IL-1 [29]. Time did not permit me to investigate whether the 
K63-Ub chains produced in TRAF6-null IL-1R* cells were generated by one or 
more members of the Pellino family of E3 ligases, Pellino1, Pellino2 and 
Pellino3. However, this important point is currently being addressed by using 
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CRISPR/Cas9 technology to knock-out the expression of Pellino1 and 
Pellino2 in TRAF6-null IL-1R* cells. Nonetheless my results raised the 
possibility that TRAF6 had other functions than merely to produce K63-Ub 
chains. 
I was surprised to discover that the IL-1-induced formation of M1-Ub 
chains was greatly diminished in TRAF6-null IL-1R* cells. Moreover, the loss 
of M1-Ub chains could not be explained by a reduction in the expression of 
LUBAC or its intrinsic E3 ligase activity (Figs. 3.4B and 3.4C). These findings 
were unexpected, because LUBAC requires pre-formed K63-Ub chains to 
generate M1-Ub chains, as discussed earlier, yet K63-Ub chain formation was 
not impaired in TRAF6-null IL-1R* cells. These findings imply that another 
signalling event(s), which depends on the expression of TRAF6, is needed to 
permit the generation of large amounts of M1-Ub chains.  
3.3.2.2 TAK1 is not activated in TRAF6-null IL-1R* cells  
It was reported that ‘unanchored’ K63-Ub chains were able to activate 
the TAK1 complex in vitro [149]. Therefore, it was possible that TRAF6 might 
catalyse the formation unanchored K63-Ub chains exclusively, explaining why 
TAK1 was not activated in TRAF6-null cells (Figs. 3.3A and 3.3B). However, 
as equivalent levels of ‘unanchored’ K63-Ub chains are formed in WT and 
TRAF6-null IL-1R* cells (Fig. 3.4E), this cannot explain the loss of TAK1 
activation. The finding that the IL-1-stimulated activation of TAK1 does not 
occur in TRAF6 KO cells even though the formation of ‘anchored’ or 
‘unanchored’ K63-Ub chains occurs normally, implies that although the 
formation of K63-Ub chains is required, it is not sufficient to activate TAK1 in 
these cells. This is supported by the observation that TAK1 activity is 
undetectable until the cells are stimulated with IL-1, even though large 
amounts of K63-Ub chains are already present in the unstimulated cells [43]. 
Moreover, I have shown that TAK1 activation is not dependent on the 
formation of M1-Ub chains and vice versa (Figs. 3.6D and 3.6E). Taken 
together, my results indicate that TRAF6 promotes the activation of TAK1 by a 
mechanism that is independent of the ability of TRAF6 to facilitate the 
production of M1-Ub chains by LUBAC. 
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3.3.2.3 The E3 ligase activity of TRAF6 is dispensable for the activation 
of TAK1 and M1-Ub chain formation 
It has been reported that TRAF6 E3 ligase activity is essential to 
restore IL-1 signalling to TRAF6 KO MEFs [129,140]. This conclusion was 
drawn from experiments in which mutant forms of TRAF6, unable to generate 
ubiquitin chains in vitro [128,129], failed to rescue IL-1 signalling to TRAF6 KO 
MEFs [138,140]. The mutant most commonly used to illustrate this point is 
TRAF6[C70A], in which a conserved Cys within the RING domain is switched 
to Ala, thereby preventing the co-ordinantion of a zinc ion and causing 
disruption to the local area. A more recently reported inactivating mutation, 
TRAF6[L74H], prevents the interaction between TRAF6 and Ubc13 in vitro, 
without causing major disruption to the RING domain [160]. Although, both 
TRAF6 mutants failed to restore the IL-1-induced activation of the canonical 
IKK complex to TRAF6 KO MEFs [129,140], they were consistently re-
expressed in these experiments at far higher levels than endogenous TRAF6 
in WT MEFs [129,140]. Potentially, this may cause the TRAF6 mutants to 
function as dominant-negative inhibitors by sequestering components of the 
IL-1-signalling system and preventing their recruitment to the Myddosome, 
however, I did not investigate this possibility. To reduce this possibility I 
expressed TRAF6[C70A] and TRAF6[L74H] in TRAF6-null IL-1R* cells under 
an inducible promoter that allowed their expression at near-endogenous levels 
(Fig. 3.5B). I was particularly interested in investigating whether the less-
disruptive TRAF6[L74H] mutant might rescue IL-1 signalling. Surprisingly 
however, both E3 ligase-inactive TRAF6 mutants were able to partially restore 
the IL-1-stimulated formation of M1-Ub chains, TAK1 phosphorylation, IKK 
activation and MAP kinase activation in TRAF6-null IL-1R* cells (Fig. 3.5B).  
This result clearly signified that TRAF6 has an essential role in aiding 
the formation of M1-Ub chains and the activation of TAK1 that is independent 
of its ability to form ubiquitin chains. However, because TAK1 phosphorylation 
and M1-Ub chain generation were only restored partially, compared to cells in 
which WT TRAF6 was re-expressed (Fig. 3.5B), the results suggested that E3 
ligase activity of TRAF6 was contributing to the strength of IL-1 signalling. On 
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the other hand, RING domain TRAF6 mutants may not be able to interact as 
efficiently as WT TRAF6 with other, as yet unidentified, components that 
facilitate M1-Ub chain generation and TAK1 activation.  
Interestingly, our lab has reported previously that TRAF6 co-
immunoprecipitates with the TAK1 complex, just two minutes after IL-1 
stimulation, before the majority of K63-Ub chains are generated [242]. 
Therefore it is possible that TRAF6 may interact directly with a component(s) 
of the TAK1 complex to facilitate its activation. However, we have been 
unable, so far, to show any interaction with TRAF6 and LUBAC in over-
expression studies (Christoph Emmerich, Cohen lab, unpublished results). 
Nonetheless, it would be of interest to investigate whether, in vitro, TRAF6 is 
capable of interaction with the TAK1 complex or LUBAC.  
3.3.3 The essential roles of TRAF6 within the IL-1 pathway in MEFs 
3.3.3.1 Ubiquitin chain formation 
 Consistent with my findings in TRAF6-null IL-1R* cells, the IL-1-
induced formation of K63-Ub chains was not reduced in TRAF6 KO MEFs, but 
the formation of M1-Ub chains was greatly reduced (Fig. 3.6B). As in IL-1R* 
cells, LUBAC expression was actually higher in TRAF6 KO MEFs than WT 
MEFs (Fig. 3.6C), indicating that this is not the reason for the loss of M1-Ub 
chain formation. These results therefore reinforce the view that other E3 
ligases must generate the majority of the K63-Ub chains in the IL-1 pathway 
and that TAK1 requires an additional input to become active.  
3.3.3.2 E3 ligase-deficient TRAF6 mutants cannot rescue IL-1 signalling 
to TRAF6 KO MEFs    
Contrary to my results in TRAF6-null IL-1R* cells, the equivalent mouse 
E3 ligase-inactive mutants of TRAF6 did not restore M1-Ub chain formation or 
TAK1 phosphorylation to TRAF6 KO MEFs (Fig. 3.7A). However, I 
consistently saw a very weak restoration of IL-1-stimulated p105 
phosphorylation, indicative of IKKβ activation, and p38 MAP kinase activation 
when the TRAF6[L74H] mutant was expressed in MEFs (Fig. 3.7A).  
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Although these results suggested that the E3 ligase activity of TRAF6 
was critical for IL-1 signalling in MEFs, it was possible that the mutations of 
mouse TRAF6 may have had a more deleterious effect on its structure 
compared to human TRAF6.  However, is does not seem likely, since these 
mouse mutants were able to partially restore IL-1-signaling in human IL-1R* 
cells (Fig. 3.7B).  Therefore, taken together, these results suggest that 
whether the E3 ligase activity of TRAF6 is essential is dictated by the species 
and/or cell type. Our lab has begun to address this issue by generating knock-
in mice in which TRAF6 is replaced by E3 ligase inactive mutants. 
The observed differences between IL-1 signalling in IL-1R* cells and 
MEFs could also be attributed to signal strength. It would be informative to 
analyse the expression levels of the IL-1R in both IL-1R* cells and MEFs in 
much the same manner as in Fig. 3.2B. If indeed IL-R* cells had much higher 
IL-1R levels then it would follow that IL-1 stimulation would induce the 
formation of much greater levels of K63-Ub chains, compared to MEFs. This 
may perhaps bypass the need for significant amounts of M1-Ub chains for IL-
1 signalling to proceed (Fig. 3.5B). To investigate this possibility I could see 
whether lower concentrations of IL-1 can still promote the activation of TAK1 
and the canonical IKK complex in IL-1R* which express E3 ligase-inactive 
mutants of TRAF6. Additionally I could test whether higher levels of IL-1α can 
rescue signalling in MEFs expressing TRAF6 E3 ligase dead mutants (Fig. 
3.7A).  
The different effects of the TRAF6 mutants on the IL-1 network in 
MEFs and human IL-1R* cells makes it difficult to relate findings made in 
MEFs to the IL-1 pathway in IL-1R* cells. For example, my conclusion that the 
formation of M1-Ub chains and the activation of TAK1 are not dependent on 
one another was based on genetic studies in MEFs. It will clearly be advisable 
to repeat these experiments in IL-1R* cells by generating HOIP and TAK1 null 
IL-1R* cell lines. Indeed, many differences between the innate immune 
systems of humans and mice have been identified [243,244]. One must 
clearly be cautious in generalising conclusions made from experiments in cells 
from different species to construct signalling models. In this connection, it 
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should also be noted that I stimulated IL-1R* cells with IL-1β but MEFs with IL-
1α. Although both forms of IL-1 are thought to bind to and signal via the same 
receptor, it is remains possible that there may be IL-1α- and IL-1β-specific 
pathways that could conceivably underlie the differences I have observed 
between MEFs and IL-1R cells. I therefore plan to compare the effects of IL-
1α and IL-1β in the TRAF6 KO MEFs I have reconstituted with E3 ligase-
inactive TRAF6 mutants. Finally, because of my contrasting results as to the 
essential function of TRAF6 E3 ligase activity in human IL-1R* cells and 
MEFs, I will need to repeat my experiments in other cell lines. It would be best 
to use human cell lines such as THP-1 monocytes and U937 monocytes, 
which endogenously express TLRs, to evaluate the function of TRAF6, with 
more confidence within the MyD88 signalling network [43,245].  
3.3.4 How does IL-1 induce the activation of TAK1? 
 My results suggest that the model for how TAK1 becomes activated in 
cells is more complicated that previously proposed. Clearly, there is no defect 
in the IL-1-induced generation of K63-Ub chains, be they ‘unanchored’ or 
covalently attached to Myddosome components, yet TAK1 is not activated in 
TRAF6 KO cells (Fig. 3.3A and 3.6A).   In TRAF6-null IL-1R* cells I was able 
to partially rescue TAK1 activation by the expression of E3 ligase-deficient 
TRAF6 mutants. This indicated that the presence of TRAF6 is paramount, but 
its ability to generate K63-Ub chains is not. Taken together, these results 
suggest that TAK1 activation may potentially require two inputs: K63-Ub chain 
formation and direct or indirect association with TRAF6.  
We have observed that K63-Ub chains are already present in a cell not 
stimulated with IL-1 [43], yet TAK1 activity is undetectable. This undermines 
the model that K63-Ub chains are sufficient to promote TAK1 activation. This 
was further brought into question by results obtained using a TAB2/TAB3 
double KO mouse.  Although the authors never measured TAK1 activity 
directly, they found that normal levels of proinflammatory cytokines were 
generated by double KO macrophages stimulated with MyD88-dependent 
TLR agonists [246]. Presumably in these cells, the TAK1 complex was still 
activated, despite losing its ability to interact with K63-Ub chains. It could be 
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argued that TAB1 binds to K63-Ub chains, yet this has never been reported 
and TAB1 does not possess an identifiable ubiquitin-binding motif. It is 
possible to conclude that TAB1 alone, is not essential for TAK1 activation 
since MEFs from TAB1-deficient mice show no defects in the IL-1-stimulated 
activation of IKKs and MAP kinases [151]. However, conversely, in a 
TAB2/TAB3-double null IL-1R* cell line, the TAB1-TAK1 heterodimer 
expressed in these cells was still activated after IL-1 stimulation (Jiazhen 
Zhang, Cohen lab, unpublished results). This strongly infers that the binding 
of K63-Ub chains to the TAB2 and TAB3 components of the TAK1 complex is 
not essential for its activation. These observations suggested that the TAB1, 
TAB2 and TAB3 components may function redundantly in the activation of 
TAK1.  To address this issue Jiazhen Zhang (Cohen lab, unpublished data) 
has deleted all three TAB subunit from IL-1R* cells. His results indicate that 
IL-1 can no longer activate TAK1 in these cells but in preliminary experiments 
the IL-1-dependent activation of TAK1 could be restored by the re-introduction 
of TAB1 or TAB2, but not by a TAB2 mutant unable to interact with K63-Ub 
chains. Taken together, the results so far suggest that IL-1 can activate the 
TAK1 complex in two ways: first by the binding of K63-Ub chains to TAB2 and 
TAB3; second by a TAB1-dependent mechanism. It would appear that both 
pathways must be inactivated to prevent the IL-1-stimulated activation of 
TAK1. 
In an attempt to delineate the process of TAK1 activation, I re-
constituted the in vitro assay in which it was reported that K63-Ub chains, 
generated by TRAF6, could activate the TAK1 complex [149]. Surprisingly, I 
found that K63-Ub chains generated by TRAF6 or Pellino1 were just as 
efficient at activating the purified TAB1/TAK1/TAB3 complex in vitro (Fig. 3.9). 
This demonstrates that, in contrast to the situation in cells, K63-Ub chains are 
required and sufficient to activate the TAK1 complex in vitro. Perhaps in cells 
the activation of TAK1 complexes is prevented by another component and 
TRAF6 is needed to overcome these inhibitory effects.  It is likely that the 
TAB1-TAK1-TAB3 complex is activated in vitro by the binding of K63-Ub 
chains to the TAB3 component.  Nevertheless, in view of the observations 
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mentioned in the preceding paragraph, it would be of considerable interest to 
investigate whether K63-Ub chains are able to activate the TAB3-TAK1 and 
TAB1-TAK1 complexes in vitro. 
3.3.5 Do additional E3 ligases, capable of forming K63-Ub chains, 
participate in the IL-1 pathway? 
In IL-1R* cells I have demonstrated that an unknown E3 ligase 
associates with TRAF6 upon IL-1 stimulation and is able to generate K63-Ub 
chains, in vitro (Fig. 3.12A). Moreover, using MEFs in which all three Pellino 
isoforms had been inactivated, l ruled out the possibility that a Pellino isoform 
was the unknown E3 ligase (Fig. 3.12B). However, due to the differences in 
IL-1 signalling that I have observed in MEFs and IL-1R* cells, I will need to 
also investigate whether the unidentified, TRAF6-associated E3 ligase is 
present in IL-1R* cells that lack expression of both Pellino1 and Pellino2. My 
findings suggest the possibility that, although the E3 ligase activity of TRAF6 
is not essential, one of its important roles is to recruit another E3 ligase that 
generates the K63-Ub chains, which are then used as the preferred substrate 
by LUBAC to form K63/M1-Ub hybrids. Clearly it will be critical to identify this 
putative E3 ligase, possibly through the mass spectrometric analysis of 
TRAF6 immunoprecipitates.   
3.3.6 The regulation of M1-Ub chains by DUBs 
The IL-1-stimulated formation of M1-Ub chains is not accompanied by 
any intrinsic increase in in LUBAC’s ability to form ubiquitin chains, indicating 
that its intrinsic activity is not regulated by a PTM [43]. Instead, it has been 
proposed that Otulin, a DUB that hydrolyses M1-Ub chains specifically, 
associates with LUBAC in cells to oppose the formation of M1-Ub chains 
[50,51]. Moreover, it has been suggested that the interaction between HOIP 
and Otulin might be prevented by the phosphorylation of LUBAC at Tyr56 
[183].  
To investigate the potential role of Otulin further, I generated a cell line 
in which the expression of Otulin was virtually undetectable. In cells not 
stimulated with IL-1, I was only able to identify a slight increase in M1-Ub 
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chain formation (Fig 3.13).  However, upon IL-1 treatment the formation of 
M1-Ub chains was markedly enhanced in Otulin knock-down cells (Fig 3.13). 
These experiments indicate that Otulin restricts the formation of M1-Ub 
chains, especially in IL-1-stimulated cells. However, only a small proportion of 
endogenous Otulin is associated with LUBAC in HEK293 cells [183]. It would 
clearly be of interest to generate cells that completely lack Otulin expression 
by CRISPR/Cas9 gene editing technology to study the roles of Otulin in 
greater detail. In addition, it will be important to study the role of CYLD in 
parallel with the role of Otulin. CYLD is another DUB that is able to hydrolyse 
M1-Ub chains in vitro, and has been shown to bind to the same region of 
HOIP as Otulin [184]. This would require the generation of a CYLD KO cell 
line, as well as an Otulin/CYLD double KO cell line. It would be interesting to 
investigate whether IL-1 stimulation induces the phosphorylation of Otulin 
(particularly at Tyr56) and CYLD and what the role of phosphorylation might 
be.  
Interestingly, the IL-1-induced formation of K63-Ub chains was 
enhanced in Otulin knock-down cells (Fig. 3.13) raising the possibility that not 
only are K63-Ub chains required for M1-Ub chain formation, but also that M1-
Ub chains can promote K63-Ub chain formation  
3.3.7 The role of Pellino E3 ubiquitin ligases within the IL-1 pathway 
The observation that the IL-1-stimulated generation of K63-Ub chains 
was not reduced in TRAF6 KO cells points to the involvement of at least one 
other E3 ligase, capable of generating K63-Ub chains. For some time our 
group has thought that the three isoforms of Pellino might be strong 
candidates and we have shown that Pellino1 is converted to an active E3 
ligase when cells are stimulated with IL-1 [29]. To this end, we generated 
three lines of knock-in mice in which each isoform of Pellino was replaced by 
an E3 ligase-deficient mutant. I have shown that MEFs from the single knock-
in mice show no defect in the IL-1-induced activation of the canonical IKK 
complex and MAP kinases (Fig. 3.10A), possibly due to functional redundancy 
between the three Pellino isoforms. However, excitingly I found that, in MEFs 
from the Pellino1/2 double and Pellino1/2/3 triple knock-in mice, the IL-1 
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stimulated formation of K63-Ub chains was greatly reduced (Fig. 3.10B). This 
indicated that Pellinos 1 and 2, and not TRAF6, generate the majority of K63-
Ub chains in IL-1-stimulated MEFs. However, the loss of a substantial 
proportion of the K63-Ub chains did not affect the formation of M1-Ub chains 
significantly (Fig. 3.10C), suggesting that the K63-Ub chains generated by 
Pellinos are not coupled to M1-Ub chain formation. Moreover, the activation of 
TAK1, the canonical IKKs and MAP kinases was not decreased significantly 
in MEFs from the Pellino1/2 double-in or Pellino1/2/3 triple knock-in mice 
while ubiquitylation of IRAK1 was only reduced partially (Fig. 3.10B). These 
findings suggest that a major proportion of the K63-Ub chains, formed in 
response to IL-1, are not involved in activating the canonical IKK complex and 
MAP kinases and their precise role remains to be discovered.  
However, the Pellino E3 ligases do appear to have an important role IL-
1-induced formation of pro-inflammatory cytokines, because the generation of 
MIP-2 mRNA and MIP-2 secretion was reduced significantly in MEFs from 
Pellino1/2 and Pellino1/2/3 knock-in mice (Figs. 3.11B and 3.11C). Based on 
these results it would be informative to isolate macrophages from Pellino1/2 
and Pellino1/2/3 knock-in mice and investigate whether the production of 
proinflammatory cytokines, induced by TLR activation, is impaired. As with 
Figs. 3.11B and 3.11C I could look as both mRNA production and cytokine 
secretion.   
Intriguingly, I found that the expression of Pellino1 was enhanced in 
TRAF6-null IL-1R* cells and TRAF6 KO MEFs (Figs. 3.4B and 3.8), indicating 
that TRAF6 may negatively regulate the expression of Pellino1. Due to the 
lack of sufficiently potent and specific antibodies, I was unable to check 
whether this was also true for Pellino2 and Pellino3. The increased levels of 
Pellino1 could potentially explain, why the ubiquitylation of IRAK1, IRAK4 and 
MyD88 was significantly enhanced in TRAF6-null IL-1R* cells (Fig. 3.4D). 
Moreover, because TAK1 and IKK are not activated in TRAF6 KO cells, it 
follows that pathways that limit the strength of MyD88 signalling by feedback 
control mechanisms also remain inactive. Loss of such feedback control could 
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also explain why the expression and activity of Pellino1, and the ubiquitylation 
of its substrates was enhanced in TRAF6 null cells (Fig. 3.4D).  
However, the evidence that the Pellinos generate K63-Ub chains in 
TRAF6-null IL-1R* cells and TRAF6 KO MEFs is not definitive. To assess this 
further I would first need to knock out the expression of both Pellino1 and 
Pellino2 in TRAF6-null IL-1R* cells. Moreover, it would be informative to see 
whether E3 ligase-inactive mutants of TRAF6 can rescue signalling in the 
absence of Pellino1 or 2. It will also be necessary to knock-out TRAF6 in 
MEFs from Pellino1/2/3 knock-in mice to see whether the K63-Ub chains 
remaining in the Pellino triple knock-in mice are formed by the action of 
TRAF6 or yet another E3 ligase(s).  
3.3.8 A model for how TRAF6 functions in IL-1-stimulated IL-1R* cells 
 In summary, based on the results presented in this Chapter, it is 
evident that the model for how TRAF6 functions within the IL-1 network is far 
more complex than anticipated. A revised model for the pathway, which takes 
into account the unexpected findings I have made in this Chapter is illustrated 
in Fig. 3.14. Understanding the molecular mechanisms underlying the 
essential roles of TRAF6 in activating TAK1 and in forming M1-Ub chains, 
which are independent of its E3 ligase activity, remain challenging problems 
for future research.  
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Figure 3.14 A model for how TRAF6 enables the production of M1-
Ub chains and the activation of TAK1 in IL-1R* cells. 
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IL-1 induces the formation of K63-Ub chains, which can be attached to 
MyD88, IRAK1, IRAK4 and Pellino1. Although this sill occurs in TRAF6-
null cells, the IL-1 -induced activation of TAK1 and consequently that of 
MAP kinases is abolished and only a small amount of M1-Ub chains are 
formed. These signalling events are independent of one another and can 
be partially rescued by the re-expression of TRAF6 E3 ligase-inactive 
mutants. This indicates that TRAF6 promotes the activation of TAK1 and 
the formation of M1-Ub chains by mechanisms that are independent of its 
ability to generate K63-Ub chains. Pellino1 and Pellino2 appear to 
generate the majority of K63-Ub chains in MEFs and their E3 ligase 
activities contributes to the production of proinflammatory cytokines. Otulin 
is a physiological DUB that opposes the formation of M1-Ub chains by 
LUBAC. However, other DUBs such as CYLD, which can hydrolyse M1-Ub 
and K63-Ub chains in vitro, are likely to be involved in the hydrolysis of 
these Ub chains in cells. 
 
 
3.3.9 Is TRAF6 E3 ligase activity required in other signalling pathways? 
The MyD88 KO mouse is both viable and fertile [91] whereas the TRAF6 KO 
mouse suffers from osteoporosis and dies within 14 days of birth [134,135]. 
This is because TRAF6 functions in the RANKL (receptor activator of NF-κB 
ligand) pathway and is required for the survival and proliferation of osteoclasts 
[135] which help to maintain and repair bones. This clearly demonstrates that 
TRAF6 is involved in additional signalling networks and not just in MyD88-
dependent pathways. To date, TRAF6 has been implicated in signalling 
networks activated by CD40 ligand, IL-17 and TGF-β (transforming growth 
factor) signalling [247–249]. In these pathways TRAF6 has been found to 
interact with and/or ubiquitylate different proteins to facilitate signalling. It will 
be interesting to investigate the pathways in which its E3 ligase activity is 
dispensable. To investigate this problem, we are in the process of generating 
a knock-in TRAF6[L74H] mouse. The exact phenotype of the homozygous 
TRAF6[L74H] mouse compared to the TRAF6 KO mouse will be of great 
interest.  
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3.3.10 Is Halo-NEMO and effective tool to investigate the IL-1-induced 
formation of K63-Ub chains? 
 Throughout this Chapter I have used full-length NEMO, coupled to 
resin, to capture Ub chains from cell protein extracts. In vitro, full-length 
NEMO can bind pure K63-Ub chains and M1-Ub chains (Fig. 1 in [224]). 
Moreover, in these experiments, NEMO appears to show preference for 
longer Ub chains over smaller Ub chains (Fig. 1 in [224]). Similarly, the UBAN 
domain alone has been shown to interact with M1-Ub dimers and K63-Ub 
dimers, although with a much greater affinity for M1-Ub dimers [159,160]. 
Consistent with this, full-length NEMO is able to deplete all M1-Ub chains from 
the extracts of IL-1-stimulated IL-1R cells (Fig. 3.15A, compare lanes 2 and 6 
in P1), but not K63-Ub chains (Fig. 3.15A, compare lanes 2 and 8 in P2). In 
cells not stimulated with IL-1 or other agonists that activate innate immune 
pathways, M1-Ub chains are virtually undetectable (Fig. 3.15A, lane 1 in P1 
and Fig. 3C in [250]). However, in IL-1R cells there are already large amounts 
of K63-Ub chains detectable in the absence of IL-1 stimulation  (Fig. 3.15A, 
lane 3, P2) and even in the absence of M1-Ub chains, NEMO does not appear 
capable of capturing these K63-Ub chains from cell extracts (Fig. 3.15A 
compare lanes 1 and 7, P2), or indeed any other form of Ub chain (Fig 3.15B, 
compare lanes 1 and 2 with lanes 3 and 4). This indicates that NEMO almost 
exclusively binds M1-Ub chains. However, NEMO is still able to enrich for 
K63-Ub chains from the extracts of IL-1R cells, in an IL-1-dependent manner 
(Fig. 3.15A compare lanes 1 and 2, P2). This is most likely because these 
K63-Ub chains are covalently attached to M1-Ub chains [43]. Moreover, it also 
appears that NEMO is able to capture the majority of K63-Ub chains formed 
upon IL-1 stimulation (Fig. 3.15A, compare lanes 3 and 4 with lanes 7 and 8 in 
P2).  This demonstrates that NEMO is an effective tool to capture both M1-Ub 
and K63-Ub chains formed following IL-1 stimulation.  
 In several instances (Figs. 3.4A, 3.5B and 3.6B) I have shown that a 
drastic reduction in M1-Ub chains does not affect my ability to detect the IL-1-
induced formation of K63-Ub chains. I do not believe that under these 
conditions, NEMO is binding directly to K63-Ub chains. Instead, it is likely that 
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the reduced amount of M1-Ub chains formed, presumably of a shorter chain 
length, will still be covalently attached to K63-Ub chains, allowing the capture 
and detection of K63-Ub chains. Additionally, in these experiments I was also 
able to capture small amounts of long K63-Ub chains with Halo-NEMO, before 
IL-1 stimulation, indicating that under these circumstances NEMO is directly 
binding to very long K63-Ub chains. However, it is possible that the very small 
amounts of M1-Ub chains, present before IL-1 stimulation (Fig. 3.15A, lane 1, 
P1) are covalently attached to K63-Ub chains, explaining K63-Ub capture in 
the absence of IL-1 stimulation. To better evaluate K63-Ub chain formation 
following IL-1 stimulation, it would be best to capture K63-Ub chains directly 
using the NZF domain of TAB2 as in Fig. 3.15A.  
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Figure 3.15 Evaluation of ubiquitin chain capture by Halo-NEMO 
and Halo-TAB2(NZF2) 
(A) IL-1R cells were stimulated for the times indicated before Halo-NEMO 
or Halo-TAB2(NZF2) was used to capture Ub chains (first pulldown (1. 
PD)) from cell extract protein. Where indicated the samples were 
subjected to a second pulldown (2. PD) using either Halo-NEMO or Halo-
TAB2(NZF2). The Ub chains were eluted by the addition of LDS and the 
samples were subjected to SDS-PAGE before immunoblotting with Ub 
linkage-specific antibodies. (B) As in A, except that only Halo-NEMO was 
used to enrich for Ub chains and the PVDF membrane was immunoblotted 
with an antibody that recognises all forms of Ub.  These experiments were 
performed by Christoph Emmerich, Cohen lab and are adapted from [43]. 
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4 The anti-inflammatory drug BAY 11-7082 
suppresses the MyD88-dependent signalling 
network by targeting the ubiquitin system 
4.1 Introduction 
Several years ago, it was discovered that mutations in MyD88 were a 
major cause of the activated B-cell subtype of DLBCL (diffuse large B-cell 
lymphoma) [5], one of the least curable forms of lymphoma. These mutations 
of MyD88 were found to promote constitutive activation of its signalling 
network [5]. One MyD88 mutation in particular, in which Leu265 is changed to 
a Pro, was found to account for nearly a third of cases of DLBCL [5]. Recently, 
the MyD88[L265P] mutation has also been identified in a number of other 
human cancers, including 69% of cases of cutaneous DLBCL [251] and 90% 
of instances of Waldenström’s macroglobulinaemia [252]. It was reported that 
MyD88[L265P] was sufficient to drive cell growth and survival [5], 
demonstrating that deregulated innate immune signalling is able to promote 
carcinogenesis. The MyD88[L265P] mutation resides within the TIR domain, a 
region which is essential for interaction with the intracellular TIR domains of 
IL-1Rs and TLRs [253]. It has been proposed that this mutation disrupts the β-
sheet structure of the TIR domain, promoting spontaneous self-
oligomerisation of MyD88 and the constitutive activation of the signalling 
network in which it participates [5,254]. Moreover, the finding that the 
MyD88[L265P] mutant is able to oligomerise with WT MyD88 in the absence 
of TLR stimulation, can explain why the heterozygous mutation is sufficient to 
drive lymphomagenesis [5,254].  These findings raised the question of 
whether inhibitors of protein kinases that are activated downstream of MyD88, 
when used alone or in combination, might prevent the proliferation of 
lymphoma cells or even induce their destruction.  
Initially, I found that inhibitors of TAK1 and the IKK family members only 
slowed the proliferation of lymphoma cells. However one compound, BAY 11-
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7082, which had been reported to inhibit IKK activity, rapidly induced the 
death of a MyD88[L265P] lymphoma cell line. This observation suggested that 
BAY 11-7082 was destroying these cells by a process that was independent 
of the inhibition of IKK activity. I therefore set out to discover what this 
mechanism might be and the results are presented in this Chapter.   
A few of the results presented in this Chapter were performed by other 
members of the MRC-PPU and this is acknowledged in the relevant figure 
legends.  
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4.2 Results  
4.2.1 BAY 11-7082 and BAY 11-7085, but not other inhibitors of IKK 
activity or activation, induce the destruction of HBL-1 cells  
I examined whether compounds reported to inhibit the activation of the 
canonical IKK complex also affected the growth and/or survival of HBL-1 cells, 
a DLBCL cell line carrying the MyD88[L265P] mutation [5]. I did not count cell 
numbers directly but instead incubated them with the compound resazurin, 
which upon entering cells, is reduced into the fluorescent compound resorufin 
[234].  This assay allowed for quantitative and high-throughput analysis of cell 
number and viability [234]. I found that BI605906 [206], a potent and selective 
inhibitor of IKKβ and two structurally unrelated inhibitors of TAK1, 5Z-7-
oxozeanol [153] and NG25 [255] only slowed cell growth but did not stop it 
(Fig. 4.1). Rather surprisingly, I found that BAY 11-7082 [226], a compound 
sold as an inhibitor of the IKKs or NF-κB activity, rapidly led to the death of 
the HBL-1 lymphoma line (Fig. 4.1). Moreover, I found that the closely related 
compound BAY 11-7085 [226], had a similar effect to BAY 11-7082 (Fig. 
4.1A). Furthermore, in a preliminary experiment, I found that BAY 11-7082 
was also able to destroy cell lines (HEK293 cells and RAW 264.7 
macrophages) that did not contain activating mutations of MyD88, indicating 
that BAY 11-7082 was not functioning solely as an IKK inhibitor (data not 
shown).   
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Figure 4.1 BAY 11-7082 and BAY 11-7085, but not other inhibitors 
of the activity or activation of the canonical IKK complex, induce 
HBL-1 cell death. 
HBL-1 cells were incubated without any inhibitor (n) or in the presence of 
the TAK1 inhibitors 5Z-7-oxozeaenol (1 µM, ●) or NG25 (1 µM, ○), the 
IKKβ inhibitor BI605906 (10 µM, ∆), BAY 11-7082 (3 µM, ▲) or BAY 11–
7085 (3 µM, □). Cell proliferation was assessed as described in Methods. 
Values are means ± S.D. for three experiments each performed in 
triplicate.   
 
4.2.2 BAY 11-7082 does not inhibit the canonical IKK complex, IRAK1 
or IRAK4 in vitro 
BAY 11-7082 was initially reported to block the TNFα-induced 
phosphorylation of IκBα [226]. It has subsequently been used in almost 500 
papers as a specific inhibitor of the canonical IKKs; IKKα and IKKβ [256], and 
as general inhibitor of NF-κB activation [257]. In contrast, the two structurally 
unrelated TAK1 inhibitors, NG25 and 5Z-7-oxozeanol, which prevent the 
activation of the IKKs and translocation of NF-κB into the nucleus, did not 
induce HBL-1 cell death (Fig. 4.1). These observations suggested that BAY 
11-7082 was destroying HBL-1 cells by a mechanism that was independent of 
its ability to inhibit IKK activity. We therefore initially assessed whether BAY 
11-7082 could block IKK activity in vitro, as this had never been reported. This 
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led to the surprising finding that BAY 11-7082 did not affect IKKα or IKKβ 
activity at 10 μM in vitro (Table 4.1). We next assessed whether BAY 11-7082 
affected the activity of kinases that are situated ‘upstream’ of the IKKs in this 
signalling network, namely: IRAKI, IRAK4 and TAK1 (Fig 1.4). The activity of 
the IRAKs was unaffected by BAY 11-7082 at 10 µM, but TAK1 was partially 
inhibited (Table 4.1), suggesting a potential explanation for why BAY 11-7082 
might inhibit the IKKs in cells. However, two other potent inhibitors of TAK1 
did not induce the death of HBL-1 cells (Fig 4.1), indicating that inhibition of 
TAK1 was unlikely to be the mechanism by which BAY 11-7082 destroyed 
these cells.   
 
Table 4.1 Effect of BAY 11-7082 on in vitro kinase activities 
Assays were performed at 0.1mM ATP in the absence of any thiol. 
The results are presented as the activity in the presence of BAY 11-
7082 divided by the activity in the absence of BAY 11-7082 multiplied 
by 100. These assays were carried out by Lorna Plater, DSTT. 
 
 
Protein 
kinase 
Percentage activity remaining at the indicated  
BAY 11-7082 concentration 
1 µM 10 µM 
IKKα  126 102 
IKKβ  96 89 
IRAK1 107 113 
IRAK4 114 115 
TAK1 102 24 
 
 
4.2.3 BAY 11-7082 prevents the activation of the canonical IKK complex 
stimulated by IL-1 and LPS 
I then assessed whether BAY 11-7082 was able to block IKK activation 
induced by exposure of human IL-1R cells to IL-1 or the mouse macrophage 
RAW 264.7 cell line to LPS (lipopolysaccharide) (Fig. 1.4). I found that BAY 
11-7082 completely suppressed the IL-1- and LPS-stimulated activation of 
IKKβ in these cells (Figs. 4.2A and 4.2B). As a consequence of this, BAY 11-
7082 also blocked the phosphorylation of the IKKβ substrate, p105 and the 
degradation of IκBα, which is triggered by the IKK catalysed phosphorylation 
of IκBα   (Figs. 4.2A and 4.2B).  
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As BAY 11-7082 partially inhibited TAK1 activity in vitro, I assessed 
whether it inhibited the IL-1-induced phosphorylation of the protein kinase 
TBK1 (TANK-binding kinase 1), which occurs independently of TAK1 [206]. 
The blockade of TBK1 phosphorylation by BAY 11-7082 suggested that this 
compound inhibited this signalling pathway ‘upstream’ of TAK1 (Fig. 4.2C). 
Moreover, I found that although BAY 11-7082 prevented the IL-1- or LPS-
stimulated activation of JNK1/2, it induced near-maximal activation of p38 
MAP kinase in the absence of IL-1 or LPS (Figs. 4.2D and 4.2E).  
Following MyD88 binding to the IL-1R or to TLR4, one of the first 
events to occur is the recruitment and auto-phosphorylation of IRAK4 
[110,116]. I found that IRAK4 autophosphorylation still occurred normally in 
cells that had been treated with IL-1 or LPS following pre-incubation with BAY 
11-7082 (Figs. 4.2F and 4.2G).  These experiments indicated that BAY 11-
7082 had not inactivated the IL-1R or TLR4 or impaired the recruitment of 
IRAK4 to MyD88.   
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Figure 4.2 BAY 11-7082 suppresses the activation of IKK family 
members and JNK 
(A) IL-1R cells were incubated for 1 h with the indicated concentrations of 
BAY 11-7082 and then stimulated for 15 min with IL-1β (0.5 ng/ml). The 
cells were lysed and aliquots of the cell extract (20 μg of protein) were 
denatured in SDS, subjected to SDS/PAGE, and immunoblotted with 
antibodies that recognize the active phosphorylated form of IKKβ, the 
IKKβ substrate p105 phosphorylated at Ser933 and all forms of IκBα and 
GAPDH. (B) Same as A, except that RAW 264.7 macrophages stimulated 
for 15 min with LPS (100 ng/ml) were used. (C) Same as A, except that IL-
1R cells were only incubated with 15 µM BAY 11-7082 where indicated 
and immunoblotted with antibodies that recognise all forms of TBK1 and 
TBK1 phosphorylated at Ser172. (D) As in C, except that the PVDF 
membranes were then immunoblotted for JNK phosphorylated at 
Thr183 and Tyr185, p38 MAPK phosphorylated at Thr180 and Tyr182 and 
GAPDH. (E) As in D, except that RAW macrophages were stimulated with 
LPS (100 ng/ml) were used. (F) Same as C, except that IRAK4 was 
immunoprecipitated from 2 mg of cell extract protein and the samples were 
immunoblotted with an antibody that recognises IRAK4 phosphorylated at 
Thr346and Ser346 (p-IRAK4) and an antibody that recognises all forms of 
IRAK4. (G) Same as F, except that RAW macrophages, stimulated with 
LPS (100 ng/ml), were used. p-, phospho-. Similar results were obtained 
on at least three other occasions.  
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4.2.4 BAY 11-7082 inhibits the formation of K63-Ub and M1-Ub chains  
This results described thus far indicated that BAY 11-7082 blocked the 
activation of the canonical IKK complex, by preventing TAK1 activation (Fig. 
1.4). This indicated it might have affected the generation of K63-Ub and M1-
Ub chains (Fig. 1.4). To investigate this possibility, I used immobilised Halo-
NEMO to capture the K63-Ub chains that had been formed in response to IL-1 
and LPS stimulation of IL-1R and RAW cells respectively. It is clear that in 
both cases, BAY 11-7082 prevented the formation of K63-Ub chains (Figs. 
4.3A and 4.3B). Based on my findings presented in Chapter 3, it was likely 
that, due to the prevention of K63-Ub chain formation by BAY 11-7082, the 
formation of M1-Ub chains would also be blocked. To assess whether this 
was true, I captured M1-Ub chains from the extracts of IL-1-stimulated IL-1R 
cells on Halo-NEMO. I was able to identify small M1-Ub chains by their 
characteristic electrophoretic mobility on SDS/PAGE, which differs from the 
mobility of K63-Ub oligomers of equivalent length (Fig. 4.3C, compare lanes 
7-8). BAY 11-7082 completely suppressed the IL-1-stimulated formation of 
M1-Ub oligomers comprising three to seven ubiquitin molecules as well as 
large ubiquitin oligomers over 100 kD, which are hybrid K63/M1-Ub molecules 
(Section 3.1) (Fig. 4.3C, compare lanes 3-6).  
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Figure 4.3 BAY 11-7082 prevents the formation of K63-Ub and M1-
Ub chains in IL-1R cells and RAW macrophages 
(A) IL-1R cells were incubated for 1 h with 15 μM of BAY 11-7082 before 
stimulation with IL-1β (0.5 ng/ml) for the times indicated. After the cells 
were lysed K63-Ub chains were captured on Halo-NEMO (top panel) from 
3 mg of cell extract protein as described in Methods. The K63-Ub chains 
were identified by immunoblotting with a specific antibody. Further aliquots 
of the cell extract were immunoblotted for IKKβ phosphorylation, p105 
phosphorylation and GAPDH (bottom three panles). (B) As in A, except 
that RAW macrophages that had been stimulated with LPS (100 ng/ml) 
were used. (C) In lanes 1–6, IL-1R cells were incubated for 1 h with (+) or 
without (−) 15 μM BAY 11-7082, then stimulated for 10 min with (+) or 
without (−) IL-1β (0.5 ng/ml). Following cell lysis, M1-Ub chains and K63-
Ub chains were captured from 6 mg of cell extract protein, using Halo-
NEMO and separated by SDS/PAGE. The membranes were cut into two 
pieces and immunoblotted for 10 s (upper half of gel) or 120 s (lower half 
of gel) with an anti-Ub antibody (Enzo Life Sciences). Authentic M1-Ub 
oligomers (lane 7) and K63-Ub oligomers (lane 8) were used as markers 
to demonstrate that the small ubiquitin oligomers formed in response to IL-
1β stimulation and captured by Halo-NEMO were M1-Ub chains and not 
K63-Ub chains. Similar results were obtained on at least two other 
occasions.  
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4.2.5 BAY 11-7082 inhibits the loading of ubiquitin onto E2 conjugating 
enzymes 
 The generation of ubiquitin chains is initiated by the transfer of ubiquitin 
onto a cysteine residue on the ubiquitin-activating enzyme, UBE1, in an ATP-
dependent manner. This is followed by transfer of the ubiquitin to a cysteine 
residue within the active site of E2 conjugating enzymes (Fig. 1.2). It was 
possible that BAY 11-7082 might prevent the conjugation of ubiquitin to UBE1 
or the transfer of ubiquitin from UBE1 to the E2, explaining the loss of K63-Ub 
and M1-Ub chains. To examine these possibilities I initially used Ubc13 (also 
known as UBE2N), which directs the formation of K63-Ub chains by TRAF6 
[128] and other E3 ubiquitin ligases [258] when it is complexed to the inactive 
‘pseudo-E2’ Uev1a. These experiments demonstrated that BAY 11-7082 did 
not affect the loading of ubiquitin to UBE1 under the conditions tested (Fig. 
4.4A), but completely blocked the transfer of ubiquitin from UBE1 to Ubc13 
(Fig. 4.4B). BAY 11-7082 also prevented the transfer of ubiquitin from UBE1 
to UbcH7 (also known as UBE2L3) (Fig. 4.4C), which is the E2 thought to act 
with RBR (RING-between-RING) E3 ligases [176] such as LUBAC. BAY 11-
7085 similarly prevented the conjugation of ubiquitin to Ubc13 and UbcH7, 
although it was slightly less potent than BAY 11-7082 (Figs. 4.4D and 4.4E). 
These findings led me to test whether BAY 11-7082 affected the loading of 
other E2 conjugating enzymes that accept ubiquitin from UBE1. I found that 
24 of 26 E2 conjugating enzymes tested were inactivated by incubation with 
10 μM BAY 11-7082 in vitro (Fig. 4.5), but the conjugation of ubiquitin to 
UBE2G1 and UBE2H was only reduced partially by this concentration of BAY 
11-7082 (Fig. 4.5).  
 124 
 
 
Figure 4.4 BAY 11-7082 prevents ubiquitin loading to many E2 
conjugating enzymes but not to the E1 activating enzyme, UBE1 
UBE1 and Ub (A), UBE1, Ubc13 and Ub (B) or UBE1, UbcH7 and Ub (C) 
were incubated for 60 min with the indicated concentrations of BAY 11-
7082 and the Ub-loading reactions were then started by the addition of 
Mg-ATP (see Methods). Proteins were subjected to SDS/PAGE and the 
gels were stained with Coomassie Instant Blue, followed by destaining in 
water. (D) As in B, except that BAY 11-7085 was also used. (E) As in C, 
except that BAY 11-7085 was also used. The experiment presented in C 
was performed by Axel Knebel. 
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Figure 4.5 BAY 11-7082 inhibits 24 out of 26 E2 conjugating 
enzymes 
The E2 conjugating enzymes (UBE) indicated, were incubated for 45 min 
at 20oC with UBE1 and Ub without any thiol and in the absence (−) or 
presence (+) of 10 μM BAY 11-7082 (see Methods). Proteins were 
subjected to SDS/PAGE and the gels were stained with Coomassie Instant 
Blue, followed by destaining in water. UBE2N is also known as Ubc13 and 
UBE2L3 is also known as UbcH7. Ubiquitin chains were formed in 
reactions containing UBE2D3, UBE2D4, UBE2Q1 and UBE2Q2, as shown 
by a ladder of bands of decreasing electrophoretic mobility.  
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4.2.6 BAY 11-7082 inhibits the recruitment of DNA repair machinery to 
sites of DNA damage 
K63-Ub chains are not just involved in IL-1- and TLR-stimulated 
signalling networks, but also in other cellular events, including the DNA 
damage response. In this pathway they enable the recruitment of components 
of the DNA-repair machinery, such as the RAP80 component of the BRCA1 
(breast cancer early-onset 1) complex, to sites of DNA damage [259,260]. The 
recruitment of RAP80 to DNA damage-induced sub-nuclear ‘foci’ has been 
shown to require Ubc13 [259]. If BAY 11-7082 inactivates Ubc13, I reasoned 
that this compound should also suppress the recruitment of RAP80 to DNA 
damage foci. To test this, I transiently expressed a GPF-tagged truncated 
form of RAP80 that encompassed the K63-Ub binding region into U2OS cells 
[261]. When I exposed U2OS cells to ionising radiation, GFP-RAP80 became 
localised to sites of DNA damage (Fig. 4.6i), which was prevented by BAY 11-
7082 (Fig. 4.6ii). In contrast, in cells that were not exposed to ionising 
radiation, RAP80 did not form foci in the absence (Fig. 4.6iii), or presence 
(Fig. 4.6iv) of BAY 11-7082. As a control experiment, the formation of the 
phosphorylated form of histone H2AX (γH2AX) at sites of DNA damage (Fig. 
4.6v), which is not dependent on the formation of K63-Ub chains [260], was 
studied. As expected, γH2AX foci were little affected by BAY 11-7082 (Fig. 
4.6vi). In contrast, cells that had not been exposed to ionising radiation did not 
form foci and so no γH2AX foci were observed (Fig. 4.6vii). However, some 
γH2AX foci were observed in cells that had not been exposed to ionising 
radiation, but had been incubated with BAY 11-7082 (Fig. 4.6viii), probably 
because the inhibition of K63-Ub chain formation by BAY 11-7082 prevents 
the repair of DNA damage that occurs spontaneously in cells at a low rate 
[262,263]. Figures 4.6ix-xii are control experiments showing DAPI (4',6-
diamidino-2-phenylindole) staining and merged images of Figures 4.6i-iv with 
Figures 4.6v-viii.  
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Figure 4.6 BAY 11-7082 prevents the DNA damage response.  
Indirect immunofluorescence images of U2OS cells transiently expressing 
GFP–RAP80[1–200]. Cells were incubated for 1 h with or without BAY 11-
7082 (15 μM) and either exposed to ionizing radiation (IR) or not exposed. 
GFP–RAP80 or γH2AX were visualized using anti-GFP and anti-γH2AX 
antibodies respectively, and nuclei were stained with DAPI. Similar results 
were obtained in two further experiments.  
 
4.2.7 The mechanism by which BAY 11-7082 inhibits Ubc13 and UbcH7 
 It is possible that in cells, BAY 11-7082 supresses the formation of 
K63-Ub chains, induced by IL-1 and LPS, by preventing the ability of Ubc13 to 
form a thioester bond with an activated ubiquitin molecule. However, the 
mechanism by which this occurs is not clear. To investigate this further I 
incubated BAY 11-7082 with Ubc13 and sent the solution for analysis by 
MALDI-TOF-MS (Matrix-assisted laser desorption/ionisation, time-of-flight 
mass spectrometer). This demonstrated that the molecular masses of the 
major and minor components of Ubc13 both increased by 51 Da (Fig. 4.7A). 
This was unexpected because the mass of BAY 11-7082 is 207 Da. However, 
a likely mechanism was that the thiol group of the only cysteine residue in 
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Ubc13 had reacted with BAY 11-7082, forming a covalent bond by Michael 
addition at the C3 carbon atom of BAY 11-7082, with the elimination of 4-
methylbenzene-sulfinic acid by the mechanism depicted in Figure 4.6B.  
The two components of Ubc13 observed after MALDI-TOF-MS with 
molecular masses of 19.32 kDa (major component) and 19.50 Da (minor 
component) was curious (Fig. 4.7A). This was because the mass of the major 
component was approximately 130 Da less than that predicted from the 
molecular mass of the expressed protein. The Ubc13 preparation used in 
these experiments had been expressed in E. coli as a His6-tagged protein. 
When this preparation was subjected to N-terminal sequencing, by David 
Campbell, it was revealed that it lacked the initiator methionine residue and 
instead started with the next amino acid, glycine. The absence of the N-
terminal methionine residue accounted for the difference between the 
determined and the predicted molecular mass of the protein in the major 
component. The minor component in the preparation, accounting for 
approximately 25% of the total material (Fig. 4.7A), was shown by mass 
spectrometric analysis of tryptic peptides to be Ubc13 in which the α-amino 
group of the N-terminal glycine residue was gluconoylated, explaining why its 
molecular mass was 178 Da greater than that of the major component. N-
gluconoylation, it transpires, is a frequently encountered modification when N-
terminally His6-tagged proteins lose their N-terminal methionine residue to 
start with the N-terminal sequence GSSHHHHHH [264]. 
To establish whether the putative covalent adduct in Figure 4.6B had 
really been formed, I digested Ubc13 and UbcH7, that had been inactivated 
by incubation with BAY 11-7082, with trypsin and sent the peptides for 
analysis by an Orbitrap Classic mass spectrometer (Thermo Scientific) by 
David Campbell in our Unit (see Methods). The Ubc13 that had been reacted 
with BAY 11-7082 and then digested with trypsin, generated peptides with 
molecular masses of 867.5, 1110.6 and 2062.1 Da, corresponding to the 
tryptic peptides ICLDILK, ICLDILKDK and ICLDILKDKWSPALQIR plus 51 Da 
respectively. MS/MS analysis of the peptides confirmed that the site of this 51 
Da modification was the single cysteine residue in each peptide.  
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Figure 4.7 BAY 11-7082 forms a covalent adduct with Ubc13 
(A) Ubc13 was incubated without or with BAY 11-7082 and subjected to 
MALDI-TOF-MS as described in the Experimental section by Stella Ritorto. 
Incubation with BAY 11-7082 increased the molecular mass of Ubc13 by 
51 Da. (B) Proposed mechanism for how BAY 11-7082 covalently 
modified Ubc13 and UbcH7. In this reaction, the active site cysteine of 
Ubc13 or UbcH7 acts as a nucleophile (electron pair donor) and targets 
the unsaturated carbon indicated, which acts as an electrophile because 
the nitrile group (-CN) is electron withdrawing. This is a nucleophilic 
addition reaction, known as a Michael addition because an unsaturated 
carbon is the electrophile [265]. (C) N-acetyl cysteine was incubated with 
BAY 11-7082 and the two products of the reaction, (R,E)-2-acetamido-3-
[(2-cyanovinyl)thio]propanoic acid (Compound 1) and 4-methylbenzene-
sulfinic acid (Compound 2) were identified by NMR and MS by Natalia 
Shpiro as described in the Methods section.  
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These tryptic peptides contain the only cysteine residue present in Ubc13 
(Cys87), the two longer peptides arising from partial tryptic cleavage of the 
lysine-aspartate and lysine-tryptophan bonds between amino acid residues 
92/93 and 94/95 of Ubc13. The unmodified forms of these peptides with 
molecular masses of 816.5, 1059.6 and 2011.1 could not be detected in this 
experiment, but were identified when Ubc13, which had not been incubated 
with BAY 11-7082, was digested with trypsin. Similarly, tryptic digestion of 
UbcH7 generated peptides with molecular masses of 1593.8, 1991.0 and 
3100.6 Da. This corresponded to the molecular masses of the peptides 
GQVCLPVISAENWK, GQVCLPVISAENWKPATK, IYHPNIDEKGQVCLPVIS-
AENWKPATK plus 51 Da respectively. These tryptic peptides contain the 
cysteine residue in UbcH7 (Cys86) that accepts ubiquitin from ubiquitin-
loaded UBE1. The two longer peptides arise from partial tryptic cleavage of 
the lysyl-proline and lysyl-glycine peptide bonds between residues 96/97 and 
82/83 of UbcH7. The unmodified forms of these peptides with molecular 
masses of 1542.8, 1940.0 and 3049.6 could not be detected after reaction 
with BAY 11-7082, but were identified when UbcH7 that had not been 
exposed to BAY 11-7082, was digested with trypsin. Taken together, these 
experiments establish that BAY 11-7082 inactivates E2-conjugating enzymes 
in the way depicted in Figure 4.7B. 
To further establish the mechanism by which cysteine residues react 
with BAY 11-7082, Natalia Shpiro, in our Unit, incubated N-acetyl cysteine 
with BAY 11-7082 and purified the reaction products and solved their 
structures by NMR as described in the Methods section (Fig. 4.7C). These 
experiments established that the reaction mechanism postulated in Figure 
4.7B was correct and also confirmed that 4-methylbenzene-sulfinic acid had 
not been generated in the ion source of the mass spectrometers. 
4.2.8 BAY 11-7082 inhibits the intrinsic E3 ligase activity of LUBAC  
I have demonstrated that BAY 11-7082 forms a covalent adduct with 
the active site cysteine of Ubc13 and UbcH7, which may explain why in IL-1-
stimulated cells, the formation of K63-Ub and M1-Ub chains is prevented. 
LUBAC, the E3 ligase responsible for the formation of M1-Ub chains [43,171], 
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contains an active site cysteine onto which an activated ubiquitin molecule is 
transferred from the E2 before it is linked to an M1-Ub chain [178]. Therefore 
it is possible that BAY 11-7082 might have suppressed the formation of M1-
Ub chains by preventing the transfer of ubiquitin from the ubiquitin-loaded E2 
to the active site cysteine residue on HOIP (LUBAC catalytic subunit). 
To test this hypothesis I incubated IL-1R cells and RAW macrophages 
with increasing concentrations of BAY 11-7082 and assayed the E3 ligase 
activity of endogenous LUBAC (see Methods). It has been shown that LUBAC 
possesses intrinsic E3 ligase activity in cells that does not increase upon 
exposure to IL-1 [43], and so the experiments were performed in cells not 
stimulated IL-1 or LPS. These experiments showed that BAY 11-7082 
irreversibly inactivated LUBAC in both IL-1R cells and RAW 264.7 
macrophages at concentrations similar to those that suppress the activation of 
IKKβ and the formation of K63-Ub chains (Figs. 4.8A and 4.8B).  
4.2.9 BAY 11-7082 enhances the formation of K48-Ub chains in cells 
The finding that BAY 11-7082 not only prevented the loading of 
ubiquitin on to Ubc13 and UbcH7, but also the conjugation of ubiquitin to 
many other E2 conjugating enzymes (Fig. 4.5) raised the possibility that it 
might inhibit every cellular ubiquitylation event. I therefore investigated its 
effect on the formation of K48-Ub chains in cells. Interestingly, BAY 11-7082 
did not suppress, but increased the formation of K48-Ub chains considerably 
in IL-1R and RAW cells (Figs. 4.9A and 4.9B). It also enhanced the formation 
of K48-Ub chains in RAW macrophages that had already been elevated by 
incubation with the proteasome inhibitor MG132 (Fig. 4.9B), but had little 
effect on MG132-stimulated K48-Ub chain formation in IL-1R cells (Fig. 4.9A). 
These observations imply that E2 conjugating enzymes that direct the 
formation of K48-Ub chains are still active at the concentrations of BAY 11-
7082 used in these experiments. For example, UBE2G1 and UBE2H, which 
are reported to direct the formation of K48-Ub chains [266], were only 
inhibited partially by BAY 11-7082 under conditions where the conjugation of 
Ub to other E2 ligases was abolished (Fig 4.5).  
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Figure 4.8 BAY 11-7082 inhibits LUBAC E3 ligase activity 
IL-1R cells (A) or RAW 264.7 macrophages (B) were incubated for 1 h 
with the indicated concentrations of BAY 11-7082. The cells were then 
lysed and LUBAC was immunoprecipitated (IP) from 1.0 mg of cell extract 
protein using anti-HOIP as described in Methods. The IPs were washed 
and LUBAC-catalysed M1-Ub chain formation was initiated by the addition 
of UBE1, UbcH7, ubiquitin and Mg-ATP. Following SDS/PAGE, Ub chain 
formation was detected by immunoblotting (IB) with an anti-Ub antibody 
(Dako). Similar results were obtained on two other occasions.  
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The observation that BAY 11-7082 enhanced the formation of K48-Ub 
chains in cells suggested that this compound might also inhibit the 
proteasome. I therefore incubated IL-1R cells (Fig. 4.9C) and RAW 
macrophages (Fig. 4.9D) in the absence or presence of BAY 11-7082 or 
MG132 followed by immunoblotting of the cell extracts with antibodies that 
recognize (hypoxia-inducible factor) HIF1α. In normoxic cells, HIF1α is barely 
detectable because it undergoes Cullin-2-mediated K48-linked ubiquitylation 
followed by proteasomal degradation [267]. I found that BAY 11-7082 induced 
the appearance of HIF1α similarly to MG132 and the ubiquitylated species of 
HIF1α could be detected, as well as unmodified HIF1α (Figs. 4.9C and 4.9D). 
These results are consistent with BAY 11-7082 inhibiting the proteasome. 
However, it was possible that BAY 11-7082 had inactivated UbcH12, the E2 
conjugating enzyme for NEDDylation, thereby preventing the NEDDylation 
and activation of Cullin-2 [267]. This possibility was excluded by showing that 
the proportion of the slower migrating NEDDylated form and the faster 
migrating de-NEDDylated form of Cullin 2 was not altered by treatment with 
BAY 11-7082 or MG132. In contrast, the formation of the NEDDylated species 
was blocked by MLN4924 (Fig. 4.9C and D), a specific inhibitor of NAE1 
[NEDD8 (neural-precursor-cell-expressed developmentally down-regulated 8)-
activating enzyme E1 subunit 1], the E1 activating enzyme for NEDDylation 
[230]. These results show that BAY 11-7082 does not inhibit the E1 activating 
enzyme for NEDD8 or the E2 conjugating enzyme UbcH12 under the 
conditions tested and indicate that BAY 11-7082 is likely to inhibit the 
proteasome. Consistent with this notion, HBL-1 cells were rapidly destroyed 
after incubation with the proteasomal inhibitor bortezomib [232] (Fig. 4.9E).  
However, the inhibition of DUBs by BAY 11-7082 may also contribute 
to the enhanced formation of K48-Ub chains, which appear to be of a different 
length compared to those formed solely by preventing proteasomal activity 
(Figs. 4.9A and 4.9B).  Most DUBs are cysteine proteinases, which are likely 
targets of attack by BAY 11-7082. Moreover, BAY 11-7082 was recently found 
to prevent the activity of a broad spectrum of DUBs in an in vitro analysis [52].  
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Figure 4.9 BAY 11-7082 enhances the formation of K48-Ub chains 
in cells and prevents the degradation of HIF1α by the proteasome 
IL-1R cells (A) or RAW 264.7 macrophages (B) were incubated for 1 h 
without (−) or with (+) 15 μM BAY 11-7082, followed by a further 1 h 
without (−) or with (+) the proteasome inhibitor MG132 (25 μM). The cells 
were lysed and aliquots of the cell extract were subjected to SDS/PAGE 
and immunoblotted with antibodies that recognise K48-Ub chains. 
(C and D) IL-1R cells (C) or RAW macrophages (D) were incubated for 2 h 
without or with 15 μM BAY 11-7082, 25 μM MG132 or 1 μM MLN4924. 
The cells were then lysed and immunoblotted with antibodies that 
recognize HIF1α and Cullin 2 and GAPDH. (A-D) Similar results were 
obtained on two other occasions. (E) HBL-1 cells were incubated without 
any inhibitor (○) or in the presence of 0.1 µM of the proteasome inhibitor 
bortezomib (*) and cell proliferation was monitored as a function of time. 
Values are means ± S.D. for three experiments performed in triplicate. 
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4.2.10 NSC697923 inactivates E2 conjugating enzymes and LUBAC E3 
ligase activity similarly to BAY 11-7082 
During my investigations into the mechanism by which BAY 11-7082 
prevents the activation of the canonical IKK complex, a small compound 
(NSC697923) was identified as an inhibitor of the Ubc13-Uev1a complex 
[268]. Moreover, it was also able to promote the destruction of HBL-1 cells 
[268]. Interestingly, although the mechanism of action of NSC697923 was not 
reported, its structure was similar to that of BAY 11-7082 (Figs 4.10A and 
4.10B). This indicated that it might also form a covalent adduct with the active 
site cysteine of Ubc13.  
 
 
 
Figure 4.10 Structures of BAY 11-7982 and NSC697923 
Similarity of the structures of NSC697923 (A) and BAY 11-7082 (B). 
 
Using MALDI-TOF MS we found that a covalent adduct with a 
molecular mass of 95 Da was formed on Ubc13 after incubation with 
NSC697923 (Fig. 4.11A). This suggested that, as occurred with BAY 11-7082, 
4-methylbenzene-sulfinic acid had been eliminated, leaving the adduct 
depicted in Figure 4.11B.  It had been reported that NSC697923 did not inhibit 
the E2 conjugating enzyme UbcH5c (UBE2D3) [268], but I found that this E2 
was inhibited partially under the conditions I used (Fig. 4.12A). Moreover, 
NSC697923 also prevented the transfer of ubiquitin to a number of other E2 
conjugating enzymes, including UbcH7 (UBE2L3), UBE2D2, UBE2G1, 
UBE2G2, UBE2L6, UBE2R2, UBE2S and UBE2T (Fig. 4.12A). However, 
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NSC697923 appears to be more selective than BAY 11-7082 as a number of 
other E2 conjugating enzymes were unaffected by this compound (Fig. 
4.12A). Similar to BAY 11-7082, NSC697923 irreversibly inhibited LUBAC E3 
ligase activity (Fig. 4.12C), increased the formation of K48-linked Ub chains in 
cells (Fig. 4.12D) and blocked the IL-1-stimulated formation of K63-Ub chains 
in IL-1R cells (Fig. 4.12B). 
 
 
 
 
Figure 4.11 NSC697923 forms a covalent adduct with Ubc13. 
(A) Ubc13 was incubated without or with NSC697923 and subjected to 
MALDI-TOF-MS by Stella Ritorto as described in the Methods section. 
Incubation with NSC697923 increased the molecular mass of Ubc13 by 95 
Da. (B) Proposed mechanism for how NSC697923 modified Ubc13.  
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Figure 4.12 NSC697923 inhibits several E2s in vitro and functions 
in a similar manner to BAY 11-7982 in cells 
(A) The E2 conjugating enzymes (UBE) indicated were incubated for 45 
min at 20oC with UBE1 and Ub without any thiol and in the absence (−) or 
presence (+) of 20 µM NSC697923. Ub loading was initiated by the 
addition of Mg-ATP and carried out for 10 min at 30oC as described in 
Methods. The reactions were subjected to SDS/PAGE and the gels were 
stained with Coomassie Instant Blue. (B) IL-1R cells were incubated with 
20 µM of NSC697923 where indicated before stimulation with IL-1β (0.5 
ng/m) for the times indicated. K63-Ub chains were captured from cell 
extracts on Halo-NEMO and immunoblotted with a K63-Ub-specific 
antibody. Aliquots of the cell extract were immunoblotted with the indicated 
antibodies. (C) IL-1R cells were incubated with the indicated 
concentrations of NSC697923 for 1 h before lysis. The LUBAC complex 
was immunoprecipitated with anti-HOIP and its ability to form Ub chains 
was assayed as described in Methods. (D) IL-1R cells were incubated for 
1 h without (−) or with (+) 20 μM NSC697923, and then for a further 1 h 
without (−) or with (+) the proteasome inhibitor MG132 (25 μM). The cells 
were lysed and aliquots of the cell extract were subjected to SDS/PAGE 
and immunoblotted with antibodies that recognize K48-Ub chains 
specifically. (B-D) Similar results were obtained in two further experiments.  
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4.3 Discussion 
4.3.1 BAY 11-7082 prevents the LPS- and IL-1-induced activation of the 
IKKs and promotes the destruction of lymphoma cells 
The discovery that a mutation of MyD88, in which Leu265 was changed 
to Pro, accounted for a significant proportion of B-cell lymphoma subtypes 
[5,252], strikingly demonstrated the tight link between aberrant immune 
signalling and cancer. The knock-down of MyD88 in a lymphoma cell line 
carrying the MyD88[L265P] mutation (HBL-1 cells) prompted cell death [5]. 
Therefore, it seemed a reasonable hypothesis that inhibitors of kinases that 
are activated downstream of MyD88, might suppress the proliferation of HBL-
1 cells and even destroy them. However, I found that inhibitors of TAK1 and 
IKKβ, which block the activation of MAP kinases and should suppress NF-κB 
transcriptional activity, only slowed lymphoma cell growth modestly (Fig. 4.1). 
Although it is unclear why HBL-1 cells were not affected more drastically, it 
may be relevant that we have found the MyD88-dependent activation of TBK1 
and IKKε to be unaffected by the loss of TAK1 protein kinase activity [206]. 
The inactivation of TAK1 does not therefore prevent the activation of every 
protein kinase. The hyper-activation of the IKK-related kinases, TBK1 and 
IKKε, has been implicated in several cancers [269,270] and this bifurcation of 
the MyD88 signalling network may enable the survival of HBL-1 cells in the 
absence of NF-κB activity. Additionally, my findings suggest that the effort by 
pharmaceutical companies to develop inhibitors of NF-κB to treat lymphomas, 
may be misdirected.  
Remarkably, I did discover that BAY 11-7082, a compound marketed 
as an IKK inhibitor, was able to rapidly induce the death of HBL-1 cells (Fig. 
4.1). Although I demonstrated that BAY 11-7082 did not inhibit IKK activity in 
vitro (Table 4.1), it has been used in over 500 papers to implicate the IKKs 
and NF-κB in a variety of cellular events. I uncovered that BAY 11-7082 
prevented the IL-1- and LPS-stimulated formation of K63-Ub and M1-Ub (Fig. 
4.3) chains by irreversibly inhibiting the E2 conjugating enzymes Ubc13 and 
UbcH7 (Figs. 4.4B and 4.4C) and the E3 ubiquitin ligase, LUBAC (Fig. 4.8). 
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The suppression of K63-Ub chains and M1-Ub chains presumably explains 
how BAY 11-7082 prevents the activation of the canonical IKK complex by 
LPS and IL-1 (Figs. 4.2A and 4.2B). 
Although the inhibition of NF-κB may have contributed to the death of 
HBL-1 cells induced by BAY 11-7082, my investigations uncovered several 
other ways in which BAY 11-7082 could have promoted cell death. I found 
that BAY 11-7082 was able to inactivate 24 out of the 26 E2s in vitro (Fig. 
4.5), presumably by covalent modification of their active site cysteine. This 
was a clear indication that BAY 11-7082 is not a specific inhibitor of K63-Ub 
and M1-Ub chain formation but is a more general inhibitor of ubiquitylation 
reactions. Therefore BAY 11-7082 will no doubt perturb a myriad of cellular 
functions, any of which could destroy lymphoma cells, similar to a non-specific 
kinase inhibitor, such as staurosporine [271,272]. Moreover, I found that BAY 
11-7082 also stalled the DNA damage response (Fig. 4.6), presumably by 
suppressing the formation of K63-Ub chains through Ubc13 inactivation. Over 
time, the accumulation of spontaneous DNA damage [262,263], is likely to 
overwhelm lymphoma cells and induce their destruction [273]. Moreover it 
was recently found that the E3 ligase activity of LUBAC protected cells against 
apoptosis induced by cisplatin-mediated DNA crosslinking [274]. Therefore 
the prevention of M1-Ub chain formation by BAY 11-7082 may cause the 
destruction of cells, which possess damaged DNA. It would therefore be 
interesting to test the effect of a specific UbcH7 or LUBAC inhibitor on HBL-1 
cells when such molecules are developed. 
Interestingly, although BAY 11-7082 inhibited the majority of E2 
conjugating enzymes in vitro, it did not completely block the ability of UBE2H 
and UBE2G1 to load with ubiquitin (Fig. 4.5). As these E2s had been reported 
to direct the formation of K48-Ub chains in vitro [266], I investigated the 
formation of K48-Ub chains in cells that had been incubated with BAY 11-
7082.  Unexpectedly, BAY 11-7082 promoted the cellular formation of K48-Ub 
chains and ubiquitylated HIF1α, which is constitutively degraded by the 
proteasome, and in a similar manner to the compound MG132, which is a 
proteasomal inhibitor [231] (Figs. 4.9A and 4.9B). This demonstrated that BAY 
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11-7082 does not completely suppress all ubiquitylation reactions 
indiscriminately and indicated that it is able to prevent the proteasomal 
degradation of proteins. Consistent with this hypothesis, I found that 
bortezomib, a proteasomal inhibitor licenced for the treatment of multiple 
myeloma [275], was also able to rapidly destroy HBL-1 cells (Fig. 4.9E). 
Although it is unclear how the blockade of proteasomal activity destroys 
cancer cells, it is likely to be through a multitude of mechanisms, which 
include, but are not limited to, the inhibition of NF-κB [276] and the 
accumulation of pro-apoptotic proteins such as p53 [277]. Moreover, rapidly 
dividing cancer cells with an increased requirement for the synthesis of new 
proteins, may be more vulnerable to proteasomal inhibition [278].  
Intriguingly, the K48-Ub chains produced by incubating cells with BAY 
11-7082 were of a higher molecular weight than those induced by MG132 
(Figs. 4.9A and 4.9B). This suggested that BAY 11-7082 may not just inhibit 
the proteasome but also inactivate proteins which function to limit the length of 
K48-Ub chains. This could potentially be explained by the recent finding that 
several DUBs, which are cysteine proteinases, could be inactivated by BAY 
11-7082 in vitro [52]. An intriguing possibility is that BAY 11-7082 inhibits the 
proteasome by inhibiting proteasome-associated DUBs, which could be 
examined by studying the effect of BAY 11-7082 on the purified proteasomal 
complex [279].  
It is obvious that BAY 11-7082 is able to covalently modify many 
reactive cysteine residues. Indeed, BAY 11-7082 has also been found to 
inhibit some protein tyrosine phosphatases by covalent modification of the 
cysteine residue required for catalysis [280]. Inhibition of the catalytic cysteine 
residues of the related dual-specificity protein phosphatases [281], could also 
explain why BAY 11-7082 induces the phosphorylation of p38 MAP kinase in 
cells not stimulated with IL-1 or LPS (Figs. 4.2D and 4.2E).  
Taken together it appears that BAY 11-7082 is likely to promote the 
destruction of lymphoma cells by multiple mechanisms due to its lack of 
specificity.  
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4.3.2 NSC697923 has similar properties to BAY 11-7082 
During my investigations into the function of BAY 11-7082 in cells, 
another compound, NSC697923, was reported to act as a specific inhibitor of 
Ubc13 [233]. I noticed that NSC697923, had structural similarities to BAY 11-
7082 (Fig. 4.10), indicating that it might function in a similar manner. My 
experiments confirmed that NSC697923 was able to inactivate Ubc13 by 
reacting with its active site cysteine (Fig. 4.11A) and prevent the formation of 
K63-Ub chains and IKK activation in IL-1-stimulated IL-1R cells, similarly to 
BAY 11-7082  (Fig. 4.12B). However, NSC697923 also inactivated LUBACs 
E3 ligase activity measured in the extracts of IL-1R cells and induced the 
appearance of K48-Ub chains (Figs. 4.12D and 4.12C), indicating that it 
wasn’t nearly as specific as reported [233]. Moreover, NSC697923 did not just 
inhibit ubiquitin loading on Ubc13, but it also inhibited nine other E2s out of 
the 26 tested (Fig. 4.12A). This was interesting because although NSC697923 
and BAY 11-7082 were both small molecules with similar structures (Fig. 
4.10), NSC697923 exerted greater selectivity. Recently, other investigators 
studied the molecular basis for the difference in selectivity between these 
molecules [282]. They discovered that a Leu residue present in the active site 
groove of many E2s is likely to prevent the binding of NSC697923, but not 
BAY 11-7082, to these enzymes preventing it from modifying their active site 
cysteines [282]. Moreover, they were able to obstruct the active site groove of 
Ubc13 with a Leu residue by a mutation, which rendered it resistant to 
inhibition by NSC697923 but not by BAY 11-7082 [282].  This demonstrates 
that even greater selectivity could potentially be achieved by modifying the 
structures of BAY 11-7082 or NSC697923, to improve their use as chemical 
probes for E2 function and, potentially, their use as drugs with fewer side 
effects to treat lymphoma and other diseases as discussed below. 
4.3.3 BAY 11-7082 and similar compounds have therapeutic potential 
Based on my evidence for how BAY 11-7082 is likely to function in 
cells, one might have anticipated that this compound would have many 
deleterious side effects when tested in animal models of disease. However, 
rather surprisingly, BAY 11-7082 was found to be well tolerated in mice given 
 142 
doses of 20 mg/kg/day, for up to 20 days. Moreover, these concentrations of 
BAY 11-7082 protected mice from developing disease in a model of systemic 
lupus erythematosus [283], enabled improved wound healing in genetically 
diabetic mice [284] and shrank tumours in mice with severe immunodeficiency 
[285]. Therefore BAY 11-7082 appears to be a compound with considerable 
therapeutic potential, although the molecular mechanism by which it exerts 
these therapeutic effects is unclear. However, rapidly dividing tumour cells 
may be less viable after exposure to BAY 11-7082 due to the accumulation of 
damaged DNA and reduced proteasomal activity. Moreover, the partial 
suppression of innate immune signalling, by the blockade of TAK1 and IKK 
activation, may prevent tissue damage caused by inflammation. It is also 
possible that a large proportion of the BAY 11-7082, administered to mice, is 
rapidly inactivated by reaction with the glutathione present in cells.  This may 
prevent the complete inactivation of the potential targets of BAY 11-7082, and 
partial inhibition of cellular targets may minimise the side effects likely to be 
caused by the complete inactivation of multiple intracellular protein targets.  
BAY 11-7082 is not the only non-specific compound shown to have 
beneficial effects in disease models. For example, bortezomib, a proteasome 
inhibitor is an effective therapy for multiple myeloma [275]. Moreover, dimethyl 
fumarate, which covalently modifies E2 conjugating enzymes in a similar 
manner to BAY 11-7082 (Simon Arthur and Vicky McGuire, University of 
Dundee, unpublished results) and has anti-inflammatory properties, was 
recently licenced for the management of multiple sclerosis [286]. Taken 
together, these findings indicate that all drugs do not need to possess 
exquisite specificity. However, it is unlikely that the many targets of non-
specific drugs will be advantageous. Therefore it is far more prudent to 
develop inhibitors that display a degree of specificity to reduce deleterious 
side effects [287].  
BAY 11-7082 has also been reported to inhibit the NLRP3 
inflammasome (Section 1.3.2.2), which is responsible for the processing of IL-
1β and IL-18 [288]. The most likely mechanism by which BAY 11-7082 would 
prevent NLRP3 inflammasome activity would be through the inactivation of 
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Caspase 1, a cysteine proteinase (Section 1.3.2.2). However, the authors 
demonstrated that, in vitro, this was not the case and reported that BAY 11-
7082 inhibited the ATPase activity of the NLRP3 inflammasome, through a 
covalent modification [288]. This would appear to be yet another anti-
inflammatory property of BAY 11-7082 and may contribute to its beneficial 
effects in mouse models of inflammation [283]. However, we have recently 
found that the kinase activity of IKKβ is essential for the activation of the 
NLRP3 inflammasome (Sambit Nanda, Cohen Lab, unpublished results). 
Therefore, the blockade of IKK activation by BAY 11-7082 could also explain 
how BAY 11-7082 is able to prevent the processing of IL-1β and IL-18.  More 
recently a compound, MCC950 [289], with structural similarity to BAY 11-7082 
and NSC697923 (Fig. 4.13) was found to prevent the activation of the NLRP3 
inflammasome in cells, at nanomolar concentrations [289]. Moreover, 
MCC950 was efficacious in a mouse model of cryopyrin-associated periodic 
syndrome in which the release of active IL-1β is unregulated due to 
constitutive NLRP3 inflammasome activity. Although the molecular 
mechanism by which MCC950 exerts its effect is unknown, it is possible that it 
may covalently modify one or more components of the NLRP3 inflammasome 
or an ubiquitin conjugation system that controls the activity of the NLRP3 
inflammasome. It would be simple and informative to assay MCC950 against 
a large panel of E2 conjugating enzymes and other enzymes with nucleophilic 
Cys residues. 
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Figure 4.13 The structures of NSC697923, BAY 11-7082 and MCC950 
 
  
In summary, the work presented in this Chapter demonstrates the importance 
of understanding how inhibitors, used to probe biological systems, actually 
work, and that the lack of this information can lead to many erroneous 
conclusions being reached. More specifically, it means that the conclusions 
drawn from the 500 or so papers published using BAY 11-7082 will need to be 
re-interpreted.  Nonetheless, it demonstrates that targeting the ubiquitin 
system to treat disease is an achievable goal. 
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5 Perspectives 
This Thesis details my investigations into the early ubiquitylation events 
triggered by IL-1 stimulation. To achieve this I have always taken the same 
approach, to first capture ubiquitin chains from the extracts of cells on 
immobilised proteins and then immunoblot with antibodies that specifically 
recognise ubiquitin linkages or ubiquitylated proteins. Although this is a 
powerful method, there are limitations. For example, the short dynamic range 
of ECL and X-ray films means that I could potentially have missed subtle 
changes in ubiquitin chain regulation. Moreover, although I have clearly 
demonstrated that IL-1 induces the formation of both K63-Ub chains and M1-
Ub chains, I am not able to quantitate the increase. This prevents an accurate 
comparison between ubiquitin chain formation in WT and TRAF6-null cells. 
Although this might not be necessary for IL-1R* cells, which respond robustly 
to IL-1, it may become more troublesome if I were to investigate pathways 
which exhibit weaker signalling intensities. This could be remedied with 
relative ease by using secondary antibodies coupled to fluorophores, which 
display a far greater dynamic range, enabling quantitative results to be 
obtained [290]. An even more powerful method would be to employ absolute 
quantification (AQUA) mass spectrometry [291,292]. AQUA peptides are 
synthetically made to match peptides of interest (K63 and M1-Ub chains), but 
contain an amino acid labelled with a stable isotope. When mixed with native 
samples before mass spectrometry analysis, they function as an internal 
standard to give the absolute quantity of native peptides [291,292]. A 
downside of using Halo-NEMO is that I am restricted to investigating only M1 
and K63-Ub chains. Instead I could replace NEMO with proteins that bind to 
all forms of ubiquitin chains, such as TUBEs [293]. In conjunction with AQUA 
mass spectrometry this would allow me to investigate whether other ubiquitin 
linkages are involved in the IL-1 signalling network. A further drawback of my 
current system is that Halo-NEMO and Halo-TAB2(NZF2) capture M1-Ub 
chains and/or K63-Ub chains, indiscriminately of whether they exist in 
separate IL-1 signalling pools. One approach to decipher whether this is the 
case would be to use FLAG-tagged IL-1β to stimulate cells. This would allow 
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the immunoprecipitation and enrichment, only of activated IL-1Rs and their 
associated signalling components. This method has been successfully 
employed in the study of TNF receptor signalling [294]. Following FLAG 
immunoprecipitation I could then subject the supernatant to a NEMO pull-
down, which would allow the identification of complexes, containing M1-Ub 
chains, not associated with the IL-1 receptor. I find that the robust signalling 
response elicited by IL-1 stimulation of IL-1R cells make them a useful tool to 
investigate this pathway. However, the fact that parent HEK293 cells do not 
respond to IL-1 until the IL-1R is overexpressed, is a caveat of this system 
[295]. Potentially, because of this, the layout of the IL-1 signalling network in 
IL-1R cells may differ when compared to cells lines, which endogenously 
express the IL-1R.  This could account for the observed discrepancies 
between MEFs and IL-1R* cells (compare Figs. 3.5 and 3.7). To further 
support my conclusions as to the function of TRAF6 within IL-1R* cells, I will 
need to use another human cell line that responds to IL-1 without the need to 
overexpress the IL-1R.  
Although most of my research has been limited to the investigation of IL-1 
pathway, my findings may provide insight into how other innate immune 
signalling networks are regulated by ubiquitylation. For example, M1-Ub 
chains are known to regulate both the TNF and NOD2 pathways [172–
174,250]. This is most likely because M1-Ub chains are involved in the 
activation of the canonical IKK complex, a central component of many innate 
immune networks (section 1.3.7). Moreover, following NOD2 activation, 
LUBAC uses pre-formed ubiquitin chains as a substrate to generate hybrid 
ubiquitin chains (Fig. 4C in [250]), indicating that its catalytic activity is 
regulated in a similar manner to that observed in the IL-1 pathway [43]. 
However, although TRAF6 is not involved in TNF or NOD2 signalling, TRAF2 
has been implicated in these pathways [294,296–298]. TRAF2 is not thought 
to possess catalytic activity, instead it is believed to function as a scaffold to 
recruit other active E3 ligases, such as the inhibitors of apoptosis family 
[294,298]. Therefore, using TRAF2 KO cells it would be of interest to 
investigate the formation of K63 and M1-Ub chain within the context of TNF 
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and NOD2 signalling. This could indicate whether a crucial function of the 
TRAF family of proteins is to aid the LUBAC-catalysed formation of M1-Ub 
chains.  
Although M1-Ub chains are involved in several innate immune signalling 
networks, only one E3 ligase, LUBAC, is responsible for their catalysis.  On 
the other hand, within the IL-1 signalling network and other innate immune 
pathways, it appears that several E3 ligases redundantly generate K63-Ub 
chains (Fig. 3.4 and [294,298]). Surprisingly however, in the absence of 
TRAF6, these K63-Ub chains are not sufficient to activate TAK1 or the IKK 
complexes following IL-1 stimulation. This further indicates that the majority of 
K63-Ub chains are unnecessary for early IL-1 signalling events. However, the 
enzymatic activity of these E3 ligases may be required for the longer-term 
consequences of IL-1 stimulation, as in the case of Pellino1 and Pellino2 (Fig. 
3.11). Therefore, the generation of a cell line in which all of these E3 ligases 
are knocked out will be required to evaluate redundancy in K63-Ub chain 
formation.  
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